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ABSTRACT 
 
 
Heart failure is a major public health issue, with its prevalence estimated to be 6.5 
million adults in the USA. Of the hospitalized heart failure (HF) cases, 50% are 
characterized by preserved ejection function (HFpEF). In HFpEF, the heart pumps a 
normal proportion of blood that enters it. However, thickening of the ventricular walls 
inhibits the chamber filling to normal volume. The direct basis of HFpEF is a slowed 
elongation of the cardiac muscle during the diastolic phase of the cardiac cycle. Elucidation 
of mechanisms that mediate relaxation of cardiac muscle could help understand the 
pathogenic mechanisms in HFpEF. 
Myocardial contraction and relaxation are tightly controlled processes that involve 
thick and thin filament regulatory proteins. β-Adrenergic signaling pathway is a major 
regulator of myocardial contraction and relaxation via the activation of protein kinase A 
(PKA). Two key myofilament proteins, troponin I (TnI) and myosin binding protein-C 
(MyBPC), are phosphorylated by PKA following β-adrenergic stimulation. The purpose of 
this thesis is to develop a liquid chromatography-mass spectrometry (LC-MS) method for 
the quantification of phosphorylation in TnI and MyBPC and measure the changes in the 
degree of phosphorylation in transverse-aortic constriction (TAC) mouse hearts, a model 
representing HFpEF, and sham (control) mouse hearts. 
The initial approach of the project was to develop a method for quantification of 
phosphopeptides using synthesized stable isotope labeled (SIL) peptides, both with and 
without phosphate modification. To accomplish this goal, a multiple reactions monitoring 
(MRM)-LC-MS method for the quantification of the synthesized SIL peptides was first 
developed. This method, using low picomole amounts, is applicable to researchers in the 
field using SIL peptides for quantification. However, when the SIL peptides were actually 
applied, we determined that there was a selective absorption of some phosphate peptides 
in the LC column, limiting the use of the SIL peptides for quantification. This result is also 
of general interest to others trying to identify phosphopeptides, not realizing that some 
peptides will go unmeasured. Thus, we returned to expanding an earlier method developed 
in our research group to quantify the degree of phosphorylation. Key to this work was the 
development of a quantification method directly from heart myofibrillar protein 
preparations without requiring isolation of individual proteins by gel electrophoresis. 
Using the LC-MS method developed, we quantified phosphorylation sites of TnI 
and MyBPC in the TAC and control mouse hearts. The phosphorylation measurements 
showed no significant difference in phosphorylation between the TAC and control mice, 
except for one site, S302 in MyBPC that had a 13% decrease in phosphorylation with TAC. 
We conclude that in our TAC model, PKA dysfunction may not play a role in the initial 
development of HFpEF.  
 
 
ii 
 
ACKNOWLEDGEMENTS  
 
The path leading up to this dissertation has been challenging and circuitous, and would not 
have been possible without the constant support and encouragement of amazing people 
around me. I am grateful to my advisor, Dr. Dwight Matthews, who over the years has 
mentored me through my graduate work and molded me to be a better analytical chemist. 
Most of all I am eternally grateful for accepting me as his student. He gave me an 
opportunity to live a life of choice, in a beautiful place like Burlington. My sincere thanks 
go to my committee Dr. Bradley Palmer, Dr. Giuseppe Petrucci, and Dr. Jose 
Madalengoitia for their trust and support. My appreciation extends to all the past and 
current members of our mass spec group, especially Mr. Bruce O’Rourke who has been a 
great teacher and an amazing friend. 
 
Graduate school without friends is impossible. I want to thank Colleen and Colleen’s entire 
family for giving me a home to go during Thanksgiving, and William, Pushwinder and 
Edward for always looking out for me. Ramya and Sanhita for the Indian movie and dinner 
nights so I don’t miss home much, and all my friends from school for your kindness, thank 
you so much. Ritika and Anshu, thank you for your unconditional friendship all these years. 
Hyma you are literally my rock. 
 
I take this opportunity to thank my family. My dear parents Nageswari, and Rama Chandra 
Reddy for your boundless love no matter what I do and for instilling in me the value of 
education, my brother Radha Krishna for encouraging and inspiring me to follow my heart. 
iii 
 
A big thank you to my sister’s amazing family Maheedar, Shresta and Vishwa for being a 
part of my everyday life in spite of being thousands of miles always.  
 
Lastly, the one person I love the most, my little sister, Prasoona. You have supported me 
unconditionally all these years. You have cherished with me, my happy moments and stood 
by me during the rough times. I never would have made it this far without you. Thank you 
for being the best sister I could ever ask for, and I would like to dedicate this dissertation 
to you, Prasoona. 
iv 
 
TABLE OF CONTENTS 
Page 
ACKNOWLEDGEMENTS ................................................................................................ ii 
TABLE OF CONTENTS ................................................................................................... iv 
LIST OF TABLES ........................................................................................................... viii 
LIST OF FIGURES ........................................................................................................... xi 
1.1. HEART FAILURE ................................................................................................ 1 
1.2. CARDIAC MUSCLE STRUCTURE AND FUNCTION ..................................... 2 
1.2.1. Thin Filament .............................................................................................. 3 
1.2.2. Thick Filament ............................................................................................ 5 
1.2.3. Muscle Contraction and Relaxation ............................................................ 7 
1.3. ROLE OF PROTEIN PHOSPHORYLATION IN REGULATION OF 
CARDIAC MUSCLE CONTRACTION ..................................................................... 9 
1.3.1. β-Adrenergic Signaling Pathway ................................................................. 9 
1.3.2. PKA phosphorylation targets of TnI ......................................................... 10 
1.3.3. PKA phosphorylation targets of MyBPC .................................................. 13 
1.4. MOUSE MODEL FOR DIASTOLIC DYSFUNCTION .................................... 16 
1.5. MASS SPECTROMETRIC QUANTIFICATION OF PHOSPHORYLATION 18 
1.5.1. Top-down Proteomics ............................................................................... 19 
1.5.2.1. Bottom-up Proteomics ............................................................................ 20 
1.5.2.2. Quantification of phosphorylation by bottom-up MS ............................ 23 
1.6. STATEMENT OF PURPOSE ............................................................................. 26 
2.1. INTRODUCTION ............................................................................................... 28 
v 
 
2.2. MATERIALS AND METHODS ........................................................................ 30 
2.2.1. Chemicals and Reagents ............................................................................ 30 
2.2.2. Sample Preparation .................................................................................... 31 
2.2.3. LC-MS Analysis ........................................................................................ 32 
2.2.4. Data Analysis ............................................................................................ 33 
2.3 RESULTS AND DISCUSSION ........................................................................... 34 
2.3.1. Background characterization ..................................................................... 42 
2.3.2. Quantification of SIL peptides .................................................................. 45 
2.4. CONCLUSIONS ................................................................................................. 53 
2.5. ACKNOWLEDGMENTS ................................................................................... 54 
3.1. INTRODUCTION ............................................................................................... 55 
3.2. MATERIALS AND METHODS ........................................................................ 58 
3.2.1. Peptide mixture preparation ...................................................................... 58 
3.2.2. Peptide mixture for MRM studies ............................................................. 59 
3.2.3. Flow injection analysis (FIA) of synthetic peptide mixtures .................... 59 
3.2.4. LC-MRM analysis ..................................................................................... 59 
3.3. RESULTS AND DISCUSSION .......................................................................... 60 
3.3.1. Effect of basic residues (R and K) and phosphate group on charge state 
distribution of peptides. ............................................................................ 61 
3.3.2. Effect of basic residues (R and K) and phosphate group on ionization 
efficiency of peptides. ............................................................................... 68 
3.3.2. LC-MS analysis of the SIL peptides ......................................................... 77 
3.4. CONCLUSIONS ................................................................................................. 95 
4.1. INTRODUCTION ............................................................................................... 97 
4.2. MATERIALS AND METHODS ........................................................................ 98 
vi 
4.2.1. Scheme for quantification of protein phosphorylation .............................. 98 
4.2.2. Label-free absolute quantification of proteins ......................................... 101 
4.2.3. Human heart samples .............................................................................. 102 
4.2.3.1. Human heart myofibrillar protein in-gel digestion preparation ........... 103 
4.2.3.2. Human heart myofibrillar proteins in-solution digestion preparation .. 104 
4.2.4. Mouse treatment ...................................................................................... 104 
4.2.4.1. Preparation of mouse samples for phosphorylation measurements. .... 105 
4.2.5. Data acquisition by LC-MS ..................................................................... 106 
4.2.6. LC-MS Data Processing .......................................................................... 108 
4.3. RESULTS .......................................................................................................... 109 
4.3.1. Recovery of myofibrillar proteins from human heart by in-solution and 
in- gel digestion preparations................................................................... 109 
4.3.2. Measurement of peptides with known phosphorylation sites in human 
heart......................................................................................................... 114 
4.3.3. Recovery of TnI and MyBPC in the control and TAC mouse tryptic 
digestions. ............................................................................................... 120 
4.3.4. Measurement of target peptides of TnI in the recombinant-TnI and the 
mouse heart myofibrillar sample preparations. ....................................... 123 
4.3.5. Phosphorylation measurements of mouse cardiac TnI. ........................... 139 
4.3.6. Measurement of target peptides of MyBPC in the recombinant-MyBPC 
and the mouse heart myofibrillar sample preparations. .......................... 150 
4.3.7. Phosphorylation measurements of mouse cardiac MyBPC .................... 163 
4.3.8. Identification of PKA phosphorylation sites in TnI and MyBPC tryptic 
peptides from mouse hearts .................................................................... 178 
4.4. DISCUSSION .................................................................................................... 195 
4.4.1. PKA phosphorylation of TnI ................................................................... 195 
4.4.2. PKA phosphorylation of MyBPC ............................................................ 196 
4.5. CONCLUSIONS ............................................................................................... 199 
vii 
 
4.5. ACKNOWLEDGMENTS ................................................................................. 200 
BIBLIOGRAPHY ........................................................................................................... 202 
 
viii 
 
LIST OF TABLES 
Table Page 
Table 2.1: MRM transitions and the optimized instrument parameters..........................38 
Table 2.2: Total amount of the background lysine and arginine ....................................45 
Table 2.3: SIL tryptic peptides quantification based of arginine and lysine 
quantification by MRM-LC-MS ...................................................................46 
Table 2.4: MRM transitions and the optimized instrument parameters..........................47 
Table 2.5: SIL tryptic peptides quantification by MRM-LC-MS ...................................52 
Table 3.1: SIL tryptic peptides quantified by MRM-LC-MS .........................................61 
Table 3.2: Relative ionization efficiency with one R, two R, one K, one PO4 and 
two PO4 .........................................................................................................75 
Table 3.3: Relative ionization efficiency with one R, two R, one K, one PO4 and 
two PO4 after correction. ...............................................................................76 
Table 3.4: MRM transitions and the optimized instrument parameters..........................78 
Table 4.1: Recovery of myofibrillar proteins from TX heart preparation: 
Comparison of in-solution vs in-gel digestion methods. ............................111 
Table 4.2: Target peptides in TX heart using the PMAX digestion protocol. ..............118 
Table 4.3: Target peptides in TX heart using the optimized overnight digestion 
protocol. ......................................................................................................120 
Table 4.4: Recovery of the myofibrillar proteins from mouse heart preparations. .......121 
Table 4.5: SIL tryptic peptide mixture. .........................................................................127 
Table 4.6: Identification of TnI target peptides and the corresponding SIL peptides 
in the mouse myofibrillar digestions...........................................................135 
Table 4.7: Expected tryptic peptides for mouse cardiac TnI and the peptides 
identified in recombinant protein and the myofibrillar samples. ................137 
Table 4.8: Target peptides with phosphorylation sites and potential reference 
peptides for TnI. ..........................................................................................139 
Table 4.9: Phosphorylation of SSANYR in mouse cardiac TnI. ..................................141 
Table 4.10: Phosphorylation of ISASR in mouse cardiac TnI......................................142 
ix 
 
Table 4.11: Phosphorylation of RPTLR in mouse cardiac TnI. ...................................143 
Table 4.12: Three-way ANOVA of mouse cardiac TnI phosphorylation. ...................146 
Table 4.13: Two-way ANOVA of mouse cardiac TnI phosphorylation. .....................147 
Table 4.14: Phosphorylation of target peptides in mouse cardiac TnI with only 
QEMER as the reference peptide. .............................................................149 
Table 4.15: Identification of MyBPC target peptides and the corresponding SIL 
peptide in the mouse myofibrillar digestions. ...........................................158 
Table 4.16: Expected tryptic peptides for mouse cardiac MyBPC and the peptides 
identified in recombinant protein and the myofibrillar samples. ..............159 
Table 4.17: Target peptides with phosphorylation sites and potential reference 
peptides for MyBPC. .................................................................................163 
Table 4.18: Phosphorylation of TSLAGAGR in the mouse cardiac MyBPC. .............165 
Table 4.19: Phosphorylation of TSDSHEDAGTLDFSSLLK in the mouse cardiac 
MyBPC. .....................................................................................................166 
Table 4.20: Phosphorylation of DSFR in the mouse cardiac MyBPC. .........................167 
Table 4.21: Phosphorylation of DSK in the mouse cardiac MyBPC. ...........................168 
Table 4.22: Three-way ANOVA of mouse cardiac MyBPC phosphorylation. ............171 
Table 4.23: Three-way ANOVA of mouse cardiac MyBPC phosphorylation with 
the finalized 3 reference peptides. .............................................................173 
Table 4.24: Two-way ANOVA of mouse cardiac MyBPC phosphorylation with the 
finalized 3 reference peptides. ...................................................................175 
Table 4.25: Phosphorylation of target peptides in mouse cardiac MyBPC with 
finalized three reference peptides ..............................................................177 
Table 4.26: SIL peptides identified in the control and TAC mouse heart MFP 
samples ......................................................................................................179 
Table 4.27: Phosphopeptides identified from the control and TAC mouse heart MFP 
samples ......................................................................................................180 
Table 4.28: Amount (pmol) of the 0, 1, and 2 phosphorylated SSANYR and its 
miscleaved forms in the mouse heart MFP samples. ................................186 
x 
 
Table 4.29: Fraction of 0, 1, and 2 phosphorylations on SSANYR in the mouse 
heart MFP samples. ...................................................................................187 
Table 4.30: Degree of phosphorylation of MyBPC from three different studies. ........197 
 
xi 
 
LIST OF FIGURES 
Figure ...................................................................................................................... Page 
Figure 1.1: Diagram depicting the major proteins of thick and thin filaments .................3 
Figure 1.2: Schematic of cardiac MyBPC. .......................................................................7 
Figure 1.3: Mechanism of MyBPC phosphorylation regulation of cardiac structure. ....14 
Figure 2.1: MS and MS/MS spectra of AQC-lysine and AQC-[M+8]lysine. ................36 
Figure 2.2: MS and MS/MS spectra of AQC-arginine and AQC-[M+6]arginine. .........37 
Figure 2.3: MRM chromatogram of AQC-lysine, AQC-arginine and AQC-
[M+8]lysine, AQC-[M+6]arginine. .............................................................39 
Figure 2.4: Calibration curves of A) lysine and B) arginine...........................................41 
Figure 2.5: Precursor ion scan of hydrolyzed blank. ......................................................44 
Figure 2.6: MRM chromatogram of AQC-[M+4]alanine, AQC-[M+7]leucine and 
AQC-[M+2]alanine, AQC-[M+3]leucine. ...................................................48 
Figure 2.7: Calibration curves of A) [M+4]alanine and B) [M+7]leucine. ....................50 
Figure 3.1: Charge state distribution of the SIL peptides. ..............................................64 
Figure 3.2: Effect of additional basic residues (R and K) residues on charge state 
distribution. ..................................................................................................65 
Figure 3.3: Effect of addition of phosphate group on charge state distribution. ............67 
Figure 3.4: Relative ionization efficiency of the SIL peptides. ......................................70 
Figure 3.5: Effect of additional basic residues (R and K) on relative Ionization 
efficiency. ....................................................................................................72 
Figure 3.6: Effect of the addition of phosphate group on relative Ionization 
efficiency. ....................................................................................................74 
Figure 3.7: MRM chromatograms of RPTLR series. .....................................................80 
Figure 3.8: Extracted MRM chromatograms of SSANYR series. Intensity 
(cps/pmol) and Area (counts/pmol). ............................................................81 
Figure 3.9: Extracted MRM chromatograms of ISASR series. Intensity (cps/pmol) 
and Area (counts/pmol). ..............................................................................82 
xii 
 
Figure 3.10: Extracted MRM chromatograms of RPTLR series with and without 
Thermo Scientific Hypersil Gold AX column. ..........................................85 
Figure 3.11: Extracted MRM chromatograms of ISASR series with and without 
Thermo Scientific Hypersil Gold AX column. ..........................................86 
Figure 3.12: Extracted MRM chromatograms of SSANYR series with and without 
Thermo Scientific Hypersil Gold AX column. ..........................................87 
Figure 3.13: Extracted MRM chromatograms of RPTLR series with and without 
Waters Atlantis HILIC column. .................................................................88 
Figure 3.14: Extracted MRM chromatograms of ISASR series with and without 
Waters Atlantis HILIC column. .................................................................89 
Figure 3.15: Extracted MRM chromatograms of SSANYR series with and without 
Waters Atlantis HILIC column. .................................................................90 
Figure 3.16: Extracted MRM chromatograms of RPTLR series with and without 
Waters Atlantis C18 column. .....................................................................92 
Figure 3.17: Extracted MRM chromatograms of ISASR series with and without 
Waters Atlantis C18 column. .....................................................................93 
Figure 3.18: Extracted MRM chromatograms of SSANYR series with and without 
Waters Atlantis C18 column. .....................................................................94 
Figure 4.1: Gel separation of the human (TX) myofibrillar preparation. .....................112 
Figure 4.2: Recovery of TnI and MyBPC by in-solution and in-gel digestions. ..........113 
Figure 4.3: Protein coverage by LC-MSE analysis of in-solution and in-gel digests 
for TnI and MyPBC. ..................................................................................114 
Figure 4.4: Amino acid sequence of human cardiac troponin I. ...................................115 
Figure 4.5: Amino acid sequence of human cardiac myosin binding protein C. ..........116 
Figure 4.6: Recovery of TnI and MyBPC in mouse myofibrillar digestions. ...............122 
Figure 4.7: Protein coverage by LC-MSE analysis of TnI and MyPBC in control and 
TAC mouse digestions. .............................................................................123 
Figure 4.8: Amino acid sequence of mouse cardiac troponin I. ...................................124 
Figure 4.9: Extracted ion chromatograms of SSANYR and SSANY*R in 
recombinant mouse troponin I. ..................................................................128 
xiii 
 
Figure 4.10: Extracted ion chromatograms of SSANYR and SSANY*R in mouse 
MFP digestion. .........................................................................................129 
Figure 4.11: Extracted ion chromatograms of ISASR and ISA*SR in recombinant 
mouse troponin I. .....................................................................................130 
Figure 4.12: Extracted ion chromatograms of ISASR and ISA*SR in mouse heart 
MFP digestion. .........................................................................................131 
Figure 4.13: Extracted ion chromatograms of RPTLR and RPTL*R in recombinant 
mouse troponin I. .....................................................................................132 
Figure 4.14: Extracted ion chromatograms of RPTLR and RPTL*R in mouse heart 
MFP digestion. .........................................................................................133 
Figure 4.15: Phosphorylation (%p) of TnI with the finalized three reference 
peptides in control and TAC mouse hearts. .............................................144 
Figure 4.16: Phosphorylation (%p) of TnI with only QEMER as reference peptide 
in control and TAC mouse hearts. ...........................................................148 
Figure 4.17: Amino acid sequence of mouse cardiac MyBPC. ....................................152 
Figure 4.18: Extracted ion chromatograms of DSFR and DSF*R in recombinant 
mouse MyBPC. ........................................................................................153 
Figure 4.19: Extracted ion chromatograms of DSFR and DSF*R in mouse heart 
MFP digestion. .........................................................................................154 
Figure 4.20: Extracted ion chromatograms of the target peptides in recombinant 
mouse MyBPC. ........................................................................................155 
Figure 4.21: Extracted ion chromatograms of the target peptides in mouse heart 
MFP digestion. .........................................................................................156 
Figure 4.22: Phosphorylation (%p) of MyBPC with the four reference peptides in 
control and TAC mouse hearts. ...............................................................169 
Figure 4.23: Phosphorylation (%p) of MyBPC with the finalized three reference 
peptides in control and TAC mouse hearts. .............................................172 
Figure 4.24: Mean phosphorylation (%p) of MyBPC for the four target peptides in 
control and TAC mouse hearts. ...............................................................176 
xiv 
 
Figure 4.25: Extracted ion chromatograms of the peptides of SSANYR-1P in 
control mouse heart MFP digestion. ........................................................182 
Figure 4.26: Extracted ion chromatograms of the peptides of RSSANYR-1P in 
control mouse heart MFP digestion. ........................................................183 
Figure 4.27: Extracted ion chromatograms of the peptides of RSSANYR-2P and 
RRSSANYR-2P in control mouse heart MFP digestion. ........................184 
Figure 4.28: MSE (high-energy) spectra of RSPSANYR at retention time 5.5 min of 
the mouse heart MFP digestion analyzed by the PLGS software. ...........185 
Figure 4.29: Extracted ion chromatograms of phosphopeptides of the target peptides 
in MyBPC in the control mouse heart MFP digestion. ............................190 
Figure 4.30: MSE (high-energy) spectra of RTSPLAGAGR at retention time 14.3 
min for the mouse heart MFP digestion analyzed by the PLGS 
software. ...................................................................................................191 
Figure 4.31: MSE (high-energy) spectra of TSPDSHEDAGTLDFSSLLK at retention 
time 56.7 min for the mouse heart MFP digestion analyzed by the 
PLGS software. ........................................................................................192 
Figure 4.32: MSE (high-energy) spectra of RTSPDSHEDAGTLDFSSLLK at 
retention time 53.3 min for the mouse heart MFP digestion analyzed 
by the PLGS software. .............................................................................193 
Figure 4.33: MSE (high-energy) spectra of RDSPKLEAPAEEDVWEILR at 
retention time 59.16 min for the mouse heart MFP digestion analyzed 
by the PLGS software. .............................................................................194 
 
1 
 
CHAPTER 1: INTRODUCTION 
1.1. HEART FAILURE 
Heart failure (HF) refers to the inability of the heart to provide sufficient blood 
flow to sustain a person’s vital organs. HF is a major public health issue, with its prevalence 
rising with age, and is estimated to affect 6.5 million adults in the USA (1). Heart failure 
can be caused due to weakening of heart muscles. This weakening of heart muscles leads 
to ineffective heart contraction, and less oxygen-rich blood is pumped out to the body. This 
is accompanied by an abnormally low fraction of chamber volume ejected, called ejection 
fraction (EF). This condition is termed heart failure with reduced ejection fraction (HFrEF). 
However, it is possible for patients with normal ejection fraction to have HF, and this form 
of the disease is referred to as heart failure with preserved ejection fraction (HFpEF). The 
2018 update of Heart Disease and Stroke Statistics by the American Heart Association 
reported that 50% of the hospitalized HF cases are characterized as HFrEF and 50% as 
HFpEF (1). In contrast to HFrEF, the prevalence of HFpEF is steadily increasing (2). 
Although there are therapies available for HFrEF, no effective treatment has proven to 
reduce mortality in HFpEF (3,4). Hence, there is a need for understanding the underlying 
mechanisms in HFpEF for the development of effective therapeutic approaches.  
The direct cause of HFpEF is a slowed elongation of the cardiac muscle during 
the diastolic (or filling) phase of the cardiac cycle (5). Diastolic dysfunction arises normally 
with age in the general population, but often develops with hypertension, obesity, diabetes 
and other disorders (6). The prevalence of HFpEF and left ventricular (LV) diastolic 
dysfunction among adults is in the range of 10-35%, and the number of adults in North 
America living with diastolic dysfunction is in the tens of millions (7). Because diastolic 
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dysfunction underlies HFpEF, elucidation of the mechanisms that mediate relaxation can 
help understand the pathogenic mechanisms in HFpEF. There is currently no acceptable 
successful treatment for diastolic dysfunction despite the need. Apart from reducing the 
original stressor, which in the case of aging is not an option, the clinical challenge in 
treating diastolic dysfunction includes facilitating those physiological mechanisms 
responsible for effective cardiac muscle elongation. Those mechanisms known to enhance 
diastolic function include (i) reducing the stiffness and accumulation of interstitial 
collagen, (ii) enhancing intracellular Ca2+ handling to curtail activation of contractile force 
during the diastolic phase, and (iii) shortening the duration of contractile force through 
post-translational modifications of the force-producing myofilament proteins. The current 
study is focused on demonstrating the presence or absence of specific post-translational 
modifications of proteins known to influence diastolic function in cardiac muscle. 
1.2. CARDIAC MUSCLE STRUCTURE AND FUNCTION 
Cardiac muscle is highly organized striated muscle tissue that has basic repeating 
functional units called sarcomeres. Sarcomeres longitudinally repeat to form myofibrils 
that extend along the entire length of a muscle cell. The striated appearance of the cardiac 
muscle is due to the alignment of the sarcomeres of neighboring myofibrils and the 
interleaving pattern of two types of protein filaments called the thin and thick filaments. 
The thin and thick filaments consist of different structural proteins that allow for molecular-
level interactions resulting in muscle force production and contraction depicted in Figure 
1.1. 
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Figure 1.1: Diagram depicting the major proteins of thick and thin filaments 
Actin backbone is shown by the light blue chain of actin molecules, wrapped by 
the tropomyosin filaments (Tm). Troponin (Tn) subunits are indicated by the red, blue and 
yellow motif (Troponin C (TnC), Troponin I (TnI), and Troponin T (TnT) respectively).  
The thick filament components are shown in the lower section where the myosin 
essential chain (ELC) and regulatory chain (RLC) bind to the myosin S1 region near the 
junction with myosin S2. Myosin binding protein C (MyBPC) is shown extending from the 
thick filament to the thin filament, but the precise position of MyBPC relative to myosin is 
not known. Individual MyBPC domains are numbered C0 to C10, starting at the N terminus 
of MyBPC; PA, indicates a proline/alanine-rich linker sequence between C0 and C1; and 
M, the position of the MyBPC regulatory motif between domains C1 and C2 that contains 
PKA phosphorylation sites. Modified from Samantha P. Harris et al. (8).  
 
1.2.1. Thin Filament 
Thin filaments are composed of three proteins: actin, tropomyosin, and troponin. 
Actin forms the backbone of the thin filament. It is found in two forms: globular (G-actin) 
and fibrous (F-actin). Kabsch et al. (9) determined the structure of the G-actin and found 
that it is composed of four different domains numbered 1 through 4. The G-actin ATPases 
enabling polymerization into a double helical F-actin, and the F-actin, in turn drives the 
muscle contraction. Subdomains 1 and 2 form the outer (or small) domain, and subdomains 
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3 and 4 constitute the inner (or large) domain. Two large clefts are formed between these 
domains: the nucleotide-binding and the target-binding clefts (10). Myosin, the force-
producing protein on the thick filament, interacts with actin at these target-binding clefts.  
Tropomyosin (Tm) is an actin-binding protein that plays a critical role in 
regulating actin-myosin interactions in cardiac muscle contraction. Tropomyosin has a 
repeated heptapeptide in its 284 amino acid sequence and forms a series of α-helical coiled 
dimers that arrange into a head to tail polymer along the groove of the double helical actin 
filament with each Tm covering 7 actin monomers. The C-terminus of one Tm interacts 
with the N-terminus of the adjacent Tm molecule forming continuous strands (11,12). The 
dimer is stabilized by the hydrophobic and the hydrophilic interactions between each chain.  
The third major thin filament protein is troponin (Tn), which is a complex of three 
subunits: troponin C (TnC), the Ca2+-binding subunit; troponin I (TnI), the inhibitory 
subunit; and troponin T (TnT), the Tm-binding subunit; in a 1:1:1 molar ratio (13). 
Troponin C belongs to the EF-hand family that has a dumbbell shape with globular N and 
C-terminal domains linked by a short central helix. The structural C-domain has two high-
affinity calcium and magnesium binding sites (III and IV) that preferentially bind to Mg2+ 
at Ca2+ concentrations <10-5 M. The regulatory N-domain has highly selective Ca2+ binding 
sites. Site I was found to be an inactive site in the cardiac isoform of TnC (14), and site II 
alone was found to be sufficient and necessary to initiate muscle contraction (15,16). 
TnI is called an inhibitory subunit because it is responsible for regulating the 
inhibition of the actin-myosin interactions. TnI plays a key role in communicating Ca2+ 
binding to TnC to TnT, which in turn pulls tropomyosin away from the actin target-binding 
clefts thus permitting myosin binding and muscle contraction. TnI has well defined 
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functional regions for this purpose. The cardiac isoform of TnI has a 201 amino acid 
sequence with a unique addition of 32 residues as an N-terminus extension. This extension 
has two phosphorylation sites at S23 and S24 (mouse including the initiating methionine) 
that are sensitive to protein kinase A (PKA) (17). Additionally, it has a region that binds to 
the C-terminus of TnC, and a region that binds to the C-terminus of TnT (18). An inhibitory 
region (residues 129-149) and a regulatory region (residues 150-165) play key regulatory 
roles in inhibiting actomyosin activity and contraction at low Ca2+ concentrations (19). 
Thus, TnI phosphorylation is of notable importance in diastolic function. 
TnT is the longest and largest component of the troponin complex and connects 
all components of the troponin complex and enables the transfer of calcium activation 
effects to Tm on the thin filament. TnT is an elongated protein with a basic C-terminal 
region (TnT2) forming part of the globular head of the troponin complex and an acidic N-
terminal region forming the tail (TnT1). TnT1 binds to the Tm-Tm overlap region and is 
responsible for cooperative myosin S1 binding to the thin filament (20).  
1.2.2. Thick Filament 
The thick filaments are made up of polymers of cardiac myosin along with 
associated proteins: titin, and myosin binding protein C (MyBPC). As a component of the 
thick filament, cardiac myosin is a hexamer and consists of two heavy chains (MHC), two 
essential light chains (ELC) and two regulatory light chains (RLC). The globular heads of 
the MHC, interact with actin of thin filament to form cross-bridges between the thin and 
thick filaments (21). The C-terminal regions of the two heavy chains form an α-helical coil 
in the elongated rod region of myosin that embeds into and makes up the thick filament 
structure. In a tightly packed thick filament, well-spaced arrays of myosin heads emanate 
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from the thick filament and are available to interact with actin of neighboring thin filaments 
thereby resulting in muscle force and contraction.  
Titin is a giant structural sarcomeric protein associated with the thick filament that 
tightly binds to myosin and MyBPC and is believed to function as a molecular ruler to 
precisely control the length of the thick filament (22-24). Titin's elasticity is responsible 
for passive resistance or stiffness in the stretch of the resting muscle (25,26). Additionally, 
titin is found to be involved in strain/stress sensing and signaling (27).  
MyBPC is a 140 kDa protein that has a strong affinity to myosin. It has 11 
domains denoted C0 to C10, with an ‘M’ domain between C1 and C2 near the N-terminus, 
as detailed in Figure 1.2. MyBPC has been implicated to play several roles in muscle 
structure and function. The C-terminal motif of MyBPC binds to myosin as well as titin 
and thereby plays a role of structural component of the thick filament. The second binding 
site is the N-terminal motif with the unique M-domain, which binds to the myosin S2 
domain that is adjacent to the myosin head. This latter interaction is regulated by the 
phosphorylation of MyBPC at the possible sites, S273, S282, S302, and S307 (mouse 
including the initiating methionine). These sites are targeted by PKA, and at least one is 
targeted by calmodulin-dependent kinase-II (CaMKII) (28). The force of contraction, Ca2+ 
sensitivity of the thin filament, and rate of force development have been reported sensitive 
to the phosphorylation status of MyBPC, although the mechanism by which MyBPC 
modulates is not yet clear. Thus, MyBPC phosphorylation is of interest with regards to its 
regulating diastolic dysfunction. 
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Figure 1.2: Schematic of cardiac MyBPC. 
MyBPC consists of 8 Ig and 3 Fn domains together with a MyBPC-specific M-
domain, containing a phosphorylation region (orange) with 4 phosphorylatable serines (P), 
a ProAla-rich domain, and a cardiac-specific insert (blue) in the C5 domain. RLC = 
Regulatory light chain, S2 = Myosin region. Modified from Ji Young Mun et al. (29)  
 
1.2.3. Muscle Contraction and Relaxation 
The mechanical contraction of the cardiac muscle occurs as described by the 
sliding filament model proposed in 1954 by Andrew Huxley and Ralph Niedergerke and 
by Hugh Huxley and Jean Hanson (30,31). In the sliding filament model, myosin in the 
thick filament attaches to actin of the thin filament and the two filaments can then slide 
past each other to shorten or lengthen the muscle fiber during contraction and re-
lengthening, respectively. The cyclic interaction between myosin and actin is driven by the 
energy derived from adenosine triphosphate (ATP) hydrolysis (32). 
In the absence of ATP, the myosin head is strongly bound to actin, forming 
actomyosin cross-brides. When ATP binds to the nucleotide-binding site, the myosin head 
is released from actin. ATP then hydrolyses to form adenosine diphosphate (ADP) and 
inorganic phosphate, Pi, still attached to myosin. The ADP.Pi.myosin complex is at a high-
energy configuration. At Ca2+ concentrations >10-5 M, the thin filament is activated, and 
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myosin attaches to actin. The release of Pi will induce a conformational change producing 
a 10-nm movement in the actin filament referred to as the power stroke (33). This leads to 
myofibrillar contraction that pushes the thick filament and thin filament to slide past each 
other. After the power stroke, ADP is released; the actomyosin interactions are restored 
again returning the muscle to relaxed state. The cycle is completed when Ca2+ is removed.  
The cross-bridge cycling needs to be regulated so that the timing of muscle 
contraction can be controlled. This is regulated by calcium signaling (34). Muscle 
contraction depends on the increase of intracellular calcium concentration accomplished 
by the regulation of cytosolic Ca2+ concentration (35). The binding of the Ca2+ to the N-
domain of the TnC produces a conformational change leading to an exposed hydrophobic 
region (36,37), triggering an interaction with the regulatory region of TnI (residues 150-
165) (38). This, in turn, causes the adjacent inhibitory region of TnI (residues 130-149) and 
the C terminal part of TnT to detach from the actin-tropomyosin, eliminating the inhibition 
of actin-myosin interaction.  
Tm and its flexibility are important for its function in the muscle contraction. 
Based on the conformational changes observed in X-ray diffraction studies in the relaxed 
and contracted state of the muscle, Hill et al. (39) proposed an ON-OFF model for the 
interaction of Tm. In the absence of Ca2+ (OFF state), Tm blocks the binding at the myosin-
binding site on actin. In the presence of Ca2+ (ON state), the Tm dislocates from the myosin 
binding sites, leading to myosin interactions with actin causing contraction. As myosin 
cross-bridges to actin and transitions into a force generating state, it promotes changes in 
the adjacent tropomyosin to expose more myosin binding sites, further increasing the 
myosin cross-bridges, thereby increasing the force generation. Therefore, the myocardial 
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contraction and ventricular pressure depend both on the Ca2+ binding and the cross-
bridging to thin filament that causes shortening when the thin filament slides past the thick 
filament (40). The cycle is completed when Ca2+ is removed, bringing back the relaxed 
state. 
Cardiac muscle relaxation is highly complex and is regulated by three main 
processes: a) calcium removal from the sarcoplasm, b) thin filament deactivation with the 
release of calcium, and c) the rate of actomyosin cross bridge cycling (41-43). The 
relaxation begins by re-sequestering Ca2+ into the sarcoplasmic reticulum (SR) via the 
SERCA pump, lowering the intercellular Ca2+ concentration, and promoting the 
dissociation of Ca2+ from the thin filament. The release of Ca2+ from TnC, moves the 
tropomyosin back into a position that blocks the myosin binding sites causing the 
detachment of the myosin head, breaking the actomyosin cross-bridges, further promoting 
thin filament deactivation (44). As the number of cross-bridges decreases, force and 
pressure are restored to a diastolic state. Therefore, ventricular relaxation not only involves 
the dissociation of Ca2+ from thin filament, but also cross-bridge detachment.  
1.3. ROLE OF PROTEIN PHOSPHORYLATION IN REGULATION OF 
CARDIAC MUSCLE CONTRACTION  
1.3.1. β-Adrenergic Signaling Pathway 
The β-adrenergic signaling pathway is a major regulator of myocardial 
contraction and relaxation through targeted phosphorylation of multiple regulatory proteins 
(45). The activation of β-adrenergic receptors leads to an increase in cAMP levels to 
activate PKA (46). PKA activation leads to accelerated Ca2+ release from SR to initiate 
ventricular contraction and also accelerates the re-sequestering of the Ca2+ into the SR to 
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promote thin filament deactivation and relaxation. Apart from modulating Ca2+ movement 
in the myocyte, PKA phosphorylates sarcomere proteins, the thick filament protein 
MyBPC, and the thin filament protein TnI to accelerate cross-bridge formation, leading to 
enhanced cardiac relaxation (47,48), thereby mediating diastolic function. Because 
diastolic dysfunction underlies HFpEF, the current study is focused on demonstrating that 
alterations in PKA phosphorylation in cardiac TnI and MyBPC can influence myocardial 
relaxation, thereby influencing the diastolic function. 
1.3.2. PKA phosphorylation targets of TnI 
PKA phosphorylation of mouse cardiac TnI involves the phosphorylation of S23 
and S24 (also S23 and S24 in humans) at the N-terminal of the protein (49). 
Phosphorylation of TnI at S23 and S24 was found to reduce cardiac myofilament Ca2+ 
sensitivity, causing an increase in the rate of Ca2+ dissociation from TnC. The dissociation 
of Ca2+ from TnC restores the tropomyosin inhibition on the actin-myosin interaction and 
accelerating of relaxation (38,50,51). In addition, some studies have shown that PKA-
dependent TnI phosphorylation increases the actomyosin cross-bridge cycling rate. The 
cross bridging cycling rates were studied by measuring the oscillating frequency (fmin) of 
the intact muscle in mice. Stimulation of the β-adrenergic receptor by isoproterenol 
increased the oscillating frequency in wild type mice suggesting that β-adrenergic 
activation of PKA speeds the cross bridge kinetics of the mice, i.e the rate of cross bridge 
detachment rate from actin, leading to an enhanced rate of relaxation (52,53). 
Transgenic (TG) mice generated with specific modifications of cardiac TnI have 
been used to establish the potential contribution of PKA phosphorylation of TnI to 
myocardial relaxation. PKA phosphorylation sites S23 and S24 are part of the 27-33 amino 
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acid N-terminal domain that is unique to cardiac TnI and is absent in slow skeletal isoforms. 
Fentzke et al. (54) generated TG mice in which slow skeletal TnI was used to replace 
cardiac TnI, thereby deleting the PKA sites. These TG mice demonstrated an increased 
Ca2+ sensitivity, an increase in the re-lengthening time causing impaired diastolic function.  
To demonstrate the role of PKA phosphorylation of TnI, TG mice were generated 
where the PKA target sites S23 and S24 residues were mutated to aspartic acid (TnI-PP) to 
mimic constitutive phosphorylation (55). The TnI-PP showed enhanced relaxation 
suggesting that PKA phosphorylation of TnI plays a role in diastolic function that into 
changes in the cardiac muscle relaxation Along with PKA, TnI is also a substrate for protein 
kinase C (PKC) at S43, S45 and T144 ( mouse) (56). To determine if it is the PKA and/or 
PKC phosphorylation of TnI that was involved in cardiac contraction or relaxation, 
Sadayappan et al. (57) generated TG mice where PKA and PKC phosphorylation was 
mimicked by replacing S23, S24 (PKA) and S43, S45, and S144 (PKC) by aspartic acid 
(TnI-AllP). The TnI-AllP mice mimic a constant state of complete phosphorylation. The 
TnI-AllP mice were compared to TG mice with only PKA sites S23 and S24 replaced by 
aspartic acid residues (TnI-PP) and to normal healthy mice. The TnI-PP hearts 
demonstrated enhanced contraction/relaxation kinetics and lusitropy i.e. myocardial 
relaxation compared to controls, while the TnI-AllP hearts did not. The authors concluded 
that PKA phosphorylation of TnI plays a role in enhanced myocardial relaxation, while the 
phosphorylation of PKC sites appears to offset the lusitropic effects of TnI-PP. The TG 
models have provided insight into the PKA phosphorylation of TnI in the role of 
myocardial relaxation i.e. diastolic function of mouse heart.  
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Top down mass spectrometry studies of mouse hearts show S23 and S24 with 0, 
1, and 2 phosphates on TnI of 41%, 46%, and 13% with no evidence of phosphorylation at 
sites other than S23, S24 (58,59). In another top-down MS study of spontaneously 
hypertensive mice, a model for hypertension and heart failure, Dong et al. (60) reported 
mono-phosphorylated TnI at 37.5%, bis-phosphorylated TnI at 31.5 % and a very low tris-
phosphorylated TnI at 3.7%. They localized the phosphorylation sites by electron capture 
dissociation fragmentation to be on the PKA targets S23/S24 and the PKC targets S43/S45. 
S23 was the primary phosphorylation site in mono-phosphorylated TnI, and S23/S24 were 
identified as the major phosphorylation sites in the bis-phosphorylated TnI. S43/S45 has 
been detected as a minor phosphorylation sites in bis-phosphorylated TnI but not in mono-
phosphorylated TnI. The same research group extended their studies to human heart biopsy 
samples and reported that the total phosphorylation (S23 and S24) in non-failing hearts was 
49.5% compared to 18.8% in end stage failing hearts (61). 
Dr. Michel J Previs, in his doctoral thesis, measured the degree of phosphorylation 
in normal and failing human heart biopsy samples. He reported a significant decrease in 
phosphorylation of SSNYR (S23 and S24) from 64 ± 3.6 % in normal hearts to 31 ±6.2% 
failing hearts, while no significant difference (statistical) was demonstrated for ISASR 
(S42 and S44) normal hearts (14 ± 1.7%) compared to failing hearts (35 ± 9.5%). No 
significant difference was reported for RPTLR (T143) either, between the normal (5.4 ± 
7.0%) and the failing hearts (20 ± 4.2%) (62). 
Zhang et al. (63) used multiple reaction monitoring mass spectrometry to assess 
end-stage human heart failure biopsies (ischemic heart disease or idiopathic dilated 
cardiomyopathy) compared to non-failing donor hearts. They found that in failing human 
13 
 
heart samples there was a decrease in the extent of phosphorylation of the known PKA 
sites (S22, S23), similar to Dr. Michel J Previs, but reported an increase in phosphorylation 
of the PKC sites (S41, S43, T142). In summary, from the human heart failure studies, we 
observe a significant decrease in PKA phosphorylation of TnI in failing hearts, implicating 
PKA phosphorylation as a determinant of cardiac function.  
1.3.3. PKA phosphorylation targets of MyBPC 
cAMP-dependent PKA phosphorylates both the thin filament protein TnI and the 
thick filament protein MyBPC. Four sites in mouse cardiac MyBPC: S273, S282, S302 and 
S307 (S275, S284, S304 and S311 in human) present in the M-domain region were found 
to be the target for PKA phosphorylation (64). The bacterially expressed C0-C3 fragment 
of mouse cardiac MyBPC when treated with PKA resulted in high phosphorylation of S273 
(100%), S282 (99%), S302 (100%) and S307 (84%), indicating that the four serines are the 
main substrates for PKA (65). 
Phosphorylation of these PKA residues in the M-domain of MyBPC produces a 
conformational change that reduces the interaction between MyBPC and myosin heads 
(66,67), as shown in Figure 1.3A. The myosin heads are available for interaction with the 
thin filament, increasing actomyosin cross bridging during systole. In diastole, MyBPC 
phosphorylation enhances cross-bridging detachment from thin filament and promotes 
myocardial relaxation (47,48,68,69). In the absence of phosphorylation, the MyBPC 
interacts with the myosin head (Figure 1.3B) confining the myosin heads closer to the thick 
filament surface, thus limiting myosin interaction with the thin filament (70).  
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Figure 1.3: Mechanism of MyBPC phosphorylation regulation of cardiac structure. 
Taylor et al. hypothesized that phosphorylation of cardiac MyBPC results in 
reduced myosin binding as shown in Panel A. M-domain labelled in green. This leads to 
enhanced actomyosin cross-bridging, stabilizing the sarcomere. While with de-
phosphorylation (M-domain labelled red) shown in Panel B, MyBPC binds to myosin 
causing reduced thick and thin filament cross-bridging thereby destabilizing the sarcomere. 
From Taylor et al. (67). 
 
Evidence that phosphorylation of MyBPC enhances the myocardial relaxation is 
presented by the mutation studies by Rosas et al. (71). They generated TG mice where 
S273, S282, and S302 in cardiac MyBPC were replaced by aspartic acid to mimic 
phosphorylation (t3SD). They also generated mutant mice to represent absence of 
phosphorylation where S273, S282, and S302 were replaced by alanine (t3SA). The t3SD 
mice were reported to show enhanced myocardial relaxation. The t3SA mice had impaired 
relaxation causing diastolic dysfunction and gave rise to phenotypes that are associated 
with HFpEF. The enhancement of relaxation in t3SD mice and impairment of relaxation in 
t3SA mice was found to be due to changes in the cross-bridging detachment rates. The 
t3SA mice showed not only impaired relaxation, but also were reported to have decreased 
contractile function as well (72). From these mutation studies it can be inferred that 
phosphorylation enhances myocardial relaxation while absence of phosphorylation impairs 
relaxation causing diastolic dysfunction. 
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Normal, healthy mice were found to have three phosphorylated forms of MyBPC 
with one, two or three phosphate groups making up >90% of the MyBPC population, 
indicating that MyBPC is extensively phosphorylated, while mice whose cardiac function 
was compromised by surgical or genetic invasion displayed a decreased MyBPC 
phosphorylation (72). The degree of phosphorylation was measured by Palmer et al. (73) 
in MyBPC isolated from mice (on an iodine deficient diet to induce hypothyroidism) at 
each of the four PKA sites: S273 (76% phosphorylation), S-282 (100%), S302 (31%), and 
S307 (11%).  
Phosphorylation of MyBPC was investigated by Jacques et al. (74) in biopsies 
from patients with hypertrophic cardiomyopathy (failing human hearts) and donor heart 
samples. They reported about 40–45% reduced phosphorylation in MyBPC of failing 
hearts compared to non-failing donor hearts. Moreover, S284 (S282 in mouse) was found 
to show 60% reduced phosphorylation in the heart failure human group compared to donor 
group (75). These results show that reduced MyBPC phosphorylation was observed in end-
stage heart failure. 
The relative contributions to cardiac function by TnI and MyBPC phosphorylation 
by PKA were investigated by Gresham et al. (76). They generated TG mice with PKA 
phosphorylation sites S23 and S24 in TnI replaced by alanine (TnIPKA-) and MyBPC PKA 
phosphorylation sites S273, S282, S302 replaced by alanine (MyBPCPKA-). The TnIPKA- 
mice were bred with MyBPCPKA- to generate mice with no PKA phosphorylation on either 
TnI or MyBPC (DBLPKA-). MyBPC dephosphorylation (represented by MyBPCPKA- and 
DBLPKA- mice) both produced increased wall thickness, i.e. cardiac hypotrophy (phenotype 
of HFpEF). These mice showed impaired systolic and diastolic function. Based on their 
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observations, the authors predicted that MyBPC dephosphorylation contributed to 
prolonged ventricular relaxation. This impaired relaxation was attributed to slow 
actomyosin cross-bridge detachment. They concluded that reduced MyBPC 
phosphorylation may be significant contributor reduced cardiac function. 
The mutation studies with the transgenic models provide insight into the role of 
phosphorylation in the regulation of myocardial function, but these studies represent 
extreme cases where a site is either fully phosphorylated or not phosphorylated at all. A 
critical question remains: are the changes in PKA phosphorylation observed in actual 
failing hearts a cause of heart failure or a result of the condition? 
Studies involving the end-stage myocardium, human or rodent provide a narrow 
view and do not reflect the changes which occur at the onset or during the progression 
towards heart failure. Both mutation studies and end-stage heart failure results have 
reported that impaired relaxation, i.e. diastolic dysfunction, is associated with 
dephosphorylation (for mutation studies) or reduced phosphorylation (end-stage heart 
failure) of the PKA sites in TnI and MyBPC. Our aim is to determine if similar reduced 
phosphorylation of the PKA sites of both TnI and MyBPC are found at the onset of 
symptoms associate with HFpEF, for this we need to select an appropriate mouse model.  
1.4. MOUSE MODEL FOR DIASTOLIC DYSFUNCTION 
Animal models have provided an essential means to understand disease 
pathophysiology and the development of effective therapeutics, particularly in 
cardiovascular diseases where there is limited access to human clinical samples. Two 
extensive reviews detail the animal models that have been successfully established for 
HFpEF (77,78). The animal models of HFpEF are based on aging, diabetes mellitus, and 
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hypertension that are known to be contributing factors to HFpEF. For the current study, 
hypertension that is associated in patients with HFpEF was selected as the phenotype of 
study. Hypertension represents a major contributor to HFpEF, showing a prevalence of 55–
86 % in HFpEF patients (79).  
Transverse aortic constriction (TAC) is a surgical technique in mice inducing 
hypertension leading to pressure overload, causing cardiac hypertrophy, diastolic 
dysfunction, and heart failure (80). To produce TAC, a suture ligature is tied around the 
transverse aorta of young mouse against a needle (placed parallel to the aorta), then the 
needle is removed after the ligature is tied. The needle diameter determines the severity of 
the constriction and the degree of limitation of blood flow. Different diameters have been 
used (e.g. 0.4 mm, 0.385 mm, and 0.375 mm) (81). A 27-gauge needle (0.4-mm outside 
diameter) was used for this study to subject mice to a mild constriction, where the mice 
showed the development of LV hypertrophy, but do not progress to heart failure. Along 
with the surgical constriction, the mice are administered deoxycorticosterone acetate 
(DOCA). DOCA is known to produce myocardial inflammation, oxidative stress, fibrosis 
and diastolic dysfunction (82). A similar model of DOCA-treated TAC mice were reported 
by Mohammed et al. (83) to show normal LV systolic pressure, elevated hypertrophy, 
fibrosis, and diastolic dysfunction, consistent with HFpEF.  
The degree of phosphorylation of the PKA sites in TnI and MyBPC will be 
measured in the TAC mice and normal healthy mice (control) to ascertain the effects of 
PKA phosphorylation at the onset of the symptoms associated with HFpEF and progression 
towards heart failure in the TAC mice.  
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1.5. MASS SPECTROMETRIC QUANTIFICATION OF PHOSPHORYLATION 
Radiolabeling protein with 32P-orthophosphate is one of the oldest methods for 
studying protein phosphorylation. Live cells are incubated with radiolabel, and the kinases 
in the cells will incorporate the radiolabeled phosphate into the substrate protein. The 
proteins are separated by gel, and the radiolabeled band detected. This technique works to 
determine if a protein is phosphorylated or not, but no site-specific information is obtained, 
nor is there any information regarding the kinase involved.  
For determining specific protein kinase activity, in vitro studies incubating the 
kinase and the protein substrate of interest are done in the presence of radiolabeled ATP 
(84). Quantification of the radioactive label incorporated into the substrate gives a measure 
of the enzyme activity. However, this method is labor intensive and needs radioisotopes. 
The availability of phospho-specific antibodies has enabled the study of protein 
phosphorylation in vivo without the use of radioactive material (85). Phospho-specific 
antibodies can be used not only to discriminate between the phosphorylated and the 
unphosphorylated forms, but can be developed to be site specific. Although phospho-
specific antibodies are highly specific and an excellent tool for quantification, the caveat is 
that the technique depends on the specificity and affinity of the antibody for the phospho-
protein of interest, and raising high quality antibody is expensive and time consuming. 
Apart from the above-mentioned methods, other techniques like phosphate-
affinity gel electrophoresis (86,87) have been used to study protein phosphorylation. With 
the advances in mass spectrometric instrumentation, methods, software tools, and 
enrichment techniques, mass spectrometry over last two decades has become an 
indispensable tool for protein research (proteomics) and phosphoprotein research (88,89).  
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1.5.1. Top-down Proteomics 
In top-down mass spectrometry, the intact protein is introduced into the mass 
spectrometer and measured as a whole or major fragments (90). Prior to mass spectrometry, 
the individual proteins need to be separated using techniques like chromatography. One of 
the critical requirements of top down approach is the high resolution mass spectrometers 
needed to detect and identify intact proteins (91) .  
Before the proteins can be detected, they need to be ionized and desorbed into the 
gas phase. By far the most preferred and widely used ionization technique for proteins (as 
well peptides) is electrospray ionization (ESI). ESI generates multiply charged ions that 
bring the molecular ion of even a large protein into the operating mass range of the mass 
analyzer. 
The top-down approach has been used for the identification of modifications like 
phosphorylation based on mass differences between the different forms of protein. 
Quantification of the relative abundance of the phosphorylated to the unphosphorylated 
protein can be directly assessed from the signal intensities of the proteins in the MS because 
of the minimal effect of the modifying groups on the physicochemical properties of the 
whole proteins (92). Ge et al. have used the top-down approach for the quantification of 
phosphorylation in mouse cardiac TnI (59), human cardiac TnI (61), swine cardiac TnI 
(93), and recombinant mouse cardiac MyBPC (94). 
Solubilizing whole proteins and sample handling is a greater challenge compared 
to that of peptides (that are generated in bottom-up approach). Detergents that are used to 
solubilize large proteins are found to be not compatible with the ESI. Proteins are more 
difficult to ionize, hence detection and identification requires high resolution mass 
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spectrometers with the ability to fragment large proteins, like FT-ICR MS (95). Hence, the 
top-down approach is not as routinely done as the more widely applied bottom-up 
proteomics.  
1.5.2.1. Bottom-up Proteomics 
The bottom-up mass spectrometry approach is the most widely used approach for 
characterization and quantification of proteins from a vast range of biological samples. 
Protein identification is based on the peptide analysis generated after proteolytic digestion. 
The most widely used enzyme is trypsin, which specifically cleaves the protein on the C-
terminal end of lysine (K) and arginine (R) (96). The presence of these basic residues, K 
and R, and the N-terminal of each tryptic peptide produces at least two sites that can be 
potentially protonated. Tryptic peptides are therefore readily ionized and detected as 
positive ions.  
Generally, owing to the complexity of proteins in biological samples, a 
fractionation step to isolate the proteins is incorporated prior to trypsin digestion of 
proteins. One dimensional or two-dimensional gel-electrophoresis is used frequently to 
fractionate protein mixtures. This also enables fractionation of high and low abundance 
proteins. The gel piece containing the isolated protein is excised and the protein in the gel 
digested with the protease of choice, usually trypsin. The resulting peptides are then 
extracted out of the gel pieces using solvent mixture contain acetonitrile that solubilize the 
peptides. 
Depending on the size of the protein and the number of K and R residues, each 
protein can produce a complex mixture of peptides of different length. Chromatographic 
separation, mostly reversed-phase chromatography, is used to separate the peptides (97). 
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The peptides are ionized by ESI that generates multiply charged ions. For peptide 
identification, the molecular ion (also called precursor ion) is acquired in the MS scan. 
Then the molecular ion is fragmented by collision-induced dissociation (CID) to generate 
fragment ions (also called product ions) in the MS/MS scan. The N-terminal b-ion 
fragments b1, b2, b3,… and C-terminal y-ions y1, y2, y3…. in the MS/MS spectrum create a 
ladder as shown in the Scheme 1.1.  
 
Scheme 1.1: b- and y-ion nomenclature for sequence ions in mass spectra of peptides 
(98). 
 
An ideal MS/MS spectrum will contain numerous b- and y-ions to build the 
peptide sequence. The mass difference between a b1 ion the adjacent b2 ion corresponds to 
an amino acid residue and so on. Similarly, the y-ion series can be used to build the 
sequence in the reverse order. For each MS/MS spectrum, software is used to correlate the 
theoretical b- and y-ion pattern of the peptide sequence generated from the proteins in the 
search database. This approach of peptide and protein identification is the most widely used 
technique to identify large numbers of proteins. The high-throughput of proteomics mass 
spectrometry is enabled by the combination of both the data acquisition protocols and the 
software tools used to interpret the resulting spectra.  
Phosphorylation can occur at S, T, and Y residues, which constitute about 15% of 
the amino acid residues in proteins. The phosphopeptides can be identified by the loss of 
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the phosphate moiety (-H3PO4) during the MS/MS fragmentation (99), an easily 
recognizable marker for phosphopeptides. Although loss of the phosphate group is an 
advantage for the identification of phosphopeptides, this is often accompanied by very few 
b and y ions that are crucial for building the rest of the peptide sequence. A peptide 
sequence with multiple potential phosphorylation sites needs identification of specific 
fragment ions to localize the phospho-site. Hence, the phosphopeptide identification is a 
challenging task.  
Typically, data-dependent acquisition (DDA) for MS/MS is utilized. DDA 
follows user-defined criteria based on intensity of the ions in the MS scan to select 
precursor ions for subsequent CID fragmentation to generate MS/MS spectra. DDA 
analysis therefore is biased towards the more intense precursor ions. To prevent the 
repetitive selection of the intense precursor ions, dynamic exclusion analysis is used. Once 
a precursor ion has been selected for CID, it is placed in an exclusion list. The ions in the 
exclusion list are not re-selected for another round of MS/MS analysis for a selected period 
of time. Therefore, every time a different set of precursor ions are selected for MS/MS, it 
increases the number of peptides that can be identified, as well as the chance of selection 
of low abundant ions e.g. phosphopeptides.  
Over the last few years, data-independent acquisition (DIA) has become an 
important strategy for the identification and quantification of simple to complex mixtures 
of proteins. The MSE data acquisition method commercialized by Waters, is one such DIA 
(100). In DIA there is no precursor selection step prior to fragmentation. Fragmentation is 
carried out on all the precursor ions present at any given time. The data are collected in 
alternating low and high-energy scans. In the low-energy scan (MS1) the precursor ion data 
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are acquired, giving molecular ion information. In the high-energy scan (MS2), all the 
peptide molecular ions are fragmented, and the resulting fragment ions are acquired. 
Because all charge states of a peptide are fragmented simultaneously, enhanced product 
ion intensity is obtained. However, simultaneously co-eluting precursor ions will also be 
fragmented. This produces a complex fragment-ion spectrum of all the precursor ions with 
no direct correlation of the precursor to product ions. To associate product ions and 
precursor ions, advanced software algorithms are used to align the retention time apex, and 
peak shape of the product ions and precursor ions (101). 
We have used two software approaches to process and align MSE data files. The 
data analysis package ProteinLynx Global Server (PLGS) developed by Waters is used to 
process the MSE data to construct precursor and product ion spectra and perform the protein 
database searches (102). Progenesis (NonLinear Dynamics, UK) is a second feature-based 
search engine, which allows multi-run alignments based on alignment of all MS1 ions 
(defined as features) and retention times and determine their abundance (103). Because the 
low and the high-energy scans are acquired at regular intervals during the LC run, the peak 
areas of the precursor ions in the low energy scan can be used to measure the amounts of 
the sample.  
1.5.2.2. Quantification of phosphorylation by bottom-up MS 
Quantification of phosphorylation is carried out by determining the fraction of 
peptide phosphorylated, 𝑝𝑝  
𝑝𝑝 =  𝑛𝑛𝑝𝑝  
𝑛𝑛𝑜𝑜  + 𝑛𝑛𝑝𝑝   (1.1) 
where 𝑛𝑛𝑝𝑝 is the amount phosphorylated, and 𝑛𝑛0 is the amount of unphosphorylated peptide.  
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The simplest approach would be determine the ratio of phosphopeptide to the 
unphosphorylated peptide, 𝑛𝑛𝑝𝑝 𝑛𝑛0� , from which 𝑝𝑝 can be calculated. The measured signal 
intensity for any peptide by mass spectrometry, 𝐼𝐼𝑖𝑖, is linearly related to the amount of 
peptide, 𝑛𝑛𝑖𝑖. 
𝐼𝐼𝑖𝑖   =  𝑘𝑘𝑖𝑖𝑛𝑛𝑖𝑖   (1.2) 
where 𝑘𝑘𝑖𝑖 is the ionization or constant. 
The phosphorylated peptide,  
𝐼𝐼𝑝𝑝   =  𝑘𝑘𝑝𝑝𝑛𝑛𝑝𝑝  (1.3) 
to the unphosphorylated peptide,  
𝐼𝐼𝑜𝑜   =  𝑘𝑘𝑜𝑜𝑛𝑛𝑜𝑜  (1.4) 
ratio is  
𝑛𝑛𝑝𝑝
𝑛𝑛0� =  𝐼𝐼p 𝑘𝑘p�𝐼𝐼0
𝑘𝑘0
�
=  𝐼𝐼p
𝐼𝐼0
�
𝑘𝑘0
𝑘𝑘p
� (1.5) 
where subscript ‘0’ refers to the unphosphorylated peptide, and subscript ‘p’ refers to the 
phosphorylated peptide, 𝐼𝐼0= signal intensity of unphosphorylated peptide, 𝐼𝐼𝑝𝑝= signal 
intensity of phosphorylated peptide. 
Relative changes between different conditions (like samples, treatment, disease 
states etc.) can be taken without determining the ionization efficiency ratio because the 
ionization constants cancel (104).  
�
𝑛𝑛𝑝𝑝
𝑛𝑛0� �𝐴𝐴
�
𝑛𝑛𝑝𝑝
𝑛𝑛0� �𝐵𝐵
=  �𝐼𝐼p 𝐼𝐼0� �𝐴𝐴
�
𝐼𝐼p
𝐼𝐼0
� �
𝐵𝐵
  (1.6) 
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where subscripts A and B are two conditions. In reality, 𝑘𝑘𝑝𝑝 𝑘𝑘0�  varies over time and 
therefore cannot be cancelled.  
Another approach to determine phosphorylation is the absolute quantification 
(AQUA) strategy by Gerber et al. (105). This technique is based on the use of synthetized 
stable isotopically labeled (SIL) peptides as internal standards for the quantification. A 
known amount of the SIL peptides (with and without phosphorylation) is added into the 
sample as internal standards. The measured signal intensity for SIL peptide by mass 
spectrometry,(𝐼𝐼𝑖𝑖∗) also is linearly related to the amount of the SIL peptide added, (𝑛𝑛𝑖𝑖∗). 
𝐼𝐼𝑖𝑖∗   =  𝑘𝑘𝑖𝑖∗𝑛𝑛𝑖𝑖∗  (1.7) 
where 𝑘𝑘𝑖𝑖∗ is the ionization constant. The ionization constant is expected to be the same 
between a labeled and unlabeled version of the peptide, i.e.𝑘𝑘𝑖𝑖 = 𝑘𝑘𝑖𝑖∗. Therefore, the amount 
of amount of phosphorylated peptide (𝑛𝑛𝑝𝑝) is given by  
𝑛𝑛𝑝𝑝 =  𝑛𝑛𝑝𝑝∗ � 𝐼𝐼p𝐼𝐼p∗� (1.8) 
where 𝑛𝑛p∗= amount of phosphorylated SIL peptide added and 𝐼𝐼𝑝𝑝= signal intensity of 
phosphorylated peptide, 𝐼𝐼p∗= signal intensity of SIL phosphorylated peptide. Similarly, the 
amount of the unphosphorylated peptide can be determined by  
𝑛𝑛0 =  𝑛𝑛0∗ � 𝐼𝐼0𝐼𝐼0∗� (1.9) 
where 𝑛𝑛0∗= known amount of unphosphorylated SIL peptide added, 𝐼𝐼0= signal intensity of 
unphosphorylated peptide, 𝐼𝐼0∗= signal intensity of SIL unphosphorylated peptide. The SIL 
peptide approach quantifies both the amounts of phosphorylated and the unphosphorylated 
peptides directly. This approach allows for multisite phosphorylation measurements (106).  
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1.6. STATEMENT OF PURPOSE 
The studies described here aim to develop an LC-MS method for the 
quantification of PKA phosphorylation sites in TnI and MyBPC. The method will be used 
to measure changes in phosphorylation in the left ventricle of TAC-treated and normal 
mice, where TAC represents a model of HFpEF.  
The first approach was to implement the SIL peptide quantification strategy by 
Gerber et al (105) for the quantification of phosphorylation in TnI. For this purpose, SIL 
peptides were procured for the target peptides in TnI with and without phosphorylation. 
Sites with multiple phosphorylation sites within the peptides were also generated. The aim 
was to add a known amount of the SIL peptides (with and without phosphorylation) to the 
sample as internal standard to determine phosphorylation stoichiometry by measuring the 
absolute amounts of the phosphorylated and the unphosphorylated forms.  
To apply the SIL peptides for quantification purposes, it is imperative to know the 
concentration accurately of each of the SIL peptides used as internal standards. Usually 
SIL peptides are procured in small amounts (nanomole) owing to their cost. Most 
researchers rely on the concentration provided by the manufacturer. In Chapter 2 we report 
developing a highly sensitive multiple reaction monitoring (MRM) LC-MS method for the 
quantification of SIL peptides. The method developed uses picomole amounts, i.e. only a 
fraction of the sample for the assay, making the method accessible for routine analysis. 
Prior to applying the SIL peptides for quantification, the ionization efficiency of 
these phospho-peptides was studied in detail in Chapter 3. The literature reports challenges 
related to phosphopeptides measurements: a) lower ionization efficiency of the 
phosphopeptides, b) selective suppression of the ionization of the phosphopeptides in the 
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presence of co-eluting peptides, and c) the loss of phosphopeptides during chromatography. 
Although Steen et al. (107) reported results that show phosphorylation does not affect the 
ionization or chromatography, the peptides studied by them were 7 to 17 amino acids in 
length. The peptides of interest in cardiac TnI are smaller, 5 amino acids in length and can 
have up to two phosphate groups. Chapter 3 details the effect of phosphate groups on the 
ionization of these smaller peptides and the evidence of selective adsorption of 
phosphopeptides in the LC-MS system, limiting the use of SIL peptides for the 
phosphorylation quantification in TnI.  
Chapter 4 describes the final LC-MS method developed for measurement of 
phosphorylation of TnI and MyBPC. The method expands on the method previously 
developed by Previs et al. (108). The main objective was to circumvent the isolation of 
proteins using gel electrophoresis and carry out a direct analysis of myofibrillar protein 
preparations. The amount of proteins recovered by the in-solution digestion and in-gel 
digestion were compared to determine the advantage of in-solution digestion over in-gel 
digestion. Additionally, a data-independent acquisition strategy (MSE) was applied for the 
identification and quantification of phosphorylation of myofibrillar proteins in mouse 
hearts. The methodology was first tested out on cadaver human heart samples and then 
successfully applied to the TAC and normal mouse heart samples.  
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CHAPTER 2: STABLE ISOTOPE LABELED PEPTIDE QUANTIFICATION 
2.1. INTRODUCTION 
For proteomic quantification, targeted MS techniques can be used by the addition 
of known internal standard to the sample. The best internal standards are stable isotope 
labeled (SIL) standards that are expected to behave identically to the target but can be 
distinguished by mass spectrometry owing to the mass difference (109). In bottom-up 
proteomics, there are three approaches to introduce a SIL standards. i) Commercially 
synthesized SIL peptides with their sequence mimicking the target peptide of interest (110). 
ii) Synthesized artificial QconCAT proteins with labeled residues that are comprised of a 
concatenation of the peptides used to quantify proteins of interest (111). iii) PSAQ 
standards (protein standard absolute quantification) that are full-length SIL proteins with 
their sequence matching the target protein (112). 
In our research laboratory, we have used the AQUA (absolute quantification) 
strategy using SIL peptides presented by Dr. Steve Gygi for developing targeted 
quantitative proteomics techniques (105). The synthetic SIL peptides correspond to the 
target peptides with a SIL amino acid (13C and/or 15N) incorporated into its sequence. The 
synthetic SIL peptides are expected to be chemically and physically indistinguishable from 
their corresponding native peptide in terms of retention time, ionization efficiency and 
fragmentation mechanism. It is the 13C and/or 15N labeling that creates an increase in the 
molecular weight (4-10 Da) relative to the native target peptide. Quantification is then 
achieved by the addition of a known amount of the SIL peptide to the protein sample before 
or after proteolytic digestions and subjected simultaneously to LC-MS analysis (109). The 
peak intensities of the SIL peptide and the sample peptide generated during digestion are 
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measured. Quantification of the sample is based on the ratio of the peak intensities between 
the sample and the isotopically labeled standard. Because the sample peptide and the added 
labeled peptides have identical chromatographic and mass spectrometric behavior but 
different m/z’s, the MS can measure them simultaneously (113). The simultaneous 
measurement eliminates variations in the performance of both the LC and MS and enables 
accurate quantification. 
The SIL peptides are usually synthesized by solid-phase peptide synthesis (SPPS), 
each synthetic peptide chromatographically purified, tested for homogeneity and quantified 
by the amino acid analysis (AAA) technique (114). This laborious process makes the 
synthesis of multiple pure SIL peptides expensive. Typically, the SIL peptides are 
purchased in small (e.g. nmol or pmol) amounts, and researchers mostly rely on the 
company producing the peptides for quantification without independently verifying the 
purity or concentration when supplied in solution. 
The analytical accuracy of the assay using the SIL peptides depends directly on 
the knowledge of the concentration and the purity of the SIL peptides to start with. Factors 
such as storage and handling conditions of the SIL peptides are also crucial (115). 
Therefore, synthetic SIL peptides must be checked routinely for the proper amino acid 
composition and concentration. There is a need for a highly sensitive, reliable assay to 
determine the concentration of these SIL peptides. Developing such an assay for 
quantification of SIL peptides is the focus of this chapter.  
Trypsin is the protease of choice in proteomics mainly because of its high 
proteolytic activity and cleavage specificity. Trypsin cleaves peptide bonds at the C-
terminal side of lysine and arginine amino acid residues. Theses resides are positively 
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charged in acidic conditions, making trypsin the protease of choice in mass spectrometry-
based proteomics as well. Hence most widely used SIL peptides are tryptic peptides that 
have either a lysine or an arginine C-terminus residue. Therefore, a generic method for the 
quantification of all tryptic SIL peptides can be accomplished by the selective 
quantification of the lysine and the arginine residues generated on hydrolysis. In this 
chapter we discuss an LC-MS assay of the SIL tryptic peptides by the selective 
quantification of lysine and arginine residues. High selectivity and sensitivity are achieved 
by implementing the multiple reaction monitoring (MRM) technique of the triple 
quadrupole MS (116). 
2.2. MATERIALS AND METHODS 
2.2.1. Chemicals and Reagents 
L-arginine, L-lysine hydrochloride, L-[13C6,15N2]lysine hydrochloride 
(abbreviated [M+8]lysine) were obtained from Sigma. L-[13C6]arginine (abbreviated 
[M+6]arginine) was bought from Cambridge Isotope Laboratories. L-[1,2-13C2]alanine 
(abbreviated [M+2]alanine) was obtained from Merck and Co., Inc, L-[2,3,3,3-2H4]alanine 
(abbreviated [M+4]alanine) was procured from KOR Isotopes. L-[4,5,5,5,5′,5′,5′-
2H7]leucine (abbreviated [M+7]leucine) from CDN Isotopes, and L-[5,5,5-2H3]leucine 
(abbreviated [M+3]leucine) was purchased from Isotec. HPLC grade water and acetonitrile 
were purchased from Fisher Scientific, and formic acid from J.T. Baker. AccQ, a Fluro 
reagent kit (consisting of the 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate (AQC) 
reagent, acetonitrile, and the sodium borate buffer) was purchased from Waters Corp. 
Cell Signaling Technology (Danvers, MA, USA) provided the labeled synthetic 
tryptic peptide standards (Table 2.3). We procured 250-μl aliquots of tryptic SIL peptides 
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of mouse cardiac troponin I: SSANYR with [13C9,15N]tyrosine (Y*) (abbreviated 
[M+10]tyrosine), RPTLR with [13C6,15N]leucine (L*) (abbreviated [M+7]leucine), and 
ISASR with [13C3,15N]alanine (A*) (abbreviated [M+4]alanine). The peptides included the 
correctly cleaved forms as well as the miscleaved forms and with one phosphate or two 
phosphate groups on serine or threonine. The expected concentration range for the SIL 
tryptic peptides from the information given by the manufacturer was 300-500 pmol/μl.  
2.2.2. Sample Preparation 
A set of stock solutions for lysine, arginine, [M+4]alanine, [M+7]leucine and the 
internal standards [M+8]lysine, [M+8]arginine, [M+2]alanine, and [M+3]leucine were 
prepared. Five-point calibration curves were prepared with the concentration of lysine and 
arginine, and [M+4]alanine and [M+7]leucine ranging from 0 to 200 fmol/µl. Synthetic 
tryptic SIL peptides were diluted in HPLC water, and aliquots of 10 μl each (about 10 
pmol) were taken. Each of the calibration point sample and each SIL peptide sample was 
spiked with a constant amount of 100 fmol/µl of the internal standards [M+8]lysine, 
[M+6]arginine, [M+2]alanine, and [M+3]leucine. Hydrolysis of the samples was achieved 
in sealed glass reaction vials.  The aliquots were heated in 50 μl of 6 M HCl at 110 °C for 
2 hours. The hydrolysates were dried under nitrogen before derivatization. 
The dried samples were re-solubilized in 80 μl of the 0.2 M borate buffer at pH 
8.5 provided in the Water AQC-kit. A 20-μl aliquot of 10-mM AQC reagent prepared in 
acetonitrile was added, vortexed, followed by heating at 55 °C for 10 min to form the amino 
acid-AQC derivatives. Derivatization was performed using the Waters AQC protocol. The 
samples were allowed to cool to room temperature and 1-μl aliquots were injected into the 
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LC-MS for analysis. Both the calibration aliquots and the SIL peptide samples were treated 
to the same hydrolysis and derivatization procedures. 
A clean step was added to remove the protein contamination in the reaction vials. 
All the reaction glass vials were acid cleaned by heating 50 μl of 6 M HCl at 110 °C for 2 
hours and then the reaction vials were rinsed in distilled water and pyrolyzed at 450 °C for 
2 hours. 
2.2.3. LC-MS Analysis 
An AB SCIEX 4000 QTRAP triple quadrupole/linear ion trap mass spectrometer 
with a Shimadzu LC20AD HPLC were used for the analysis. Separation of the amino acid-
AQC derivatives was achieved on a C18 column (Phenomenex Jupiter 5μm C18 300 Å, 
150 mm x 1 mm column). The mobile phase consisted of water with 0.1% formic acid 
(solvent A) and acetonitrile with 0.1% formic acid (solvent B). The gradient started at 5% 
B and was increased in 2 min to 16% followed by a slower linear ramp to 34% in the next 
12 mins. The gradient was raised to 95% B within the next 1 min, followed by a 4-min 
isocratic at 95% to clean the column. Solvent flow rate was set at 80 μl/min. 
The MS was operated in positive ESI mode. The ion source parameters were set 
to ion spray voltage at 5500 V, temperature of ion source at 400 °C, curtain gas at 30 psi, 
nebulizer gas at 30 psi, drying gas at 40 psi, collision gas at 10 psi, entrance potential at 10 
V and collision cell exit potential at 8 V.  
Direct infusion experiments were carried out to optimize the analyte-specific 
parameters: declustering potential (DP) and collision energy (CE). The DP voltages were 
optimized by ramping the DP voltage from low to high to ensure maximum efficiency of 
the ion transfer of the precursor ion into the MS instrument. The CE was optimized by 
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ramping the CE voltage to maximize the generation of the fragment ion in MS/MS. This 
optimization ensures maximum signal intensities for each of the MRM transitions. The 
prominent precursor and product ion and the most favorable DP and CE parameters to 
obtain the best sensitivity for each MRM transition are listed in Table 2.1. Q1 and Q3 were 
set at a unit resolution for the MRM acquisitions with a 200 msec dwell time for each MRM 
transition. 
2.2.4. Data Analysis 
Analyst 1.5 software was used to automatically integrate the area under the 
respective MRM chromatograms of AQC derivatized lysine and arginine and the internal 
standards [M+8]lysine and [M+6]arginine. The same quantification method was used for 
both the calibration points and the tryptic SIL peptide hydrolysates. The area for the 
unlabeled, 𝐴𝐴𝑢𝑢 (lysine and arginine) and the internal standards, 𝐴𝐴𝑙𝑙 ([M+8]lysine and 
[M+6]arginine) were measured. For the standard calibration curves, the area ratio 𝑅𝑅𝑢𝑢
𝑙𝑙�
  is 
determined for each point by: 
𝑅𝑅𝑢𝑢
𝑙𝑙�
   = �𝐴𝐴𝑢𝑢 𝐴𝐴𝑙𝑙� � (2.1) 
The area ratio, 𝑅𝑅𝑢𝑢
𝑙𝑙�
 is a linear function of the mole ratio of the unlabeled 𝑛𝑛𝑢𝑢 and the internal 
standard 𝑛𝑛𝑙𝑙  defined by the linear regression equation: 
𝑅𝑅𝑢𝑢
𝑙𝑙�
   = 𝑅𝑅0
𝑙𝑙�
+  𝑘𝑘𝑢𝑢
𝑙𝑙�
   �𝑛𝑛𝑢𝑢 𝑛𝑛𝑙𝑙� � (2.2) 
where, 𝑘𝑘𝑢𝑢
𝑙𝑙�
   is the molar response factor of the LC-MS (ideally unity) and 𝑅𝑅0
𝑙𝑙�
 is the area 
ratio measurement when only internal standard, 𝑛𝑛𝑙𝑙, is injected (ideally zero). The equation 
can be rearranged to measure the mole ratio as a function of the measured area ratio. 
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𝑛𝑛𝑢𝑢 𝑛𝑛𝑙𝑙� =  [𝑅𝑅𝑢𝑢 𝑙𝑙�    −  𝑅𝑅0 𝑙𝑙�   ]𝑘𝑘𝑢𝑢
𝑙𝑙�
    (2.3) 
The amount of unlabeled i.e. the arginine or lysine produced on hydrolysis of the 
synthetic tryptic peptides can be determined by the measured area ratio and the moles of 
internal standard by rearranging Eq. (3) 
𝑛𝑛𝑢𝑢 =  𝑛𝑛𝑙𝑙 �𝑅𝑅𝑢𝑢 𝑙𝑙�    −  𝑅𝑅0 𝑙𝑙�   𝑘𝑘𝑢𝑢
𝑙𝑙�
   � (2.4) 
2.3 RESULTS AND DISCUSSION 
There are a plethora of derivatization reagents that have been used in liquid 
chromatography/electrospray ionization, especially for small molecules, to improve 
chromatographic retention, ionization enhancement and MS/MS fragmentation (117-119). 
For amino acids, derivatization reagents can either react with the amino and/or the 
carboxylic acid group. Uutela et al. (120) and Rebane et al. (121) compared different amino 
acid derivatization reagents. Among the available reagents, we selected AQC–tag, because 
the reagent 6-aminoquinolyl-N- hydroxysuccinimidyl carbamate (AQC) reacts readily (t1/2 
< 1 s) with both primary and secondary amino acids to give stable urea derivatives. There 
is no interference from the excess reagent and each AQC derivatized amino acid can be 
chromatographically separated (122). The general scheme of the AQC reaction is: 
+ +
OH
N
O
O
NH2 R
OHO
Amino acid (AA) 6-aminoquinolyl-N- 
hydroxysuccinimidyl 
carbamate (AQC)
AQC-AA N-Hydroxyscccinimide
N
H
N
O
O
N
O
O
N
H
N
O
H
N R
HO O
 
Scheme 2.1: Derivatization schematic of AQC reaction with amino acids. 
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To determine the precursor and fragment ions for the MRM transitions, MS and 
MS/MS spectra were obtained for each of the AQC derivatized amino acids. The mass 
spectrum of AQC-lysine is shown in Figure 2.1A. AQC derivatized lysine showed an 
increased in the lysine mass by 340 Da, indicating an addition of two AQC derivative units. 
The singly charged molecular ion is at m/z 487, and the predominant ion is the doubly 
charged molecular ion at m/z 244. Figure 2.1B shows the MS/MS spectrum of the 
predominant doubly charged ion, m/z 244 at the optimized DP and CE conditions. The 
most intense fragment ion is m/z 171, corresponding to the AQC derivative fragment.  
The mass spectrum of AQC-[M+8]lysine has the doubly charged ion at m/z 248 
as the predominant molecular ion shown in Figure 2.1C. The corresponding MS/MS 
spectra also produced the fragment at m/z 171 at the optimized DP and CE conditions 
(Figure 2.1D). Based on the MS and the MS/MS spectra, the MRM transitions were 
selected to be m/z 244171 and m/z 248171 for AQC-lysine and AQC-[M+8]lysine 
respectively.  
The mass spectrum for AQC-arginine is shown in Figure 2.2A. A singly charged 
molecular ion at m/z 345 and the predominant doubly charged molecular ion at m/z 173 
were observed. In the case of arginine, there is an addition of only one AQC derivative 
unit. The MS/MS spectrum of the doubly charged ion m/z 173 shown in Figure 2.2B 
generates the predominant fragment m/z 171 of the AQC fragment and a second fragment 
at m/z 175. This m/z 175 fragment corresponds to the ion with the charge on the arginine 
fragment as shown by the structure in the inset (Figure 2.2B). 
The AQC-[M+6]arginine produced the doubly charged ion at m/z 176 as the 
predominant molecular ions. The MS/MS of m/z 176 produced the expected AQC-
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fragment, m/z 171 and the corresponding arginine fragment at m/z 181. The MS and 
MS/MS spectrum are given in Figure 2.2C and D respectively. The transitions m/z 
173171 and m/z 176171 were selected for MRM for AQC-arginine and AQC-
[M+6]arginine respectively. All the MRM transitions and their optimized instrument 
parameters are summarized in Table 2.1. 
 
 
Figure 2.1: MS and MS/MS spectra of AQC-lysine and AQC-[M+8]lysine.  
A 20-pmol aliquot of each amino acid was injected on to the column  
A) MS spectrum of AQC-lysine, Q1MS scan at high resolution from 150-550 Da with the 
DP ramp of 40-80 V.  
B) Product ion (MS/MS) spectrum of AQC lysine with Q1 and Q2 at unit resolution 
scanned from 50-500 Da at the optimized DP and CE conditions.  
C) MS spectrum of AQC-[M+8]lysine with same conditions as the AQC-lysine. 
D) Product ion (MS/MS) spectrum of AQC-[M+8]lysine at the optimized DP and CE. 
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Figure 2.2: MS and MS/MS spectra of AQC-arginine and AQC-[M+6]arginine.  
A 20-pmol aliquot of each amino acid was injected on to the column. 
A) MS spectrum of AQC-arginine, Q1MS scan at high resolution from 150-550 Da with a 
DP ramp of 40-80 V.  
B) Product ion (MS/MS) spectrum of AQC-arginine with Q1 and Q2 at unit resolution 
scanned from 50-500 Da at optimized DP and CE.  
C) MS spectrum of AQC-[M+6]arginine at the same conditions as AQC-arginine. 
D) Product ion (MS/MS) spectrum of AQC-[M+6]arginine at the optimized  DP and CE 
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Table 2.1: MRM transitions and the optimized instrument parameters 
Amino acid Precursor ion Product ion DP CE 
Lysine 244 171 50 22 
[M+8]Lysine 248 171 50 22 
Arginine 173 171 40 18 
[M+6]Arginine 176 171 40 18 
Q1 and Q3 were at unit resolution. 
 
The MRM chromatogram of AQC-lysine (244 171) and AQC-arginine 
(173171) is shown in Figure 2.3A and Figure 2.3B displays the labeled internal standards 
AQC-[M+8]lysine (248171) and AQC-[M+6]arginine (176171). AQC-lysine and 
AQC-[M+8]lysine eluted at the same retention time of 10.6 min, while the AQC-arginine 
and AQC-[M+6]arginine eluted together at 9.1 min.  
We observed an additional peak at 11.4 min for the transition (244171) that 
matched with the lysine transition (244171). All the standard amino acids for calibration 
curves were subjected to hydrolysis and derivatization, as per the SIL peptide samples. The 
peak at 11.4 min was found to be an artifact of the hydrolysis, which is confirmed by the 
absence of the peak in Figure 2.3C where the standards were not subjected to hydrolysis 
prior to derivatization. The LC profile described in the experimental section enabled the 
separation of this hydrolysis artifact transition from the lysine MRM transition. 
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Figure 2.3: MRM chromatogram of AQC-lysine, AQC-arginine and AQC-
[M+8]lysine, AQC-[M+6]arginine. 
A total of 100 fmol of lysine, [M+8]lysine, arginine, and [M+6]arginine were 
injected on to the column.  
A) The extracted ion chromatogram of lysine and arginine LC-MRM run.  
B) The extracted ion chromatogram of [M+8]lysine and [M+6]arginine.  
C) The extracted ion chromatogram of lysine and arginine LC-MRM run with no 
hydrolysis step prior to derivatization showing the disappearance of the hydrolysis artifact 
peak at 11.4 in A)  
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A standard calibration curve of lysine with the internal standard [M+8]lysine was 
prepared, plotting the measured MRM area ratios, 𝑅𝑅𝑢𝑢
𝑙𝑙�
 of AQC-lysine and AQC-
[M+8]lysine against the corresponding mole ratios, �𝑛𝑛𝑢𝑢 𝑛𝑛𝑙𝑙� � as defined by Eq. 2.2. The 
lysine calibration curve is shown in Figure 2.4A. The lysine linear regression ± SE is:  
𝑅𝑅𝑢𝑢
𝑙𝑙�
   = (0.113 ±  0.019) + (0.913 ±  0.019 )�𝑛𝑛𝑢𝑢 𝑛𝑛𝑙𝑙� �. 
Figure 2.4B displays the calibration curve generated for arginine with the internal standard 
[M+6]arginine. The the arginine linear regression ± SE is: 
𝑅𝑅𝑢𝑢
𝑙𝑙�
   = (0.143 ±  0.014 ) + (0.992 ±  0.014 )�𝑛𝑛𝑢𝑢 𝑛𝑛𝑙𝑙� �. 
Both the curves were found to be linear (𝑟𝑟2 = 0.999) in the range of analytical interest (0 
to 20 pmol). The 95% confidence limit of the regression line and the SE of the intercept 
from the calibration curves were used to determine the limit of detection (LOD). The 
LOD’s were calculated to be 4.51 fmol/μl for lysine and 3.10 fmol/μl for arginine, i.e. 0.45 
pmol and 0.31 pmol in the sample vial of 100 μl for lysine and arginine, respectively.  
The molar response factor (slope) for the lysine curve was found to be statically 
different from unity. This could be attributed to the concentration of the internal standards 
being greater than that calculated. This small deviation from unity will not affect the 
linearity of the calibration curves or the measurements because the same amount of the 
internal standard is also added to the samples as well. However, the nonzero intercept of 
both lysine and arginine calibration curves indicates a background of amino acid that needs 
to be characterized.  
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Figure 2.4: Calibration curves of A) lysine and B) arginine. 
Each point on the graph represents the mean of four replicates with the error bar 
representing the standard error (SE).  
A) The slope and the intercept with SE for lysine/[M+8]lysine calibration curve are 0.913 
± 0.019 and 0.113 ± 0.019 respectively with r2 of 0.999. 
 B) The arginine/[M+6]arginine curve had the slope and the intercept of 0.992 ± 0.014 and  
0.143 ± 0.014 respectively with r2 of 0.999.  
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2.3.1. Background characterization 
To determine if the background lysine and arginine are due to the hydrolysis of 
protein contamination in the reaction vials, an aliquot containing just the internal standards 
[M+8]lysine and [M+6]arginine (i.e. no lysine or arginine) was taken for characterization 
of the contamination. AQC derivatization was performed with and without hydrolysis. The 
amount of background arginine or lysine,𝑛𝑛0, was determined by the measured area 
ratio 𝑅𝑅0
𝑙𝑙�
 when only internal standard, 𝑛𝑛𝑙𝑙, was injected: 
𝑛𝑛0 =  𝑛𝑛𝑙𝑙 �𝑅𝑅0 𝑙𝑙�   � (2.5) 
The total amount of lysine increased from 0.19 ± 0.02 pmol with no hydrolysis to 4.39 ± 
0.50 pmol when hydrolysis was carried out indicating that the background was generated 
due to hydrolysis of protein contamination in the reaction vials. A similar increase was 
observed for arginine from 0.76 ± 0.02 pmol with no hydrolysis to 5.93 ± 0.50 pmol when 
the hydrolysis step was included. The results are summarized in Table 2.2.  
The protein background after hydrolysis should produce other amino acids as 
well. Like lysine and arginine, all amino acids react with AQC and produce the m/z 171 
fragment ion on MS/MS (123). To check for the presence of other amino acids, a precursor 
ion scan was performed where the third quadrupole Q3 was fixed on m/z 171, while 
scanning the first quadrupole Q1. The precursor ion scan was performed on a blank. To 
amplify the protein contamination to a substantial amount to be identified by precursor 
scan, the blank was hydrolyzed multiple times, every time in a new reaction vial using the 
same conditions as described in the sample preparation. After the initial 2-hour hydrolysis 
in a reaction vial, the blank was transferred to a new reaction vial and the hydrolysis 
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continued for another 2 hours. This step was repeated in two more reaction vials. Post 
hydrolysis derivatization was carried out using the AQC derivatization protocol.  
Figure 2.5A shows the total ion chromatogram (TIC) of the precursor ion scan at 
m/z 171. The chromatogram clearly shows the AQC-amino acids generated from the 
hydrolysis of protein contamination from the reaction vials separated on the C18 column. 
Figure 2.5B shows the extracted ions chromatogram of each of the identified amino acids 
labeled by the corresponding abbreviation in the figure. The large peak at 8.3 min 
corresponding to precursor m/z 188 and the peak at 16.6 min corresponding to m/z 315 
identified to be products of the AQC reagent itself. Hydrolysis of AQC reagent results in 
6-aminoquinoline (AMQ), N-hydroxysuccinimide and carbon dioxide. The presence of 
excess AQC was found to generate adducts with ammonia (m/z 188) and with AMQ to 
produce a di-urea, N,N’-bis (6-quinolinyl)urea (m/z 315) (122).  
To reduce the protein background from the reaction vials, the vials were acid 
cleaned and then pyrolyzed at 450 °C for 2 hours prior to use. To prevent any external 
contamination the entire procure was done under the hood wearing nitrile gloves. In the 
aliquots containing just the internal standards [M+8]lysine and [M+6]arginine (i.e. no 
lysine or arginine) the background lysine and arginine in cleaned reaction vials was found 
to be 1.13 ± 0.07 pmol and 1.73 ± 0.11 pmol for lysine and arginine respectively. We found 
almost a four-fold decrease in the background in the cleaned vials. The results comparing 
the unclean and cleaned reaction vials with and without hydrolysis, are summarized in 
Table 2.2. The cleaned reaction vials were used for all the subsequent calibration standards 
and the SIL peptide preparations. 
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Figure 2.5: Precursor ion scan of hydrolyzed blank. 
A 10-μl aliquot of the derivatized blank was injected on to the column.  
A) TIC of the precursor ion scan of m/z 171. Scanned from 150-600 Da at a DP of 45 V 
and CE of 20.  
B) The extracted ion chromatograms of the identified amino acids, arginine (R), serine (S), 
glycine (G), aspartic acid (D), glutamic acid (E), threonine (T), alanine (A), proline (P), 
lysine (K), valine (V), isoleucine( I)/ leucine (L) and phenylalanine (F) and the peaks 
marked * are the AQC adducts. 
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Table 2.2: Total amount of the background lysine and arginine 
Reaction condition Reaction vials cleaning 
Amount 
 (pmol K)  
Amount  
(pmol R) 
No hydrolysis, Only AQC No 0.19 ± 0.02 0.76 ± 0.02 
Hydrolysis + AQC No 4.39 ± 0.50 5.93 ± 0.50 
Hydrolysis + AQC Acid cleaned and pyrolyzed 1.13 ± 0.07 1.73 ± 0.11 
Evaluated over 7 days, 4 replicates each. N = 28, error represented by SE. 
 
2.3.2. Quantification of SIL peptides 
A preliminary evaluation of the purity of tryptic SIL peptides procured was 
carried out by MS to check for the molecular ion and the peptide sequence verified by 
MS/MS (124). About 10-pmol aliquots of SIL tryptic peptides were taken for the 
hydrolysis and AQC derivatization. The internal standards [M+8]lysine and [M+6]arginine 
were added to each replica prior to the hydrolysis. The calibration curves shown in Figure 
2.4 were used to determine the concentration of K and/or R. The concentration of the SIL 
peptides was estimated taking into consideration the number of K or R residues in the 
peptide sequence.  
The concentration of the peptides procured determined using the MRM-LC-MS 
method are summarized in Table 2.3. In the peptides analyzed, the lowest in concentration 
was ISPA*SPR (126.7 ± 3.7 pmol/ μl) and the highest concentration was ISA*SPRK (2096.5 
± 39.5 pmol/μl), clearly a wider concentration range than expected. These results reiterate 
the need for the accurate determination of the concentration of SIL peptides before they 
can be used as internal standards.  
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Table 2.3: SIL tryptic peptides quantification based of arginine and lysine 
quantification by MRM-LC-MS 
 Quantification 
 based of arginine 
Quantification 
 based of lysine 
SIL peptide pmol/μl ± SE pmol/μl ± SE 
SSANY*R 544.0 ± 11.2  ±  
SSPANY*R 392.3 ± 13.5  ±  
RSSANY*R 185.9 ± 2.7  ±  
RSSPANY*R 571.2 ± 18.4  ±  
RSPSA*NY*R 442.7 ± 5.6  ±  
RSPSPANY*R 578.1 ± 9.1  ±  
RRSSPANY*R 244.8 ± 6.0  ±  
RRSPSA*NY*R 221.1 ± 6.2  ±  
RRSPSPA*NY*R 353.8 ± 6.4  ±  
ISASR 590.7 ± 9.4  ±  
ISA*SR 726.2 ± 19.5  ±  
ISA*SPR 513.4 ± 11.1  ±  
ISPA*SR 1062.4 ± 28.7  ±  
ISPA*SPR 121.1 ± 6.0  ±  
ISA*SRK 653.0 ± 13.1 668.6 ± 8.3 
ISA*SPRK 2096.5 ± 39.5 2526.2 ± 36.1 
ISPA*SRK 1251.7 ± 23.7 1503.2 ± 31.2 
ISPA*SPRK 240.5 ± 8.1 309.6 ± 9.6 
RPTLR 220.6 ± 13.7  ±  
RPTL*R 190.1 ± 1.9  ±  
RPTPL*R 677.8 ± 16.5  ±  
RPTPL*RR 286.9 ± 3.6  ±  
In the SIL peptides * indicates labeled amino acid. A*: [M+4]alanine, Y*: [M+10]tyrosine 
and L*: [M+7]leucine respectively and (P) for phosphorylation. Each of these peptides 
show different combinations of miscleaved and phosphorylated (P) forms at an expected 
concentration range of 300-500 pmol/μl.  
 
The differences in the quantification between arginine and lysine for the SIL 
peptides that contained both the amino acids could be due to the protein contamination in 
the vials. Alternately, we could measure the isotope labeled amino acid incorporated into 
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the SIL peptide sequence instead of the naturally occurring amino acids. This approach has 
the advantage that the protein background is not labeled and will not interfere with the 
quantification of the SIL amino acid. In the peptides we procured, most of them had 
[M+4]alanine (A*) or [M+7]leucine (L*) labeling. Therefore, the concentration of the 
peptides were determined by the quantification of [M+4]alanine and [M+7]leucine signal 
intensities upon the hydrolysis of the peptides. [M+2]Alanine and [M+3]leucine were used 
as the internal standards.  
As described in the experimental section, direct infusion studies were carried out 
to determine the precursor ion and the predominant m/z 171 fragment ion for the MRM 
transitions. The precursor ions selected, and the optimized DP and CE conditions are listed 
in Table 2.4.  
Table 2.4: MRM transitions and the optimized instrument parameters 
Amino acid Precursor ion Product ion DP CE 
[M+4]Alanine 264 171 70 30 
[M+2]Alanine 262 171 70 30 
[M+7]Leucine 309 171 80 35 
[M+3]Leucine 305 171 80 35 
 
Figure 2.6 displays the MRM chromatogram of AQC-[M+4]alanine, AQC-
[M+7]leucine, and the internal standards AQC-[M+2]alanine and AQC-[M+3]leucine. 
AQC-[M+4]alanine and AQC-[M+2]alanine both eluted at the same retention time of 10.5 
min, while the AQC-[M+7]leucine and AQC-[M+3]leucine eluted together at 14.8 min.  
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Figure 2.6: MRM chromatogram of AQC-[M+4]alanine, AQC-[M+7]leucine and 
AQC-[M+2]alanine, AQC-[M+3]leucine.  
A 100 fmol of AQC-[M+4]alanine, AQC-[M+7]leucine, AQC-[M+2]alanine and 
AQC-[M+3]leucine were injected on to the column.  
A) The extracted ion chromatogram of [M+4]alanine and [M+7]leucine LC-MRM run.  
B) The extracted ion chromatogram of [M+2]alanine and [M+3]leucine. 
 
A calibration curve of [M+4]alanine with the internal standard [M+2]alanine was 
prepared by plotting the measured MRM area ratios of AQC-[M+4]alanine to AQC-
[M+2]alanine against the corresponding mole ratios as defined by Eq. 2.2. The 
[M+4]alanine/[M+2]alanine calibration curve is shown in Figure 2.7A. The calibration 
curve for [M+7]leucine/[M+3]leucine is displayed in Figure 2.7B. In the range of analytical 
interest 0 to 20 pmol, both the curves were found to be linear (𝑟𝑟2 = 1.00).  
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The [M+4]alanine linear regression ± SE was:  𝑅𝑅�4 2� �𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎   = (0.008 ±  0.007 ) + (1.090 ±  0.007)�𝑛𝑛4 𝑛𝑛2� �𝑎𝑎𝑙𝑙𝑎𝑎𝑎𝑎𝑖𝑖𝑎𝑎𝑎𝑎 
and that for [M+7]leucine was:  𝑅𝑅�7 3� �𝑎𝑎𝑎𝑎𝑙𝑙𝑙𝑙𝑎𝑎𝑎𝑎𝑎𝑎   = (0.005 ±  0.007 ) + (0.959 ±  0.007)�𝑛𝑛7 𝑛𝑛3� �𝑙𝑙𝑎𝑎𝑢𝑢𝑙𝑙𝑖𝑖𝑎𝑎𝑎𝑎.  
The 95% confidence limit of the regression line and the SE of the intercept from the 
calibration curves were used to determine the limit of detection (LOD). The LOD were 
calculated to be 1.32 fmol/μl for [M+4]alanine and 1.53 fmol/μl for [M+7]leucine i.e. 0.13 
pmol and 0.15 pmol in the total reaction volume of 100 μl for [M+4]alanine and 
[M+7]leucine respectively. 
The molar response factor (slope) for both the curves was found to be statically 
different from unity. This could be attributed to the concentration of the internal standards 
being greater than that calculated, but this deviation from unity does not affect the linearity 
of the calibration curves or the measurements because the same amount of the internal 
standard is also added to the samples as well. However, unlike the arginine and lysine 
curves, the intercept of [M+4]alanine and [M+7]leucine curves were found to be 
statistically not different from zero, indicating no background contribution. 
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Figure 2.7: Calibration curves of A) [M+4]alanine and B) [M+7]leucine. 
Each point on the graph represents the mean of four replicates with the error bar 
representing the Standard error (SE). 
A) The slope and the intercept with SE for [M+4]alanine /[M+2]alanine calibration curve 
are 1.090 ± 0.007 and 0.008 ± 0.007 respectively with r2 of 1.00.  
B) For the [M+7]leucine/[M+3]leucine curve the slope and the intercept with the SE are 
0.959 ± 0.007 and 0.005 ± 0.007 respectively (r2 = 1.00). 
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The sensitivity was increased when measuring the stable isotope labeled residues 
in the SIL peptides compared to arginine and lysine, which is evident from the LOD of 
0.13 pmol and 0.15 pmol for [M+4]alanine and [M+7]leucine respectively compared to 
0.45 pmol and 0.31 pmol for lysine and arginine respectively.  
The MRM-LC-MS method was used to determine the concentration of the SIL 
peptides that had either [M+4]alanine or [M+7]leucine and the results are summarized in 
Table 2.5. From these results it can be concluded that the concentration of the SIL peptides 
using the [M+4]alanine or [M+7]leucine quantification followed the same trends as the 
lysine and arginine curve. In the peptides analyzed, the lowest in concentration was again 
ISPA*SPR (91.1 ± 1.9 pmol/ μl) and the highest concentration was ISA*SPRK (1998.6 ± 
36.0 pmol/μl). The concentration range is about 20 fold compared to the expected 300-500 
pmol/μl. These results reinforce the absolute need for the accurate determination of the 
concentration of SIL peptides before they can be used as internal standards. 
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Table 2.5: SIL tryptic peptides quantification by MRM-LC-MS 
In the SIL peptides * indicates labeled amino acid. A*: [M+4]alanine, Y*: [M+10]tyrosine and L*: [M+7]leucine respectively 
and (P) for phosphorylation. 
Quantification 
 based on arginine 
Quantification 
 based on lysine 
Quantification 
 based on [M+4]alanine 
Quantification 
based on[M+7]leucine 
SIL peptide pmol/μl ± SE pmol/μl ± SE pmol/μl ± SE pmol/μl ±  SE 
RSPSA*NY*R 442.7 ± 5.6 371.7 ± 5.8 
RRSPSA*NY*R 221.1 ± 6.2 258.4 ± 4.3 
RRSPSPA*NY*R 353.8 ± 6.4 420.3 ± 6.7 
ISA*SR 726.2 ± 19.5 568.9 ± 8.5 
ISA*SPR 513.4 ± 11.1 417.3 ± 5.5 
ISPA*SR 1062.4 ± 28.7 769.2 ± 20.8 
ISPA*SPR 121.1 ± 6.0 91.1 ± 1.9 
ISA*SRK 653.0 ± 13.1 668.6 ± 8.3 520.0 ± 11.6 
ISA*SPRK 2096.5 ± 39.5 2526.2 ± 36.1 1998.6 ± 36.0 
ISPA*SRK 1251.7 ± 23.7 1503.2 ± 31.2 1215.4 ± 22.6 
ISPA*SPRK 240.5 ± 8.1 309.6 ± 9.6 259.8 ± 4.1 
RPTL*R 190.1 ± 1.9 111.0 ± 1.3 
RPTPL*R 677.8 ± 16.5 362.8 ± 10.0 
RPTPL*RR 286.9 ± 3.6 182.1 ± 2.7 
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2.4. CONCLUSIONS 
Routine quantification of SIL peptides is challenging due to the small (nmole) 
amounts prepared or purchased. In our method, we used a total amount of about 30 pmol 
(for triplicate measurements) of the SIL peptide sample for assay, a small fraction of the 
total amount. The method could go lower, except for the background protein 
contantamination we encountered. Amino acids from the protein contamination in the 
reaction vials cannot be distinguished from those of the sample after hydrolysis. Special 
care in sample handling is required before hydrolysis. We demonstrated that the use of acid 
cleaning and pyrolysis of the reaction vials reduced the background almost four-fold, 
compared to the uncleaned reaction vials.  
Another approach to improving the sensitivity was the quantification of the stable 
isotope labeled residue instead of lysine or arginine. Typically, the SIL peptides are 
synthesized with one or two amino acid residues that have 13C and/or 15N isotope labeling. 
The isotope labeled residue increases the molecular weight by 4-10 Da relative to the 
naturally occurring amino acid. Therefore, quantification of the labeled residue of higher 
mass will have no natural abundance background interference as evident from the zero 
intercept of [M+4]alanine and [M+7]leucine curves. Depending on the amount of SIL 
peptides available, the sensitivity required, either lysine or arginine can be used for 
quantification or the labeled amino acid residue in the SIL peptide. Because only a fraction 
of any SIL peptide is used, the quantification of SIL peptides can be carried out routinely 
using the MRM-LC-MS method developed in this chapter. 
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CHAPTER 3: TARGETED QUANTIFICATION OF PHOSPHORYLATED AND 
NON-PHOSPHORYLATED PEPTIDES USING STABLE ISOTOPE LABELED 
PEPTIDES  
3.1. INTRODUCTION  
Electrospray ionization (ESI) is one of the most widely used techniques for 
ionization of biomolecules, such as peptides, in mass spectrometry. ESI is a soft ionization 
technique that produces gas phase ions with little or no fragmentation and gives molecular 
weight information of peptides. ESI yields multiply charged ions [M+nH]n+ where, n is the 
number of protons and the charge on the ion. In ESI the analyte is introduced in solution 
phase. The production of gas phase ions occurs under atmospheric pressure with the 
formation of charged droplets at the heated ES capillary with a high voltage (2-6 kV) 
applied to the capillary tip. This strong electric field causes the dispersion of the sample 
solution into an aerosol of highly charged droplets. The shrinkage of the charged droplets 
due to solvent evaporation (assisted by N2 used as drying gas) and fission cascade results 
in highly charged gas phase ions.  
The ESI response, i.e. the signal intensity and the charge state of the peptides, 
depends on the experimental conditions like the source parameters, flow rate, mobile phase 
conditions etc. More importantly, the ESI response can vary significantly among peptides 
of equimolar concentrations even under identical concentrations and instrument conditions. 
This is because different peptides have different ionization efficiencies and thus result in 
different magnitudes of ESI response (125). The ionization efficiency of a peptide depends 
on the physiochemical properties of the peptide including peptide hydrophobicity (126), 
the number of amino acids (length) in the peptide (127), the nature of the amino acids in 
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the peptide sequence, and i.e. the ability of the constituent amino acids to retain the proton 
(pKa) (128).  
Ideally a peptide should be protonated in the solution even before the spray (gas 
phase) (128,129). The presence of basic residues (R, K and H, and the N-terminus of 
peptide with higher pKa) and the number of basic residues play an important role in the 
charge state of a peptide as they hold protons during the ESI (130). A mobile phase with 
0.1% formic acid is typically used to enable protonation. 
Post-translational modifications of a peptide such as phosphorylation leads to 
addition of phosphate group on the side chain of the amino acid backbone of the peptide. 
This modification changes the physiochemical properties of the peptide, and often induces 
a change in the ionization efficiency of the peptide, a concern for application of mass 
spectrometric techniques for the quantitative measurement of post translational 
modifications.  
The effect of the phosphate group on the overall charge state of the peptide can 
be understood by looking at the pKa values of O-phosphoserine. The first pKa of O-
phosphoserine is the deprotonation of –H2PO4 group, and is reported to be very low (< 1.7). 
The pKa for the next three consecutive deprotonations of the –COOH, –HPO4- and –NH3+ 
groups of O-phosphoserine are at 2.19, 5.78, and 9.85, respectively, as shown in Scheme 
3.1 (131,132) indicating that prominently the phosphate group tends to lose a proton and 
is negatively charged.  
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Scheme 3.1: Deprotonation and the ionic forms of O-phosphoserine with the 
corresponding pKa values (132). 
The negatively charged phosphate group can lower the charge state and decrease 
the ionization of the peptides in ESI. Some of the discussed challenges related to 
phosphopeptides in the literature are a) the lowering of the ionization efficiency of the 
phosphopeptides than their unmodified cognates, b) selective suppression of the ionization 
of the phosphopeptides in presence of coeluting peptides, and c) loss of phosphopeptides 
due to their hydrophilic nature during the reversed phase chromatography (107,133-135). 
Steen et.al (107) used synthetic peptides to review some of the concerns 
associated with phosphopeptides and reported that in the peptides they studied ionization 
efficiency of the phosphopeptides was not lower than the unphosphorylated peptides. 
Moreover, suppression of both phosphopeptides and the unphosphorylated peptides signal 
intensities were observed in the presence of high concentration of other peptides. 
In contrast, Gropengiesser et.al (136) studied 132 different peptides with and 
without phosphorylation and demonstrated that phosphorylated peptides exhibited 
decreased signal intensities compared to their non-phosphorylated analogs. Similar results 
of decreased ionization efficiency with phosphorylation were reported by Choi.et.al. (133).  
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Kim et al. (135) studied peptides and their corresponding phosphopeptides 
ranging from 4 to 35 amino acid residues and reported that small peptides displayed larger 
shifts in retention time, while longer peptides displayed limited changes in elution time due 
to phosphorylation. These results suggest that the effect of phosphorylation on the 
physiochemical properties of the peptide is significant on smaller peptides, and as the 
peptide backbone length increases, the effect of phosphorylation decreases.  
In order to develop a sensitive method for the quantification of phosphorylated 
peptides using the SIL peptide standards, it is crucial to understand the influence of 
phosphorylation on the signal intensity and chromatography. This is especially important 
in the case of TnI peptides that are have multiple sites of phosphorylation and multiple 
miscleavage sites on small tryptic peptides. One way to investigate the effects of 
phosphorylation on the ionization behavior of the TnI phosphopeptides would be to use the 
SIL peptides of known concentrations to study the charge state distribution and the 
ionization efficiencies of the peptides. 
3.2. MATERIALS AND METHODS 
3.2.1. Peptide mixture preparation 
The synthetic tryptic SIL peptides were divided into three groups shown in Table 
3.1. Each group contained 10 µl-aliquots of the stock solution of the synthetic peptides. 10 
µl-aliquots of RPTLR were added to all three groups. The three peptide mixtures were 
dried to completeness in Thermo Scientific SpeedVac SPD111V. The dried peptide 
mixtures were brought up in 100 µl of 97.5:2.5% water and acetonitrile with 0.1% formic 
acid and 0.05% trifluoroacetic acid.  
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3.2.2. Peptide mixture for MRM studies 
For MRM method development, a smaller set consisting of 10 SIL peptides was 
prepared in 0.1% formic acid in water. The same peptide mixture was used for the with- 
and without-column studies.  
3.2.3. Flow injection analysis (FIA) of synthetic peptide mixtures 
The ESI measurements were made on an AB SCIEX 4000 QTRAP triple 
quadrupole/linear ion trap mass spectrometer with a Shimadzu LC20AD HPLC. The SIL 
peptides are expensive, limited in volume and concentration. Hence, to reduce the amount 
of sample consumed flow injection analysis (FIA) was employed. In FIA the samples are 
injected into the mobile phase without the column. A 1-µl aliquot of the peptide mixture 
using the Shimadzu SIL20AC auto sampler was injected into a 5 μl/min flow of 50:50 
water and acetonitrile with 0.1% formic acid.  
The MS was operated in positive ionization mode. The data was collected for 10 
minutes between the injections. The ion source parameters were optimized to be: ion spray 
voltage at 2800 V, temperature of ion source at 175 °C, curtain gas at 30 psi, nebulizer gas 
at 20 psi, collision gas at 0 psi, entrance potential at 10 V and collision cell exit potential 
at 16 V. A declustering potential (DP) of 60 was selected. Two sets of FIA measurements 
were carried out with Q3 at a unit resolution and at high resolution and scanned from 150 
to 1200 m/z in 4 sec. 
3.2.4. LC-MRM analysis 
A Thermo Scientific Hypersil gold AX 5 µm, (1 x 150) mm column was selected 
for chromatographic separation. The mobile phase consisted of water with 0.1% formic 
acid (solvent A) and acetonitrile with 0.1% formic acid (solvent B). The gradient started at 
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1% B and was increased in 40 mins to 60% followed by a ramp to 98% within the next 1 
min, followed by a 4-min isocratic 98% step to clean the column. The solvent flow rate 
was set at 80 μl/min. The MS was operated in positive ionization mode. The ion source 
parameters were set to ion spray voltage at 5500 V, temperature of ion source at 400 °C, 
curtain gas at 30 psi, nebulizer gas at 30 psi, drying gas at 40 psi, collision gas at 12 psi, 
entrance potential at 10 V and collision cell exit potential at 8 V. FIA experiments were 
carried out to optimize the analyte-specific parameters: declustering potential (DP) and 
collision energy (CE). This optimization ensures maximum signal intensities for each of 
the MRM transitions. The most intense charge state of the peptide was selected as the 
precursor ion and the most intense fragment ions as the product ion. In the case of 
phosphopeptides, the loss of the phosphate group was found to be the main fragment ion. 
The prominent precursor and product ions and the most favorable DP and CE parameters 
to obtain the best sensitivity for each MRM transitions for the SIL peptides are listed in 
Table 3.4. Q1 and Q3 were set at a unit resolution for the MRM acquisitions with a 100 
msec dwell time for each MRM transitions.  
3.3. RESULTS AND DISCUSSION 
The synthetic SIL peptides with 13C and/or 15N have the same physicochemical 
properties compared to the unlabeled peptides of the same sequence. Hence, for the purpose 
of this chapter, the stable isotope labeled peptides and the unlabeled peptides will be 
represented as one. 
FIA were conducted on the synthesized SIL peptides. To prevent ion suppression 
that can occur if all the peptides were infused simultaneously into the ESI, the peptides 
were aliquoted into three fractions as shown in Table 3.1. The same amount of RPTLR was 
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added to each group to enable comparison of results across the three groups of peptides. 
The intensity of RPTLR peptide was used to normalize any variations between the three 
groups during the FIA measurements. 
Table 3.1: SIL tryptic peptides quantified by MRM-LC-MS 
Group 1 pmol/μl Group 2 pmol/μl Group 3 pmol/μl 
SSANYR 54.4 ISASR 72.6 ISPASPRK 24.0 
SSPANYR 39.2 ISASPR 51.3 RRSSPANYR 24.5 
RSSANYR 18.6 ISPASPR 12.7 RRSPSPANYR 35.4 
RSSPANYR 55.3 ISASRK 65.3 RPTPLRR 28.7 
RSPSPANYR 57.8 ISASPRK 209.6 RPTPLR 67.8 
RPTLR 22.1 RPTLR 22.1 RPTLR 22.1 
SIL peptides with labeled amino acids: [13C315N]alanine, [13C915N]tyrosine, and 
[13C315N]leucine respectively. The concentration of each peptide in the 100-µl sample 
aliquot is given. RPTLR was added to each group to normalize differences between the 
groups. 
 
3.3.1. Effect of basic residues (R and K) and phosphate group on charge state 
distribution of peptides. 
For an MRM method, the most intense molecular (precursor) ion is selected for 
fragmentation. In ESI, peptides are multiply charged. For MRM, ideally, the most intense 
charge state would be selected as the precursor ion. The charge state depends on the nature 
of the peptide itself, like the amino acid residues of the peptides, the length of the peptide, 
the modifications on the peptide, etc. The peptides we are currently studying are smaller (5 
to 8 residue) with multiple R and K residues and with one or two phosphate groups. Hence, 
the effect of multiple R and K residues and the addition of phosphate groups on the 
distribution of charge states was studied. 
The intensities of the singly, doubly, and triply charged ions of each of the 
synthetic tryptic peptides were extracted from the FIA mass spectra of the two runs with 
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Q3 at unit resolution and Q3 at high resolution. The average relative charge state 
distribution for each peptide is shown in Figure 3.1. The results are grouped into three 
series: ISASR series, SSANYR series, and RPTLR series. From Figure 3.1, a general 
conclusion can be derived that the doubly charged ion is the predominant charge state of 
the molecular ion in the peptides infused. To understand the influence of the basic residues 
(R and K) and phosphorylation modification on the charge state distribution of the peptides, 
the results from Figure 3.1 were rearranged and grouped differently. Figure 3.2 displays 
the effect of adding basic residues (R and K) on the charge state distribution of the peptides. 
Figure 3.2A shows the charge state distribution of RPTPLR vs RPTPLRR. Both peptides 
had singly, doubly and triply charge states with the doubly charge state being the 
predominant ion. The extra R residue on the C-terminus RPTPLRR decreased the singly 
and doubly charged states, and produced an expected shift in intensity towards the triply 
charged molecular ion.  
The charge state distribution for the ISASR series is shown in Figure 3.2B. ISASR 
produced both singly and doubly charged ions with the doubly charged being the 
predominant ion. With the addition of K at the C-terminus, ISASRK, the triply charged 
molecular ion was also observed, along with the singly and doubly charged ions. A similar 
trend was observed for ISASPR depicted in Figure 3.2C. Doubly charged molecular ion is 
the predominant ions, and with the addition of K at the C-terminus, ISASPRK formed triply 
charged molecular ions along with the doubly charged molecular ion. Both peptides have 
one phosphate group on the serine residue and one R at the C-terminus, so any change in 
the charge distribution is due to the additional K. Similarly, ISPASPRK in Figure 3.2D 
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showed a decrease in the formation of the singly charged ion and an increase in formation 
of the doubly and triply charged molecular ions. 
The charge state distribution for the SSANYR series is shown in Figure 3.2E. 
SSANYR produced only singly and doubly charged molecular ions, but RSSANYR with 
an extra R on the N-terminus formed a triply charged molecular ion along with the singly 
and doubly charged molecular ions. The same trend is observed for the three peptides: 
SSPANYR, RSSPANYR, and RRSSPANYR (Figure 3.2F). With the addition of extra R 
residue on the N-terminus, there is a proportional decrease in the formation of singly 
charged molecular ions and an increase in the formation of triply charged molecular ions. 
We observed a shift in the distribution of charge state towards the triply charged especially, 
with increasing R residues.  
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Figure 3.1: Charge state distribution of the SIL peptides. 
Each charge state is an average of two FIA. (Q3 at unit resolution and Q3 at 
high resolution). 
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Figure 3.2: Effect of additional basic residues (R and K) residues on charge state 
distribution. 
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Figure 3.3 summarizes the influence of phosphorylation on the charge state 
distribution. Both singly, doubly, and triply charged molecular ions were observed for 
RPTLR and RPTPLR (Figure 3.3A). With the addition of a phosphate group, we observed 
a modest increase in the singly charged, while the triply charged ion decreased.  
For ISASR (Figure 3.3B), the addition of one phosphate group (ISASPR) did not 
produce a noticeable change in the charge state distribution. With the addition of two 
phosphate groups (ISPASPR) a modest increase in the singly charged molecular ion was 
observed, while reducing the doubly charged molecular ion. For ISASRK (Figure 3.3C), 
three charge states were observed with the doubly charge molecular ion being the 
predominant one. The addition of one phosphate group (ISASPRK) produced a modest 
decreased in the triply charged ion. With the addition of two phosphate groups (ISPASPRK) 
there was a redistribution of charge state. A decrease of both the singly and the triply 
charged ion was observed with the increase of the doubly charge ion.  
For SSANYR vs SSPANYR (Figure 3.3D), phosphorylation leads to a slight 
decrease in the singly charged molecular ion. For both SSANYR and SSPANYR the doubly 
charged molecular ion was the predominant ion. This trend was not as expected. Figure 
3.3E shows the addition of one and two phosphate groups to RSSANYR. The first 
phosphate group increased the singly charged ion, while decreasing the triply charged ions 
whereas the addition of second phosphate group led to no remarkable difference in charge 
state distribution. A modest increase in singly charged ion was observed for RRSPSPANYR 
(Figure 3.3E) when compared to RRSSPANYR.  
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Figure 3.3: Effect of addition of phosphate group on charge state distribution. 
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Summarizing the observations, the addition of phosphate groups produced only 
modest reduction in the higher charge states with the two exceptions of ISPASPRK vs 
ISASPRK, and SSPANYR vs SSANYR, where there was a decrease in the singly charge 
states compared to the doubly charged states. Although the peptides described here 
represent a very limited data set, we conclude that the number of basic residues contributes 
more to the charge state distribution than the phosphate group, which had much less 
influence than expected. For the synthesized tryptic peptides that we used, the doubly 
charged molecular ion was the predominant charge state for all the peptides.  
3.3.2. Effect of basic residues (R and K) and phosphate group on ionization 
efficiency of peptides. 
ESI ionization efficiency can be significantly different between peptides of 
equimolar concentrations even under the same instrument conditions. The ionization 
efficiency depends on the physiochemical properties of the peptide, like the length of the 
peptide as well as the nature of the amino acids in the peptide sequence.(128). The presence 
of basic residues R (pKa = 12.3) and K (pKa = 10.4) and the number of basic residues play 
an important role in the ionization efficiency (proton attachment). Hence, it is important to 
establish the influence of the basic residues and the phosphorylated peptides on the 
ionization efficiency of the peptides  
For the ionization efficiency studies, either the intensity of the predominant 
doubly charged ion of each peptide could be used or the sum of the intensities of all the 
charge states of the peptides. We decided to use the sum of intensities of all the charge 
states for the determination of ionization efficiency to account for any changes in charge 
state distribution.  
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As noted in Chapter 1, the signal intensity of the peptide is directly related to the 
concentration of the peptide. 
   𝐼𝐼𝐴𝐴1   = 𝑘𝑘𝐴𝐴1 .𝐴𝐴1  (3.1) 
where 𝐼𝐼𝐴𝐴 is the signal intensity (counts) of the peptide, 𝑘𝑘𝐴𝐴 is the ionization efficiency of the 
peptide, and 𝐴𝐴 is the amount of the peptide (pmol). Instead of finding the absolute values 
of ionization efficiency for each of the peptides, relative ionization efficiency (RIE) values 
were measured by determining the intensities via the FIA of the peptides as a mixture at 
the same instrument and sample preparation conditions 
i.e. 𝑅𝑅𝐼𝐼𝑅𝑅
�𝐴𝐴1 𝐴𝐴2
� �
 = 𝑘𝑘𝐴𝐴1 𝑘𝑘𝐴𝐴2� =  𝐼𝐼𝐴𝐴1 𝐴𝐴1�𝐼𝐼𝐴𝐴2
𝐴𝐴2
�
 (3.2) 
where 𝑅𝑅𝐼𝐼𝑅𝑅
�𝐴𝐴1 𝐴𝐴2
� �
  is the relative ionization efficiency of peptide 𝐴𝐴1 compared to peptide 
𝐴𝐴2. The RIE ratio was determined with respect to RPTLR, which was added to the three 
peptide mixtures prepared for FIA (Table 3.1). 
Figure 3.4 shows the RIEs of all the peptides with respect to RPTLR. The sum of 
the intensities of all charge states of each peptide was taken and compared to the sum of 
the intensities of all the charge states of RPTLR. There are three sets of peptide series, the 
ISASR series, SSANYR series, and RPTLR series. Between the three series, the RPTLR 
series has better ionization efficiency than the ISASR or SSANYR series. Within each 
series, there is a variability of ionization efficiency among the peptides. In order to better 
understand the influence of the basic residues (R and K) and phosphorylation modification 
on the ionization efficiencies of the peptides, the results from Figure 3.4 were rearranged 
differently. 
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Figure 3.4: Relative ionization efficiency of the SIL peptides.  
The sum of the intensities of all charge states of each peptide was taken and 
normalized to the sum of the intensities of all charge states of RPTLR. 
 
Figure 3.5 represents the effect on RIE with the addition of basic residues to the 
peptide sequence. For example, when an extra R residue is on the C-terminus end, a higher 
RIE is observed as seen in Figure 3.5A for the case of RPTPLRR vs RPTPLR. The addition 
of K at the C-terminus of ISASR (Figure 3.5B) increased the RIE compared to ISASR. In 
the case of ISASPR (Figure 3.5C) there was an increase in RIE with an additional K at the 
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C-terminus (ISASPRK). In Figure 3.5D, ISPASPRK showed a much higher increase in RIE 
compared to ISPASPR. 
Addition of extra R on the N-terminus, i.e. RSSANYR, increased the RIE 
compared to SSANYR (Figure 3.5E). The same trend is observed (Figure 3.5F) for 
SSPANYR, RSSPANYR, and RRSSPANYR. With the extra R residue on the N-terminus, 
RSSPANYR showed a higher RIE compared to SSPANYR, while, with the two R residues 
on the N-terminus, RRSSPANYR was higher compared to RSSPANYR. RRSPSPANYR 
showed an increase in RIE compared to RSPSPANYR (Figure 3.5G). Both the peptides had 
two phosphate groups, so the increase in RIE is due to the additional R residue.  
Overall, the increase in RIE reflects the charge state distribution trends observed. 
There is an increase in RIE as well as a shift towards higher charge state with addition of 
the basic residues arginine and lysine. 
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Figure 3.5: Effect of additional basic residues (R and K) on relative Ionization 
efficiency. 
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Figure 3.6 summarizes the influence of phosphorylation on the RIE of the 
peptides. RPTPLR (Figure 3.6A) showed a lowering RIE compared to RPTLR with the 
addition of a phosphate group. For ISASR the RIE decreased with the addition of one 
phosphate group, ISASPR, (Figure 3.6B), and it decreased modestly with the addition of a 
second phosphate group, ISPASPR. Addition of a phosphate group to ISASRK (i.e. 
ISASPRK) caused a lowering of RIE (Figure 3.6C), but addition of a second phosphate 
group ISPASPRK increased the RIE. This was an exception to the expected trend.  
Addition of a phosphate group on SSANYR led to a decrease in the RIE (Figure 
3.6D). A similar trend was observed for RSSANYR. One phosphate group (RSSPANYR) 
lowered the RIE (Figure 3.6E). Addition of a second phosphate group (RSPSPANYR) 
caused a further decrease in RIE, following the expected trend. Even with multiple arginine 
residues, like RRSSPANYR and RRSPSPANYR (Figure 3.6F), a reduction in RIE was 
observed with the addition of the phosphate group.  
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Figure 3.6: Effect of the addition of phosphate group on relative Ionization 
efficiency.  
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The RIE values for each the peptide measured with the addition of one K, one R, 
two Rs, one phosphate, and two phosphate groups are summarized in Table 3.2. The 
ISPASPRK peptide values were found to be statistically an outlier. Hence, the RIE values 
associated with the ISPASPRK peptide were not included in Table 3.3. The average RIE 
fold-factor increase with the addition of one K is 1.24, one R is 2.57, and two Rs is 3.72. 
A significant increase in ionization is observed with the addition of basic residues. The 
average RIE fold-factor decrease with the addition of one phosphate and two phosphate 
groups are 0.47 and 0.20 respectively. A significant decrease in ionization is observed with 
the addition of phosphate groups. 
Table 3.2: Relative ionization efficiency with one R, two R, one K, one PO4 and two 
PO4 
Peptide sequence  + K  + R  + 2R  + PO₄   + 2PO₄  
RPTLR    0.55   
RPTᴾLR  2.35     
ISASR 1.19   0.35 0.31 
ISASᴾR 1.28   0.88   
ISᴾASᴾR 5.63      
ISASRK    0.38 1.45 
ISASᴾRK    3.89   
SSANYR  4.09  0.48   
SSᴾANYR  1.72 3.72    
RSSANYR    0.20 0.09 
RSSᴾANYR  2.18  0.43   
RSᴾSᴾANYR  2.52     
RRSSᴾANYR       0.50   
Average 2.70 2.57 3.72 0.85 0.62 
SD 2.54 0.90  1.15 0.73 
The ratios in red are statistically found to be outlier.  
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Table 3.3: Relative ionization efficiency with one R, two R, one K, one PO4 and two 
PO4 after correction. 
Peptide sequence  + K  + R  + 2R  + PO₄   + 2PO₄  
RPTLR    0.55   
RPTᴾLR  2.35     
ISASR 1.19   0.35 0.31 
ISASᴾR 1.28   0.88   
ISᴾASᴾR        
ISASRK    0.38   
ISASᴾRK        
SSANYR  4.09  0.48   
SSᴾANYR  1.72 3.72    
RSSANYR    0.20 0.09 
RSSᴾANYR  2.18  0.43   
RSᴾSᴾANYR  2.52     
RRSSᴾANYR       0.50   
Average 1.24 2.57 3.72 0.47 0.20 
SD 0.07 0.90  0.20 0.16 
p 5.5E-03 3.7E-04  1.8E-08 2.0E-03 
The RIE values associated with ISᴾASᴾRK peptide were discarded. The p value displays if 
the RIE is significantly different from 1. 
 
To summarize, for the peptides we studied: a) there was an increase in ionization 
efficiency with an increase in the number of basic residues (R and K). The increase in 
ionization efficiency is because the basic residues arginine (pKa = 12.3) and/or lysine (pKa 
= 10.4) are readily protonated in the mobile phase condition used. b) There was a reduction 
in the ionization efficiency with the addition of phosphate groups that can be explained by 
the negative charged phosphate group on the peptide. The exception is the doubly 
phosphorylated ISPASPRK. This peptide did not follow the decreased ionization trend we 
were anticipating.  
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3.3.2. LC-MS analysis of the SIL peptides  
In spite of the variations observed in ionization efficiency, the MRM technique 
can be used to selectively improve the sensitivity of the analysis. In MRM, the instrument 
conditions can be optimized for each target peptide to enhance the signal corresponding to 
the precursor and the fragment ion. Preliminary method development was carried out on a 
smaller set of SIL peptide mixture. The peptides selected correspond to ISASR series, 
SSANYR series, and RPTLR series, with no, one, and two phosphate groups respectively. 
The doubly charged molecular ion was the most predominant charge state as 
shown in the charge state distribution studied for all the peptides and was selected as the 
precursor ion. The most intense fragment produced on MS/MS of the precursor ion was 
selected as the fragment ion for the MRM transition. For phosphopeptides, the phosphate 
group is relatively labile and competes with the backbone fragmentation. As a result, the 
loss of a phosphate group (-H3PO4) is the most intense ion (137) and was selected as the 
precursor ion for MRM of phosphopeptides. The peptides and the MRM conditions 
optimized via FIA are listed in Table 3.4.  
A Thermo Scientific Hypersil gold AX 5 µm, (1 x 150) mm column was selected 
for chromatographic separation of the peptides. This column was selected to improve the 
retention of the small peptides. The MRM chromatograms representing the intensity in 
counts/pmol of each of the peptides injected on the column were extracted.  
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Table 3.4: MRM transitions and the optimized instrument parameters. 
Peptide 
sequence 
Concentration 
(pmol/µl) 
Precursor ion  
[M+2H]2+ Fragment ion DP CE 
RPTLR 5 321 486 60 27 
RPTᴾLR 17.6 365 316 40 20 
ISASR 23.3 269 424 60 16 
ISASᴾR 16.2 309 260 70 15 
ISᴾASR 22.8 309 260 70 15 
ISᴾASPR 11.7 349 300 40 20 
SSANYR 10.9 354 533 45 20 
RSSᴾANYR 11.3 472 423 80 25 
RSᴾSANYR 18.3 474 425 80 25 
RRSᴾSᴾANYR 12.6 592 543 75 30 
Precursor ions of each peptide is doubly charged. Q1 and Q3 were at unit resolution. 
 
The extracted MRM chromatograms of RPTLR series (Figure 3.7) display the 
intensity/pmol of the peptides loaded on the column. The top panel corresponds to RPTLR 
MRM transition (321486). The bottom panel is the trace of MRM transition (365316) 
of RPTPLR. There is no decrease in intensity of the phospho-peptide as expected from the 
RIE. Instead, RPTPLR has better signal intensity because the acquisition is in MRM mode 
were the most intense fragment i.e. the loss of phosphate (m/z 316) is being measured in 
instrument-optimized conditions.  
Figure 3.8 shows the extracted MRM chromatograms of the SSANYR series. The 
top panel is the chromatogram of SSANYR. The second panel shows the chromatogram 
for the singly phosphorylated RSSPANYR and RSPSANYR, respectively. In this case, 
complete separation of the two singly phosphorylated peptides was not achieved on the 
column. The peak eluting at 21.7 min is that of RSSPANYR, closely followed by 
RSPSANYR at 22 min. The bottom panel in Figure 3.8 is the MRM chromatogram of the 
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doubly phosphorylated RRSPSPANYR. The intensity of the doubly phosphorylated peptide 
was much lower than that expected from RIE. 
The MRM chromatograms of the ISASR series are shown in Figure 3.9. The top 
panel is the chromatogram for ISASR. The middle panel shows the chromatogram for the 
singly phosphorylated ISASPR and ISPASR. These peptides have the same MRM 
transitions because of the identical sequence except for the position of the phosphate group. 
These peptides were chromatographically separated on the Hypersil gold AX column. The 
peak at 27.5 min corresponds to ISASPR and the peak at 29.3 min corresponds ISᴾASR 
respectively. The intensity of ISᴾASR per pmol was found to be lower than that of ISASPR. 
In the case of the doubly phosphorylated ISPASPR shown in the bottom panel of Figure 
3.9, no peak for the transition was observed. Based on the ionization efficiency studies, we 
expected a lowering in the intensity, complete absence of the peak was not expected.  
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Figure 3.7: MRM chromatograms of RPTLR series. 
The separation was carried out on Thermo Scientific Hypersil gold AX 5 µm, (1 
x 150) mm column. Intensity and area are per pmol of RPTLR and RPTPLR respectively. 
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Figure 3.8: Extracted MRM chromatograms of SSANYR series. Intensity 
(cps/pmol) and Area (counts/pmol). 
The separation was carried out on Thermo Scientific Hypersil gold AX 5 µm, (1 
x 150) mm column. Intensity and area are per pmol of SSANYR, RSSPANYR, 
RSPSANYR, and RRSPSPANYR respectively. 
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Figure 3.9: Extracted MRM chromatograms of ISASR series. Intensity (cps/pmol) 
and Area (counts/pmol). 
The separation was carried out on Thermo Scientific Hypersil gold AX 5 µm, (1 
x 150) mm column. Intensity and area are per pmol of ISASR, ISASPR, ISPASR, and 
ISPASPR respectively. 
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The selective loss of the phosphopeptides, especially the doubly phosphorylated 
peptides, is a concern as it limits the detection limit of the phosphopeptides and becomes 
crucial when dealing with complex samples like tissue digests. Studies by Tuytten et.al 
(138) and Liu et.al (139) demonstrated that phosphopeptides can form phosphopeptide-
metal ion complexes, leading to the adsorption on the stainless steel surfaces in the LC-
ESI components. They reported stronger retention or trapping, especially of multiply 
phosphorylated peptides.  
There are predominantly two sources of stainless steel components in the flow 
path of the sample from initial vial to the ESI source that are potential adsorption surfaces: 
1) the injector that consists of the sample loading syringe needle and injector six-port valve 
and 2) the stainless steel frits of the column. 
The FIA of the SIL peptides show measurable intensities for all the peptides, 
including the doubly phosphorylated peptides. Direct infusions using a syringe pump (data 
not shown) also gave measurable intensities for all the SIL peptides including the doubly 
phosphorylated peptides. These observations suggest that the loss of phosphopeptides is 
not due to the injector, but could be the stainless steel frits on the column. To determine if 
the signal loss is due to the selective interaction with the stainless steel frits of the column, 
FIA measurements of the SIL peptides with and without the column was performed. These 
studies were carried out on three different columns procured from two different 
manufacturers: a) a Thermo Scientific Hypersil gold AX, 5 µm, (1 x 150) mm column, b) 
a Waters Atlantis HILIC column, 5 µm, (1 x 50) mm column and c) a Waters Atlantis C18, 
5 µm, (1 x 150) mm column. 
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For with and without column studies, 1-μl aliquot of the 10-peptide mixture was 
injected at an isocratic flow of 80:20 water and acetonitrile with 0.1% formic acid at 80 
µl/min. The intensities of the MRM transitions (Table 3.4) for the SIL peptides were 
monitored. The first three injections using the Shimadzu SIL20AC auto sampler were on 
the Thermo Scientific Hypersil gold AX column (both injector and column in sample line), 
then the column was removed (only injector in sample line), and three more injections were 
done, this time without the column. Figure 3.10 shows the extracted MRM intensities of 
RPTLR and RPTPLR. Both RPTLR and the singly phosphorylated RPTPLR showed about 
30% higher intensity with column than without the column. This can be attributed to the 
20% acetonitrile the peptides elute in when on column. Without column, the peptides reach 
the ESI source in 100% water the sample was prepared in. This is because higher the 
organic phase content higher is the ionization (140). Hence with-column intensities are 
expected to be higher than without-column intensities for the peptides tested and the 
RPTLR series follows the trend also depicted by the bar graph on the right that represent 
the average area of the injections and their standard deviations. 
The results for the with-column and without-column injections of the ISASR 
series are shown in Figure 3.11. The top panel is the extracted chromatogram of ISASR. 
The intensity of ISASR is higher with-column than the direct infusion without-column as 
expected from the 20% acetonitrile solvent. The middle panel shows the with- and without-
column trace of the MRM transition of singly phosphorylated ISASPR. Again, with-column 
intensity was higher than without column, but this did not follow suit for the doubly 
phosphorylated ISPASPR (shown in the bottom panel). The intensity is low with-column 
for the three injections compared to without-column. The average area of the three 
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injections on column was about 5% of the injections without-column clearly showing a 
signal loss of the doubly phosphorylated peptide. 
The extracted MRM chromatograms of the SSANYR series are shown in Figure 
3.12. The top panel shows with- and without-column injections of SSANYR. The next 
panel that of the singly phosphorylated RSSPANYR both showed results similar to RPTLR 
and ISASR series. However, unlike the doubly phosphorylated ISPASPR, there was no 
signal loss for the doubly phosphorylated RRSPSPANYR (see bottom panel).  
 
Figure 3.10: Extracted MRM chromatograms of RPTLR series with and without 
Thermo Scientific Hypersil Gold AX column.  
1, 2, and 3 injections are with-column and 4, 5, and 6 are without column. The bar 
graph is the average area of the three injections with-column and without-column. 
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Figure 3.11: Extracted MRM chromatograms of ISASR series with and without 
Thermo Scientific Hypersil Gold AX column. 
1, 2, and 3 injections are with-column and 4, 5, and 6 are without column. The bar 
graph is the average area of the three injections with-column and without-column. 
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Figure 3.12: Extracted MRM chromatograms of SSANYR series with and without 
Thermo Scientific Hypersil Gold AX column.  
1, 2, and 3 injections are with-column and 4, 5, and 6 are without column. The bar 
graph is the average area of the three injections with-column and without-column. 
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column, unlike the doubly phosphorylate ISPASPR that had lower intensity. The average 
area of the three injections with-column dropped by about 33% compared to without-
column. 
The extracted MRM chromatograms of the SSANYR series are displayed in 
Figure 3.15. The unphosphorylated and the singly phosphorylated forms followed the 
expected trend of the with-column higher intensity due to the 20% acetonitrile solvent. In 
the case of the doubly phosphorylated peptide RSPSPANYR, there was a signal loss with-
column. The average area depicted in the bar graph shows a 50% drop in area compared to 
without-column. 
 
 
Figure 3.13: Extracted MRM chromatograms of RPTLR series with and without 
Waters Atlantis HILIC column. 
1, 2, and 3 injections are with-column and 4, 5, and 6 are without column. The bar 
graph is the average area of the three injections with-column and without-column. 
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Figure 3.14: Extracted MRM chromatograms of ISASR series with and without 
Waters Atlantis HILIC column. 
1, 2, and 3 injections are with-column and 4, 5, and 6 are without column. The bar 
graph is the average area of the three injections with-column and without-column. 
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Figure 3.15: Extracted MRM chromatograms of SSANYR series with and without 
Waters Atlantis HILIC column. 
1, 2, and 3 injections are with-column and 4, 5, and 6 are without column. The bar 
graph is the average area of the three injections with-column and without-column. 
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The MRM chromatograms of RPTLR and RPTPLR are shown in Figure 3.16. The 
intensity of RPTLR and RPTPLR with and without-column remain close to the expected 
trend. For the ISASR series (Figure 3.17), the top panel of the figure reinforces the fact 
that the with-column is at a slightly higher intensity due to the solvent gradient compared 
to the without-column. The singly phosphorylated ISASPR shown in the middle panel does 
not show a change in intensity with and without-column. With the doubly phosphorylated 
ISPASPR (bottom panel of Figure 3.17), there is a loss of signal intensity on column 
compared to without-column injections, clearly showing a strong adsorption of the doubly 
phosphorylated peptide. The average area shown in the bar graph indicates only 2% 
recovery with-column compared to without-column. 
The extracted MRM chromatograms of the SSANYR series in the peptide mixture 
with-column and without-column are displayed in Figure 3.18. The extracted MRM 
chromatogram of the SSANYR displayed in the first panel showed the expected trend of 
with-column intensities higher than the without-column due to the solvent composition. 
The second panel corresponds to the singly phosphorylated RRSSPANYR. The singly 
phosphorylated does not show a conclusive change in the intensity, on the other hand the 
doubly phosphorylated RSPSPANYR (bottom panel) there is a lower recovery of the 
peptide with-column vs without-column. The bar graph on the right indicates about 15% 
recovery with-column compared to without-column.  
 
92 
 
 
Figure 3.16: Extracted MRM chromatograms of RPTLR series with and without 
Waters Atlantis C18 column.  
1, 2, and 3 injections are with-column and 4, 5, 6, and 7 are without-column. The 
bar graph is the average area of the three injections with-column and without-column. 
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Figure 3.17: Extracted MRM chromatograms of ISASR series with and without 
Waters Atlantis C18 column.  
1, 2, and 3 injections are with-column and 4, 5, 6, and 7 are without-column. The 
bar graph is the average area of the three injections with-column and without-column. 
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Figure 3.18: Extracted MRM chromatograms of SSANYR series with and without 
Waters Atlantis C18 column. 
1, 2, and 3 injections are with-column and 4, 5, 6, and 7 are without-column. The 
bar graph is the average area of the three injections with-column and without-column. 
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is leading to selective adsorption of the phosphorylated peptides, especially the doubly 
phosphorylated peptides. 
From the with- and without-column studies conducted on three different columns, 
it can be concluded that the issue that complicates the analysis of phosphopeptides by LC-
MS is the selective interaction of phosphopeptides with the stainless steel surfaces of the 
column that can lead to loss of these phosphopeptides. 
3.4. CONCLUSIONS 
In conclusion, though there is a redistribution of charge states due to the presence 
of basic residues R and K and the presence of phosphate groups, the most intense charge 
state is the doubly charged molecular ion in all the peptides studied. Hence, the doubly 
charged molecular ion can be selected as the precursor ion for the MRM method 
development.  
The ionization efficiency studies concluded that there is a decrease in RIE with 
phosphorylation, which further lowered with two phosphate groups. Our results are 
comparable to the results reported by Gropengiesser et.al. (136) who demonstrated that 
phosphopeptides gave lower ionization efficiency in ESI mass spectrometry. 
Gropengiesser et.al reported a mean relative intensity of 0.51 ± 0.21 (SD) of the 
phosphopeptides comapred to the nonphosphorylated peptides. This agrees well with our 
results of 0.47 ± 0.20 (SD), as shown in Table 3.2. These results are contrary to those of 
Steen et al. (107) who stated that in the peptides they studied the phosphopeptides showed 
no difference in ionization to the nonphosphorylated cognates. A point worth mentioning 
is that the peptides studied by the Steen group were longer in length compared to the 
peptides used in this study.  
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In addition to ionization efficiency, phospho-specific adsorption to stainless steel 
components can contribute to challenges in mass spectrometric analysis of 
phosphopeptides. The with and without-column studies carried out on three different 
columns demonstrate that the selective adsorption of phospho-peptides on stainless steel 
frits of the column is more prominent with the doubly phosphorylated peptides. Similar 
observations were reported by Tuytten et.al (138) who studied different phosphorylated 
organic compounds, including phosphopeptides and their selective trapping on steel 
components.  
The initial approach of the thesis project was to develop a method for 
quantification of phosphopeptides of TnI using synthesized stable isotope labeled (SIL) 
peptides, both with and without phosphate modification. The target peptides in mouse 
cardiac TnI are small tryptic peptides, with multiple sites of phosphorylation and have 
multiple miscleaved forms. From this chapter it is clear that quantification using the SIL 
peptides is challenging for these phosphopeptides. Hence for the quantification of target 
peptides of TnI in the mouse heart biopsy samples, it was decided to use the label-free, 
mass balance approach developed by Previs.et al. (108). This method circumvents the need 
to quantify the phosphorylated peptides. The SIL peptides will be used for the identification 
of the small peptides of TnI instead.  
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CHAPTER 4: QUANTIFICATION OF TROPONIN I AND MYOSIN BINDING 
PROTEIN C PHOSPHORYLATION IN TRANSVERSE AORTIC 
CONSTRICTED AND SHAM (CONTROL) MOUSE HEARTS 
4.1. INTRODUCTION  
The goal of the current thesis study is to determine the degree of phosphorylation 
of PKA sites in TnI, and MyBPC in the transverse aortic constriction (TAC) mouse that 
represents an HFpEF mouse model and the sham (control) mouse with no constriction that 
represents normal hearts. TnI has two PKA target sites at N-terminus: S23, and S24. 
MyBPC contains four PKA targeted residues: S273, S282, S302 and S307 in the M-domain 
region of its sequence. Along with the PKA sites of phosphorylation, reported PKC target 
sites of TnI: S43, S45, and T144 will also be measured.  
Protein separation by gel electrophoresis and in-gel digestion of selective proteins 
has been widely accepted as the method of choice for sample preparation in proteomics 
(141). This approach is robust; however, the main limitation is the technique is laborious 
and time-consuming. Moreover, the recoveries of the digested peptides from the gel can be 
lower due to the risk of entrapment of large hydrophobic peptides in the gel matrix. With 
the advancement in instrument technologies in handling complex protein/peptide mixtures, 
we wanted to assess the efficiency of direct, in-solution digestion of the mouse myofibrillar 
preparation (MFP) over the in-gel digestion of selective proteins.  
The original proposal of the experiment was to develop a quantification method 
using SIL peptides, generated with and with-out phosphorylation, but Chapter 3 highlights 
the problems associated with phosphopeptides, especially the loss of signal intensities with 
the presence of two phosphate groups. Hence, the label-free, mass balance approach 
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developed by Previs et al. (108) was adopted for the phosphorylation quantification. This 
method circumvents the need to quantify the phosphorylated peptides. The mass balance 
approach along with the MSE data acquisition technique has been combined to develop an 
LC-MSE analytical method for the label-free quantification of phosphorylation in mouse 
cardiac TnI and MyBPC. 
Preliminary method development was carried out on cadaver human (TX) heart 
to verify the sample preparation method, the LC- MSE methodology, and the data 
processing parameters prior to the actual mouse model studies.  
4.2. MATERIALS AND METHODS 
4.2.1. Scheme for quantification of protein phosphorylation 
As noted in Chapter 1, the quantification of phosphorylation is determined by the 
fraction of peptide that is phosphorylated, 𝑝𝑝 is given by:  
 𝑝𝑝 =  𝑛𝑛𝑝𝑝  
𝑛𝑛𝑜𝑜  + 𝑛𝑛𝑝𝑝   (4.1) 
where 𝑛𝑛𝑝𝑝 is the amount phosphorylated, and 𝑛𝑛0 is the amount of unphosphorylated peptide. 
Equation 4.1 can be rearranged as  1 − 𝑝𝑝 =  𝑛𝑛𝑜𝑜  
𝑛𝑛𝑜𝑜  + 𝑛𝑛𝑝𝑝   (4.2) 
To determine the total amount (𝑛𝑛𝑜𝑜  + 𝑛𝑛𝑝𝑝) in the denominator, Previs et al. (108) split the 
sample into two fractions 𝐹𝐹 and (1 − 𝐹𝐹). One fraction got an alkaline phosphatase (AP) 
treatment, where the phosphorylated peptides are dephosphorylated to give only 
unphosphorylated peptide = (𝑛𝑛𝑜𝑜  + 𝑛𝑛𝑝𝑝).The other fraction is left intact to measure the 
fraction of unphosphorylated amount (𝑛𝑛𝑜𝑜). Fraction 𝐹𝐹 is not AP treated prior to trypsin 
digestion, while (1 − 𝐹𝐹) is AP treated. 
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The measured signal intensity for any peptide by mass spectrometry, 𝐼𝐼, should be linearly 
related to the amount of peptide, 𝑛𝑛. i.e.  
𝐼𝐼  =  𝑘𝑘n  (4.3) 
where 𝑘𝑘 is the ionization constant. When a sample is split into fractions 𝐹𝐹 and (1 − 𝐹𝐹), the 
signal intensities for a peptide, 𝑧𝑧, will be: 
𝐼𝐼𝑧𝑧 =  𝑘𝑘𝑧𝑧𝐹𝐹𝑛𝑛 𝑧𝑧 (4.4) 
𝐼𝐼𝑧𝑧(1−𝐹𝐹) =  𝑘𝑘𝑧𝑧(1 − 𝐹𝐹)𝑛𝑛 𝑧𝑧 (4.5) 
The ratio will be: 
𝐼𝐼z(F)
𝐼𝐼𝑧𝑧(1−𝐹𝐹)   =  𝑘𝑘𝑧𝑧𝐹𝐹 𝑛𝑛z𝑘𝑘𝑧𝑧(1 − 𝐹𝐹)𝑛𝑛z =  𝐹𝐹(1 − 𝐹𝐹) (4.6) 
The amount of unphosphorylated peptide 𝑛𝑛0 in fraction 𝐹𝐹, will have a signal intensity of:  
𝐼𝐼0   =  𝑘𝑘0𝐹𝐹 𝑛𝑛0  (4.7) 
The signal intensity in the dephosphorylated fraction will be: 
𝐼𝐼0+p   =  𝑘𝑘0(1 − 𝐹𝐹) (𝑛𝑛0 + 𝑛𝑛p)  (4.8) 
The ratio of the signals will be: 
𝐼𝐼0
𝐼𝐼0+𝑝𝑝
  =  𝐹𝐹 𝑛𝑛0(1 − 𝐹𝐹)(𝑛𝑛0 + 𝑛𝑛p)   (4.9) 
The signal intensity ratio of the unphosphorylated reference peptide, 𝑧𝑧, provides the 
fraction of splitting, 𝐹𝐹 (1−𝐹𝐹) shown in Equation 4.6. 
Substituting in Equation 4.9,  
𝐼𝐼0
𝐼𝐼0+𝑝𝑝
  = � 𝐼𝐼𝑧𝑧(F)
𝐼𝐼𝑧𝑧(1−F)�  �  𝑛𝑛0𝑛𝑛0 + 𝑛𝑛p�   (4.10) 
rearranging, 
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  𝐼𝐼0 𝐼𝐼𝑧𝑧(F)�𝐼𝐼0+𝑝𝑝
𝐼𝐼𝑧𝑧(1−F)�
=  𝑛𝑛0
𝑛𝑛0 + 𝑛𝑛p = 1 − p  (4.11) 
and the fraction of the peptide that is phosphorylated is  
    𝑝𝑝 = 1 −
⎝
⎛
𝐼𝐼0
𝐼𝐼𝑧𝑧(F)�
𝐼𝐼0+𝑝𝑝
𝐼𝐼𝑧𝑧(1−F)� ⎠
⎞ (4.12) 
Instead, of splitting the sample and adding an additional step of alkaline 
phosphatase treatment, a recombinant protein with no phosphorylation can be used (62,73). 
The use of recombinant protein eliminates any inefficiencies associated with alkaline 
phosphatase treatment, especially because some phosphorylation sites are resistant to 
dephosphorylation by alkaline phosphatase.  
To account for the different amounts of starting material digested and any the run-
to-run measurement variations, normalization is applied by using one or more reference 
peptides, 𝑧𝑧, selected from the same protein of study, i.e. present both in the sample and the 
recombinant. Thus, the “F” subscript in Equation 4.12 is changed to “0” for the sample 
peptide and “r” for the recombinant peptide: 
    𝑝𝑝 = 1 − �𝐼𝐼0 𝐼𝐼𝑧𝑧0�𝐼𝐼r
𝐼𝐼𝑧𝑧r
�
� (4.13) 
where, 𝐼𝐼0, is the measured signal intensity of the unphosphorylated peptide in sample; 𝐼𝐼𝑟𝑟, 
is the measured signal intensity of the unphosphorylated peptide in recombinant; 𝐼𝐼𝑧𝑧(0), is 
the measured signal intensity of the reference peptide in sample and 𝐼𝐼𝑧𝑧(𝑟𝑟), is the measured 
signal intensity of the reference peptide in the recombinant protein. This scheme allows for 
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the measurement of phosphorylation without actually measuring the phosphorylated 
peptide signal.  
Recombinant cardiac TnI expressed in E.coli was purchased from LifeSpan 
BioSciences, Inc. The lyophilized recombinant protein was reconstituted in 20 mM Tris, 
150 mM NaCl buffer. Recombinant cardiac C0-C3 fragment of MyBPC, that contained the 
M-domain was bacterially expressed from mouse cardiac cDNA and was kindly provided 
by Michael J. Previs (66).  
4.2.2. Label-free absolute quantification of proteins 
The LC-MSE data were used for identification and quantification of proteins. 
Quantification of the proteins was performed by the PLGS software. The technique is a 
label-free approach developed by Silva.et al. (142). The quantification method is based on 
the evidence that the sum of the intensity of the three most intense peptides, ∑ 𝐼𝐼𝑖𝑖31 , from 
any protein has a linear correlation to the amount of protein, 𝑁𝑁𝑖𝑖, regardless of the sequence 
or the size of the protein.  
Absolute quantification of proteins is accomplished by the addition of a known 
amount of intact reference protein to the protein mixture prior to the enzymatic digestion. 
The sum of the MS signal intensities of each of the characterized proteins is compared to 
the spiked reference protein to determine the molar amounts of the proteins in the sample: 
∑ 𝐼𝐼𝑖𝑖
3
1
𝑁𝑁𝑖𝑖
=  ∑ 𝐼𝐼𝑗𝑗31
𝑁𝑁𝑗𝑗
=  ∑ 𝐼𝐼𝑘𝑘31
𝑁𝑁𝑘𝑘
= ⋯ = ∑ 𝐼𝐼𝑟𝑟31
𝑁𝑁𝑟𝑟
 (4.14) 
where 𝑖𝑖, j, k… refer to each protein quantified and r refers to the reference protein added. 
Therefore, the amount of any protein in the sample will be  
𝑁𝑁𝑖𝑖 = 𝑁𝑁𝑟𝑟 �∑ 𝐼𝐼𝑖𝑖31∑ 𝐼𝐼𝑟𝑟31 � (4.15) 
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Alcohol dehydrogenase 1 (ADH1) from yeast which has a distinguishable 
sequences from the mouse ADH1 was used as the reference protein for the absolute 
quantification purposes.  
4.2.3. Human heart samples 
Frozen human cadaver left ventricular tissues heart (TX heart) was kindly 
provided by Dr. Martin LeWinter, Department of Medicine and Molecular Physiology and 
Biophysics, the University of Vermont. On the day of the experiment, three 20-mg pieces 
of frozen TX heart were thawed and left in Kreb-Hepes buffer for 20 min. The tissue 
samples were transferred to skinning solution (10 mM BES, 2.5 mM EGTA, 0.5 mM 
MgCl2, 0.5 mM DTT, 0.125 mM phosphate pH 7 buffer, 2.5 mM ATP, 50% glycerol, and 
0.5% Triton X-100 with PhosSTOP) overnight at 4 °C. The tissue slices were then 
transferred to the storage solution (2.5 mM EGTA, 0.5 mM MgCl2, 0.5 mM DTT, 0.125 
mM phosphate pH 7 buffer, 2.5 mM ATP, and 50% glycerol) for 20 min and then prepared 
for homogenization in an ice cold glass tissue grinder with volume of homogenizing buffer 
at 30 X wet weight of the tissue. Each of the homogenized myofibrillar preparations (MFP) 
has a concentration of 33.3 µg of wet tissue/µl of the homogenizing buffer. The MFP of 
the tissue samples were carried out in the Department of Molecular Physiology and 
Biophysics at the University of Vermont by Dr. Yuan Wang.  
Each of the three homogenized MFP samples was split into two fractions. One 
fraction was stored at -80 °C for in-solution digestion. The other fraction was prepared for 
polyacrylamide gel electrophoresis separation. The MFP samples were prepared for gel 
separation by adding 5X sample preparation buffer (312.5 mM Trizma pH 6.8, 50% 
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glycerol, 10% SDS, and 0.05% bromophenol blue) along with 2% β-mercaptoethanol then 
heated for 5 min at 100 °C and stored at -20 °C until use.  
4.2.3.1. Human heart myofibrillar protein in-gel digestion preparation 
The myofibrillar proteins were separated by gel electrophoresis on 7.5 % large 
format gel at 220 V for 4 h. In the gel picture shown in Figure 4.1, 30-µl and 40-µl aliquots 
of the Bio-Rad Protein ladder (Precision Plus Protein™ Standards) (10-250kD) were 
loaded in the 1st and the 2nd lanes, respectively. Lanes 3, 4, and 5 were loaded with 
homogenized sample volume equivalent to 1 mg wet tissue weight. Gels were stained with 
simply blue stain and imaged using an Epson smart panel.  
TnI and MyBPC protein bands were cut from the gel shown in Figure 4.1. The 
protein gel bands were placed in Eppendorf tubes and further cut into smaller pieces rinsed 
with water and destained using 50% acetonitrile. The samples were dehydrated in a 
Vacufuge for 1 h. A 10-pmol aliquot of the reference protein ADH1 was added along with 
100 µl of 0.02-µg/µl trypsin (in 50 mM ammonium bicarbonate buffer) to each sample and 
left for 1 h on ice. If required, additional buffer was added to ensure the gel pieces were 
completely submerged. The samples were left overnight at 37 °C for digestion, after which 
a 10-µl aliquot of 5% formic acid was added to quench the reaction. To extract the peptides 
from the gel pieces, 100-µl aliquot of ammonium bicarbonate buffer with 50% acetonitrile 
was added to each tube. After 20 min, the supernatant liquid was collected. This step was 
repeated 4 times and all the supernatant collected was pooled and dried down in a Vacufuge 
for 3 h. Each of the TnI and MyBPC band extracts were brought up to a total volume of 20 
μl in 98:2 water and acetonitrile with 0.1% trifluoroacetic acid and stored at -20 °C until 
further analysis. 
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4.2.3.2. Human heart myofibrillar proteins in-solution digestion preparation 
Duplicate digests were prepared for each of the homogenized MFP samples. 
Homogenized MFP samples had a concentration of 33.3 µg of wet tissue/µl of the 
homogenizing buffer. Sample volume equivalent to 1 mg wet tissue weight, i.e. 30.03 µl, 
of the TX heart MFP samples, were dried under vacuum along with a 10-pmol aliquot of 
the reference protein ADH1 added. The dried samples were re-suspended in 25 μl of 50 
mM ammonium bicarbonate buffer. PMAX surfactant was added to bring the detergent 
concentration to a final concentration of 0.01% in the total volume. Proteolytic digestion 
was initiated by adding a 1-μg aliquot of modified trypsin (Promega). The digestion was 
carried out using the Promega PMAX protocol. Samples were incubated at 50 °C for 1 h 
and the digestion quenched by heating at 95 °C for 5 min. Each of the digested mixtures 
was dried down and brought up to a total volume of 20 μl in 98:2 water and acetonitrile 
with 0.1% trifluoroacetic acid and stored at -20 °C until further analysis by LC-MSE.  
4.2.4. Mouse treatment  
All procedures followed guidelines outlined in the Guide for Animal Care and 
Use of Laboratory Animals published by the National Institutes of Health and were 
approved by the University of Vermont Institutional Animal Care and Use Committee 
(IACUC 14-042). Male FVB mice (Charles River Laboratories, Canada) 10 to 12 week old 
were anesthetized in an induction chamber with 2% isoflurane. An aortic banding 
procedure was used to constrict the transverse aorta. A 27-gauge needle (0.4 mm outside 
diameter) was placed parallel to the transverse aorta and a suture was tied tightly around 
the aorta and the needle together. The needle was then removed to create a constriction 
around the transverse aorta of the diameter of the needle (0.4-mm) (81). The transverse 
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aortic constriction (TAC) was performed on 14 mice. A 50 mg/pellet deoxycorticosterone 
acetate (DOCA), 21-day release was also implanted subcutaneously. The entire procedure 
was identical for the 11 sham (control) mice except that there was no constriction of the 
aorta and a placebo pellet was implanted instead of the DOCA pellet. The control and TAC 
mice underwent echocardiography post-surgery once a week to demonstrate hypertrophy 
of the left ventricles in the TAC group. After 4-5 weeks, mice were euthanized by 
undergoing anesthesia with 2% isoflurane, followed by removal of the hearts. Tissue from 
the left ventricle was cut and placed in cryo vials, sealed and frozen in liquid nitrogen. 
They were stored at -80 °C.  
4.2.4.1. Preparation of mouse samples for phosphorylation measurements.  
Homogenized mouse MFP samples of the 14 TAC mice and 11 control mice were 
prepared in the Department of Molecular Physiology and Biophysics, the University of 
Vermont by Dr. Yuan Wang using the same protocol used for the human heart tissues stated 
earlier. The homogenized mouse MFP samples were stored at -80 °C for later in-solution 
digestions.  
A few changes were made to the in-solution digestion protocol that was used for 
the human heart samples. Homogenized MFP sample had a concentration of 33.3 µg of 
wet tissue/µl of the buffer. Sample volume equivalent to 2 mg wet tissue weight i.e. 60.06 
µl of the homogenized MFP samples were dried under vacuum along with a 25-pmol 
aliquot of the reference protein ADH1. Three replicates of each tissue sample were 
prepared. The dried samples were re-suspended in 25 μl of 50-mM ammonium bicarbonate 
buffer, vortexed, and left to sit for 15 min. PMAX surfactant was added to bring the 
detergent concentration to a final concentration of 0.01% in the total volume, vortexed at 
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intervals for 15 to 20 min until the sample was homogeneous. The enzyme to substrate 
ratio was increased to 1:20 ratio by weight. A 5-µl aliquot of the corresponding amount of 
modified trypsin (Promega) was added. Samples were incubated at 37 °C overnight to 
improve peptide cleavage. The digestion was quenched by adding 5% formic acid to bring 
the final acid concentration to 0.5% in the total volume.  
Three 2.5-μg (103.6 pmol) aliquots of the recombinant TnI and three 2-μg (33.8 
pmol) of the recombinant MyBPC were trypsin digested using the same procedure. An 
aliquot of 25-pmol amounts of ADH1 was added to every sample prior to the trypsin 
digestion. All samples were dried down and were stored at -20 °C for later analysis by LC-
MSE. 
A solution (0.5 pmol/μl) of SIL peptides (concentrations determined in Chapter 
3) was prepared in 98:2 water and acetonitrile with 0.1% trifluoroacetic acid. Additional 
SIL peptides for MyBPC were also added: DSFR, its miscleaved form RDSFR, and their 
respective phosphorylated forms DSPFR and RDSPFR. These MyBPC SIL peptides were 
procured from Cell Signaling Technology (Danvers, MA, USA). To each of the 
recombinant and mouse MFP samples, 5-pmol of each SIL peptides (Table 4.5) were 
added. All the samples had a final volume of 10 μl prepared in 98:2 water and acetonitrile 
with 0.1% trifluoroacetic acid.  
4.2.5. Data acquisition by LC-MS 
The Waters Xevo G2-XS QTOF instrument was coupled to a Waters Acquity 
UPLC M class system with an ESI interface. Separation of the peptide mixture was 
performed with a Waters Acquity HSS T3 (1.0 x 150 mm, 1.8 μm) column maintained at 
45 °C. The separation was carried out with aqueous mobile phase A, water with 0.1% 
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formic acid and organic mobile phase B, acetonitrile with 0.1 % formic acid. The sample 
was loaded on the column at a starting condition of 2% B, which was maintained for the 
first 4 min of the gradient. The peptides were eluted from the column with a 60-min 
gradient from 2% B to 35% B followed by a 6 min column clean at 85% B. A re-
equilibration to the initial column condition of 2% B was carried out for 10 min. The total 
UPLC run time was 80 min at a flow rate of 50 μl/min.  
For the mouse samples, the gradient profile was changed to a longer 100-min 
method. Samples were loaded on the column at a starting condition of 2% B, which was 
maintained for the first 4 min of the gradient. The peptides were eluted from the column 
with an 80-min gradient from 2% B to 35 %B followed by a 6 min column clean at 90% 
B. A re-equilibration to the initial column condition of 2% B was carried out for 10 min. 
The total LC run time was 100 min at a flow rate of 50 μl/min.  
The mass spectrometer was operated in MSE mode in the range of m/z 100-2000. 
In this mode, the collision energies were alternated from a low energy of 4 eV to collect 
MS spectra then elevated by an energy ramp of 15-40 eV to collect the MSE spectra at a 
scan time of 0.5 sec. The ionization was positive ESI in sensitivity mode. High purity 
nitrogen was used as the nebulizer and auxiliary gas. Argon was used as the collision gas. 
The source parameters were optimized to capillary voltage 3.2 kV; sampling cone 40; 
source temperature 100 °C; desolvation temperature 280 °C, cone gas flow 80 l/h; 
desolvation gas flow 900 l/h. 
Mass accuracy was maintained using the Lock-mass [Glu1]-fibrinopeptide 
molecular ion, [M+2H]2+ = 785.8426 that was acquired at an interval of every 30 sec, an 
average of 3 scans with a mass window of  ± 0.3 Da. Lock-mass [Glu1]-fibrinopeptide was 
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infused at 400 fmol/μL in 50:50 water and acetonitrile with 0.1% formic acid using the 
auxiliary pump to the source at a 5 μl/min flow rate for accurate mass correction. 
Calibration of the mass spectrometer was performed using sodium iodide, 2 μg/μl in 50:50 
isopropanol: water in the range m/z 100-2000. Data acquisition for all experiments was 
carried out by MassLynx 4.1 Waters software.  
4.2.6. LC-MS Data Processing  
The LC-MSE data was processed using the Waters ProteinLynx Global Server 
3.0.1 (PLGS). Protein identification of the TX heart samples was carried out by searching 
against a consolidated human database, which contained the sequences of all myofibrillar 
proteins in different isoforms reported in Uniprot. To this human database, the ADH1 
sequence was appended as well. Mass spectral data was lock-mass corrected post-
acquisition. The threshold for the low energy scan, high-energy scan, and intensity were 
set at 250, 100, 750 counts respectively. The search threshold used are, minimum fragment 
ion matches per peptides are 3, minimum fragment ion matches per protein are 7, minimum 
peptides per protein 1. For the mouse recombinant proteins, and the mouse heart tissue 
samples the protein identification was carried out by searching against modified mouse 
database that contained the sequences of all myofibrillar proteins in different isoforms 
reported in Uniprot with the ADH1 sequence appended as well. 
The output of PLGS is the sum of intensities of all the charge states and their 
isotopes. Ideally, this would be the best-integrated value for quantification, as all charge 
states are pooled together. The output files final_peptide.csv and final_protein.csv 
generated by PLGS gave the list of peptides and the corresponding proteins identified. 
Another software package, Progenesis 2.0 (Nonlinear Dynamics Ltd.), was used for 
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feature-based searching. This software gives the abundance of each charge sate separately, 
but has the advantage of identify peptides in multiple runs by alignment of the LC-MS data 
of multiple runs simultaneously. The same database and search parameters were used as 
that of PLGS to keep the condition of filtering the data consistent with the PLGS.  
4.3. RESULTS  
4.3.1. Recovery of myofibrillar proteins from human heart by in-solution and in-
gel digestion preparations. 
The major proteins of cardiac muscle myofibrils are the troponin complex, 
tropomyosin, actin, MyBPC, and myosin. Troponin complex consists of troponin I, T, and 
C in a 1:1:1 ratio. Each troponin complex interacts with a tropomyosin in a stoichiometric 
ratio of 1:1. There are 7 actin molecules per tropomyosin and 4 actins for one myosin and 
a 1:6 ratio of MyBPC to myosin heads (143,144). The overall stoichiometry of the proteins 
in the myofibrils was expected to be TnC: TnT: TnI: Tm: Actin: Myosin: MyBPC = 1: 1: 
1: 1: 7: 1.75: 0. 
The amount of myofibrillar proteins in a tissue sample was calculated based on 
the assumption that protein content constitutes 20% of wet muscle tissue mass, and 
myofibrillar protein accounts for 50% of the protein content. Therefore, 1 mg of wet tissue 
would have 0.2 mg of total protein and 0.1 mg of myofibrillar protein. The actin content 
was said to be 15% of the myofibrillar proteins (145). Using this information, the actin 
content in 1 mg of wet tissue would be 15 µg = 357.2 pmol. Based on the stoichiometry of 
the myofibrillar proteins the amounts of the proteins TnI, TnT, TnC, Tm, and MyBPC can 
be estimated and are summarized in Table 4.1. Our calculated amounts were in line with 
those estimated by Murakami U et al. (146) in dog cardiac muscle. 
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To determine the efficiency of direct in-solution digestion of the MFP samples 
over in-gel digestion of isolated proteins, recoveries of the proteins were found for both 
techniques and compared to the expected amounts based on the mole ratio. For this 
purpose, cadaver human (TX) heart tissue, which was readily available in substantial 
amounts, was used. 
For the in-solution vs in-gel comparative studies, homogenized MFP samples of 
30.3-µl (equivalent to 1-mg wet tissue weight) aliquots were taken. Six tryptic digestions 
were prepared from three separate TX heart tissue MFP samples. The amount of each 
protein present in the MFP samples was determined by the label-free, absolute protein 
quantification method (Section 4.2.2). A 10-pmol aliquot of ADH1 was added as the 
reference protein. The amounts of the myofibrillar proteins in pmol per mg of the wet tissue 
digested were obtained based on the internal standard ADH1 added. The recoveries are 
summarized in Table 4.1. Troponin C had the lowest recovery and tropomyosin had the 
highest recovery, relative to the expected amounts. The in-solution recoveries of TnI and 
MyBPC were 32.0 ± 5.4, and 8.2 ± 1.0 pmol/mg of wet tissue respectively.  
For in-gel digestions, three TX heart MFP samples were loaded on the gel. An 
aliquot equivalent to 1-mg of the wet tissue was loaded into each lane, i.e. the same amount 
that was taken for the direct in-solution digestion. Prior to the trypsin digestion a 10-pmol 
aliquot, of the reference protein ADH1 was added to each of the MyBPC and TnI gel bands 
(Figure 4.1) for absolute quantification. The amount of TnI and MyBPC in the three gel 
samples was found to be 4.1 ± 1.0 (SE), and 1.6 ± 0.3 pmol/mg of wet tissue, respectively.  
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Table 4.1: Recovery of myofibrillar proteins from TX heart preparation: 
Comparison of in-solution vs in-gel digestion methods. 
Description 
 
 
Measured amount  
(pmol/mg wet tissue) 
Expected In-solution In-gel 
Mole  
ratio 
Amount 
(pmol/mg wet tissue) Mean  ± SE Mean  ± SE 
Actin, alpha 7 357.2 169.7 ± 20.6    
Myosin-binding protein C 0.3 15.3 8.2 ± 1.0 1.6 ± 0.3 
Tropomyosin alpha-1 1 51 54.4 ± 9.8    
Troponin C 1 51 13.4 ± 2.3    
Troponin I 1 51 32.0 ± 5.4 4.1 ± 1.0 
Troponin T 1 51 22.7 ± 3.6    
An aliquot of 10 pmol of ADH1 was added as the reference protein to both in-solution and 
in-gel digests for absolute quantification. N = 6 for in-solution (3 biopsies x 2 digests each), 
and N = 3 for in-gel (3 bands for TnI and MyBPC each). Only MyBPC and TnI bands were 
cut out of the gel and digested; no other protein gel bands were analyzed.  
 
The in-gel recoveries were much lower compared to that of in-solution recoveries. 
The recoveries for both TnI and MyBPC proteins in the case of in-solution digest were 
about 50% of the theoretical amounts, whereas the recoveries were about 10% of the 
theoretical amounts in the case of in-gel, as shown in Figure 4.2. These results show that 
in spite of the complexity of the sample, the in-solution digestion of the MFP samples was 
significantly more efficient than the in-gel samples, in spite of isolation of the desired 
proteins using gel electrophoresis. The low recoveries of in-gel digestions could be due to 
the multiple steps involved in the gel digestion and the loss of sample associated with these 
steps. For example, the gel limits trypsin’s access to the proteins. Typically, gel bands are 
cut into smaller pieces to enhance enzyme activity, but the efficiency of trypsin diffusing 
into the gel to digest the protein can be limited. Moreover, there can be post digestion losses 
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during the extraction of digested peptides from the gel. For example, large peptides are 
difficult to extract out of the gel matrix (147,148).  
 
Figure 4.1: Gel separation of the human (TX) myofibrillar preparation. 
A 7.5% large gel format was run at 220 V for 4 hours. Bio-Rad Protein ladder 
(10-250 kD) was loaded in lanes 1, and 2. Lanes 3, 4, and 5 each have 1 mg of three 
preparations of TX heart myofibrillar proteins. MyHC = myosin heavy chain, MyBPC = 
myosin binding protein C, TnT = Troponin T, Tm = tropomyosin, and TnI = Troponin I.  
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Figure 4.2: Recovery of TnI and MyBPC by in-solution and in-gel digestions. 
A 10-pmol aliquot of ADH1 was added as the reference protein for both in-
solution and in-gel digests. Green bars display the recovery of protein by in-solution 
digestion of the TX heart myofibrillar preparation. Red bars display the recovery of protein 
by in-gel digestion of TnI and MyBPC gel bands respectively. Error bar is SD. (N = 6 for 
in-solution and N = 3 for in-gel) 
 
Protein coverage is an indication of the fraction of the protein sequence covered 
by the identified peptides in the protein. Therefore, increase in the number of peptides 
identified, increases the protein coverage. Figure 4.3 shows the protein coverage of TnI 
and MyBPC by in-solution, and in-gel digestions. The coverage was considerably higher 
in the in-solution compared to in-gel. The protein coverage results assert that the in-
solution digestion of the MFPs was advantageous over the in-gel digestion.  
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Figure 4.3: Protein coverage by LC-MSE analysis of in-solution and in-gel digests 
for TnI and MyPBC. 
Green bars display the percent of protein amino acid sequence identified by 
analysis of in-solution digests of the TX heart myofibrillar preparation. Red bars display 
the percent of protein sequence identified by in-gel digestion of TnI and MyBPC. Error bar 
is SD. (N = 6 for in-solution and N = 3 for in-gel) 
 
4.3.2. Measurement of peptides with known phosphorylation sites in human heart 
The amino acid sequence of human cardiac TnI is displayed in Figure 4.4. The 
known PKA target sites are S23 and S24. Additionally, the known PKC sites are S42, S44 
and T143. All phosphorylation sites are indicated in red in Figure 4.4. The potential tryptic 
peptides are marked by an underline in black, along with possible miscleavages.  
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Figure 4.5 shows the amino acid sequence of human cardiac MyBPC. The known 
PKA phosphorylation sites are S275, S284, S304, and S311. The phosphorylation sites of 
interest are indicated in red, and the potential tryptic peptides, along with possible 
miscleavages that can form, are indicated by a black underline.  
Our target peptides are those that contain the known phosphorylation sites. The 
peptides that were identified by PLGS by in-solution digest of the TX heart MFP samples 
are given in Table. 4.2. Both correctly cleaved and miscleaved peptides were identified by 
PLGS. For quantification purposes, the correctly cleaved peptides are preferred. However, 
trypsin digestion is known to produce miscleaved peptides, depending on the residues 
flanking the arginine or lysine at the tryptic cleavage sites. The total intensity of miscleaved 
forms is reported to be usually at about 20% (149). In Table 4.2, the peptides identified, 
along with their fractional intensity (i.e. intensity of peptide/ total sum of the intensity of 
both the correctly cleaved and the miscleaved forms), are given.  
  
10         20         30         40         50          
MADGSSDAAR EPRPAPAPIR RRSSNYRAYA TEPHAKKKSK ISASRKLQLK 
TLLLQIAKQE LEREAEERRG EKGRALSTRC QPLELAGLGF AELQDLCRQL 
HARVDKVDEE RYDIEAKVTK NITEIADLTQ KIFDLRGKFK RPTLRRVRIS 
ADAMMQALLG ARAKESLDLR AHLKQVKKED TEKENREVGD WRKNIDALSG 
MEGRKKKFES 
Figure 4.4: Amino acid sequence of human cardiac troponin I. 
(Uniprot: P19429) Length: 210 amino acids, Mass: 24,008 Da. The sites 
highlighted in red are the known phosphorylation sites, with the underlines indicating the 
tryptic peptides along with possible miscleavages that can form. 
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        10         20         30         40         50         
MPEPGKKPVS AFSKKPRSVE VAAGSPAVFE AETERAGVKV RWQRGGSDIS 
ASNKYGLATE GTRHTLTVRE VGPADQGSYA VIAGSSKVKF DLKVIEAEKA 
EPMLAPAPAP AEATGAPGEA PAPAAELGES APSPKGSSSA ALNGPTPGAP 
DDPIGLFVMR PQDGEVTVGG SITFSARVAG ASLLKPPVVK WFKGKWVDLS 
SKVGQHLQLH DSYDRASKVY LFELHITDAQ PAFTGSYRCE VSTKDKFDCS 
NFNLTVHEAM GTGDLDLLSA FRRTSLAGGG RRISDSHEDT GILDFSSLLK 
KRDSFRTPRD SKLEAPAEED VWEILRQAPP SEYERIAFQY GVTDLRGMLK 
RLKGMRRDEK KSTAFQKKLE PAYQVSKGHK IRLTVELADH DAEVKWLKNG 
QEIQMSGSKY IFESIGAKRT LTISQCSLAD DAAYQCVVGG EKCSTELFVK 
EPPVLITRPL EDQLVMVGQR VEFECEVSEE GAQVKWLKDG VELTREETFK 
YRFKKDGQRH HLIINEAMLE DAGHYALCTS GGQALAELIV QEKKLEVYQS 
IADLMVGAKD QAVFKCEVSD ENVRGVWLKN GKELVPDSRI KVSHIGRVHK 
LTIDDVTPAD EADYSFVPEG FACNLSAKLH FMEVKIDFVP RQEPPKIHLD 
CPGRIPDTIV VVAGNKLRLD VPISGDPAPT VIWQKAITQG NKAPARPAPD 
APEDTGDSDE WVFDKKLLCE TEGRVRVETT KDRSIFTVEG AEKEDEGVYT 
VTVKNPVGED QVNLTVKVID VPDAPAAPKI SNVGEDSCTV QWEPPAYDGG 
QPILGYILER KKKKSYRWMR LNFDLIQELS HEARRMIEGV VYEMRVYAVN 
AIGMSRPSPA SQPFMPIGPP SEPTHLAVED VSDTTVSLKW RPPERVGAGG 
LDGYSVEYCP EGCSEWVAAL QGLTEHTSIL VKDLPTGARL LFRVRAHNMA 
GPGAPVTTTE PVTVQEILQR PRLQLPRHLR QTIQKKVGEP VNLLIPFQGK 
PRPQVTWTKE GQPLAGEEVS IRNSPTDTIL FIRAARRVHS GTYQVTVRIE 
NMEDKATLVL QVVDKPSPPQ DLRVTDAWGL NVALEWKPPQ DVGNTELWGY 
TVQKADKKTM EWFTVLEHYR RTHCVVPELI IGNGYYFRVF SQNMVGFSDR 
AATTKEPVFI PRPGITYEPP NYKALDFSEA PSFTQPLVNR SVIAGYTAML 
CCAVRGSPKP KISWFKNGLD LGEDARFRMF SKQGVLTLEI RKPCPFDGGI 
YVCRATNLQG EARCECRLEV RVPQ  
Figure 4.5: Amino acid sequence of human cardiac myosin binding protein C. 
(Uniprot: Q14896) Length: 1,274 amino acids, Mass: 140,762 Da. The sites 
highlighted in red are the known phosphorylation sites, with the underlines indicating the 
tryptic peptides along with possible miscleavages that can form. 
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For the TnI peptides, SSNYR was not identified by PLGS, but the miscleaved 
RSSNYR form was found. ISASR was correctly cleaved and was the predominant peptide 
and best suited for quantification. In the case of PTLR, the C-terminal to arginine is directly 
followed by a proline residue that hinders the specificity of trypsin, so the most probable 
peptide is RPTLR (150), but multiple miscleaved forms were identified by PLGS. No 
PTLR or RPTLR were found. 
For MyBPC peptides, TSLAGGGR was correctly cleaved and was the 
predominant form. The ISDSHEDTGILDFSSLLK peptide was found as the 
phosphorylated form RISPDSHEDTGILDFSSLLK. The phosphorylated form of the 
peptide was the most intense peptide. However, the non-phosphorylated 
ISDSHEDTGILDFSSLLK was not identified by PLGS in any of the samples due to the 
low signal intensity. DSFR was not found by PLGS. This could be because the software 
relies on sufficient b and y ions generated during fragmentation for identification of the 
peptide, and small peptides tend to produce very few b and y ions. 
DSK that has the PKA site of phosphorylation was too small to be retained on the 
reversed phase column. Hence, the adjacent correctly cleaved peptide 
LEAPAEEDVWEILR that was successfully used by Palmer et al. (73) was selected for the 
quantification of degree of phosphorylation of DSK peptide. PLGS found the miscleaved 
unphosphorylated DSKLEAPAEEDVWEILR as the predominant peptide in the in-
solution digestions of the TX heart MFP samples. 
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Table 4.2: Target peptides in TX heart using the PMAX digestion protocol. 
 Target peptides Identified peptides Peptide 
Type 
Fractional 
Intensity 
TnI SSNYR RSSNYR Miscleaved  
 ISASR ISASR  94.0% 
 RPTLR GKFKRPTLR Miscleaved 11.7% 
  FKRPTLRR Miscleaved 46.9% 
  FKRPTLR Miscleaved 29.0% 
  RPTLRR Miscleaved 12.1% 
MyBPC TSLAGGGR RTSLAGGGR Miscleaved 9.4% 
  TSLAGGGR  90.6% 
 ISDSHEDTGILDFSSLLK -   
 DSFR -   
 LEAPAEEDVWEILR DSKLEAPAEEDVWEILR Miscleaved 99.6% 
Target peptides are peptides with known phosphorylation sites. Fractional intensity is the 
ratio of the intensity of the peptide to the sum intensity of all forms identified. Peptides 
with fractional intensity <10% are not included. The phosphorylated form of 
ISDSHEDTGILDFSSLLK is the most intense ion, the fractional intensity of 
unphosphorylated ISDSHEDTGILDFSSLLK <10%. 
 
These results identified two major problems that needed to be resolved before the 
protocol could be applied for the analysis of actual mouse hearts. RPTLR in TnI and 
LEAPAEEDVWEILR in MyBPC have miscleaved forms as the predominant peptides that 
are ideally not suitable for quantification. Moreover, PLGS was not able to find the small 
peptides like SSNYR, DSFR.  
To alleviate the miscleavages formation, multiple iterations to the digestion 
protocol were carried out, changing the enzyme amounts, digestion conditions, 
temperatures and times. The final protocol described in the experimental section was the 
optimized protocol where the enzyme to substrate ratio was changed to 1: 20 by weight 
and the digestion time was increased to overnight. The target peptides containing known 
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phosphorylation sites that were identified by using this new digestion protocol on TX heart 
MFP samples are given in Table. 4.3. 
For TnI peptides, SSNYR was not identified by PLGS, and we do not see the 
miscleaved form RSSNYR either. ISASR was not identified by PLGS, but was found 
manually based on the retention time and precursor ion information obtained from the 
previous runs. RPTLR with the new protocol fell in line with the expected peptides. Two 
peptides were identified by PLGS with RPTLR being the predominant peptides (87.4%) 
and the miscleaved FKRPTLR (12.6%). Thus, RPTLR can now be used for quantification.  
For MyBPC, TSLAGGGR was the correctly cleaved and the predominant form. 
ISDSHEDTGILDFSSLLK, the phosphorylated form RISPDSHEDTGILDFSSLLK was 
the most intense peptide. The non-phosphorylated ISDSHEDTGILDFSSLLK was not 
found by PLGS in the samples due to low intensity. DSFR was not found by PLGS. 
LEAPAEEDVWEILR with the new protocol was the predominant peptide with the 
fractional intensity of 96.1% and can now be used for the phosphorylation quantification. 
DSKLEAPAEEDVWEILR, the miscleaved peptide that was earlier a problem with the 
new digestion protocol was < 5% in intensity. Therefore, the new digestion protocol, 
reduced the formation of miscleaved peptides and favored the correctly cleaved peptides 
that will be used for the quantification of phosphorylation. 
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Table 4.3: Target peptides in TX heart using the optimized overnight digestion 
protocol.  
 Peptide of interest Identified peptides Peptide Type Fractional 
Intensity 
TnI SSNYR -   
 ISASR ISASR  100% 
 RPTLR FKRPTLR Miscleaved 12.6% 
  RPTLR  87.4% 
MyBPC TSLAGGGR RTSLAGGGR Miscleaved 15.7% 
  TSLAGGGR  84.3% 
 ISDSHEDTGILDFSSLLK -   
 DSFR -   
     
 LEAPAEEDVWEILR LEAPAEEDVWEILR  96.1% 
Fractional intensity is the ratio of the intensity of the peptide to the sum intensity of all 
forms identified. Peptides with fractional intensity <10% are not included. The 
phosphorylated form of ISDSHEDTGILDFSSLLK is the most intense ion, the fractional 
intensity of unphosphorylated ISDSHEDTGILDFSSLLK <10%. 
 
4.3.3. Recovery of TnI and MyBPC in the control and TAC mouse tryptic 
digestions. 
Three replicate tryptic digestions were prepared using the finalized in-solution 
digestion protocol for each of the 14 TAC and 11 control mouse heart MFP samples. For 
each digestion, aliquots of MFP sample equivalent to 2 mg of wet tissue weight were taken. 
The expected amounts of the myofibrillar proteins in mouse heart preparation were 
estimated based on the stoichiometry of the proteins described in section 4.3.1. The 
absolute protein content was determined by the addition of 25 µg of ADH1 as reference 
protein to each sample prior to tryptic digestion. The expected amounts of the myofibrillar 
proteins in 2 mg of the wet tissue and the amount found in the mouse MFPs are summarized 
in Table 4.4. 
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Table 4.4: Recovery of the myofibrillar proteins from mouse heart preparations. 
Description 
Expected 
Measured amount (pmol) 
Control TAC 
Mole 
ratio 
Amount 
(pmol) Mean ± SE Recovery ± SE Mean ± SE Recovery ± SE 
Actin 7 713.8 1310.2 ± 71.1 184% ± 10% 816.9 ± 74.5 114% ± 10% 
Myosin-binding protein C 0.3 30.6 48.4 ± 4.8 173% ± 13% 38.6 ± 2.3 133% ± 8% 
Tropomyosin alpha-1 1 102.1 358.1 ± 22.5 351% ± 22% 247.8 ± 19.8 243% ± 19% 
Troponin C 1 102.1 152.0 ± 9.3 149% ± 9% 139.1 ± 11.8 136% ± 12% 
Troponin I 1 102.1 95.7 ± 5.1 94% ± 5% 77.4 ± 3.2 76% ± 3% 
Troponin T 1 102.1 87.8 ± 4.3 86% ± 4% 68.4 ± 3.4 67% ± 3% 
About 2 mg of wet tissue weight was taken for each digestion. Three trypsin digests per mouse heart MFP were prepared (except 
control 13 that has 2 digests). A 25-pmol aliquot of ADH1 was added to each sample as a reference protein for the absolute 
quantification of protein content.  
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The overall recoveries of the myofibrillar proteins were much higher (>100% for 
some of the myofibrillar proteins) when compared to the TX heart recoveries. This could 
be due to better homogenization and dissolution of the mouse hearts when compared to 
human cardiac tissue that is difficult to homogenize and to solubilize. Moreover, the 
expected amount is based on the assumption that the aliquot of homogenized MFP sample 
had 2 mg of wet tissue. There is a possibility that the aliquot had more than 2 mg of wet 
tissue. The consistency of the aliquots can be inferred from the SE of all the control and 
TAC digestions. In the mouse MFP samples, MyBPC had a higher recovery than TnI, as 
shown in the bar graph shown in Figure 4.6.  
 
Figure 4.6: Recovery of TnI and MyBPC in mouse myofibrillar digestions. 
A 25-pmol aliquot of ADH1 was added as the reference protein in both control 
and TAC mouse digests. Blue bars display the recovery of protein in the control mice. 
Purple bars display the recovery of protein in TAC mice. Error bar is SD. (N = 32 for 
control mouse digests and N = 42 for TAC mouse digests). 
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For TnI and MyBPC in the control and TAC mouse heart digests, the protein 
coverages are displayed in Figure 4.7. Both proteins had >80% coverage in the control and 
TAC MFP digestions, with better coverage of MyBPC, as expected from the recovery of 
MyBPC in the mouse MFP samples.  
 
Figure 4.7: Protein coverage by LC-MSE analysis of TnI and MyPBC in control and 
TAC mouse digestions. 
Blue bars display the percent of protein amino acid sequence identified in the 
mouse control heart myofibrillar preparations. Purple bars display the percent of protein 
sequence identified in the TAC mouse heart myofibrillar preparations. Error bar is SD. (N 
= 32 for control mouse digests and N = 42 for TAC mouse digests). 
 
4.3.4. Measurement of target peptides of TnI in the recombinant-TnI and the 
mouse heart myofibrillar sample preparations. 
The amino acid sequence of mouse cardiac TnI is given in Figure 4.8. The known 
PKA target sites, S23 and S24 are indicated in red. Additionally indicated in red are S43, 
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S45, and T144 the known PKC target sites. The potential tryptic peptides along with 
possible miscleavages that can form are indicated by the underline.  
 
 
 
 
 
 
 
 
The SIL peptides given in Table 4.5 that were added to each digestion (all 
recombinants as well as mouse heart MFP samples) were used to identify the peptides, 
especially important for small target peptides that were not identified by the software.  
Figure 4.9 displays the LC-MSE chromatograms of recombinant mouse TnI. The 
top panel displays the base peak chromatogram of the recombinant TnI showing the TnI 
peptides elution times. The second panel corresponds to the extracted doubly charged 
molecular ion of SSANYR, [M+2H]2+ = 349.17. It elutes at a retention time of 6.46 min. 
The bottom panel is the extracted doubly charged molecular ion of the SIL peptides 
SSANY*R, [M+2H]2+ = 354.18 at a retention time of 6.44 min, where Y* is 
[13C915N]tyrosine labeled.  
The extracted chromatograms of SSANYR and SSANY*R in a mouse MFP 
tryptic digestion are displayed in Figure 4.10. The top panel displays the base peak 
chromatogram and the complexity of the preparation by the dense number of 
chromatographic peaks of the peptides. The second panel corresponds to the extracted 
        10         20         30         40         50          
MADESSDAAG EPQPAPAPVR RRSSANYRAY ATEPHAKKKS KISASRKLQL 
KTLMLQIAKQ EMEREAEERR GEKGRVLRTR CQPLELDGLG FEELQDLCRQ 
LHARVDKVDE ERYDVEAKVT KNITEIADLT QKIYDLRGKF KRPTLRRVRI 
SADAMMQALL GTRAKESLDL RAHLKQVKKE DIEKENREVG DWRKNIDALS 
GMEGRKKKFE G 
Figure 4.8: Amino acid sequence of mouse cardiac troponin I. 
(Uniprot: P48787) Length: 211 amino acids, Mass: 24,259 Da. The sites 
highlighted in red are the known phosphorylation sites with the underlines indicating the 
tryptic peptides along with possible miscleavages that can form. 
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doubly charged molecular ion of SSANYR, [M+2H]2+ = 349.17 at a retention time of 5.56 
min. In spite of the small extraction widow of 0.015 m/z, we observe multiple extracted 
peaks in the second panel. This again reflects the complexity of the in-solution mouse MFP 
digests. There are base peak ions within the 349.688-349.703 m/z window that correspond 
to other ions in the digestion. Knowledge and confirmation of the doubly charged 
molecular ion of SSANY*R, [M+2H]2+ = 354.18 (extracted in the bottom panel at a 
retention time of 5.59 min) confirms the identification of SSANYR in the sample. There is 
a retention time change (<1 min) compared to the recombinant run, not unexpected because 
the recombinant and the mouse sample data were acquired a week apart.  
The LC-MS extracted chromatograms of ISASR from the recombinant TnI are 
shown in Figure 4.11. The top panel displays the base peak chromatogram. The second 
panel corresponds to the extracted doubly charged molecular ion of ISASR, [M+2H]2+ = 
267.15 at a retention time of 7.78 min. The bottom panel is the extracted doubly charged 
molecular ion of ISA*SR, [M+2H]2+ = 269.16 at a retention time of 7.75 min, where A* is 
[13C315N]alanine labeled.  
Figure 4.12 displays the chromatograms of ISASR and ISA*SR in a mouse MFP 
digestion. The top panel displays the base peak chromatogram of the mouse heart MFP 
digestion. The second panel corresponds to the extracted doubly charged molecular ion of 
ISASR, [M+2H]2+ = 267.15 of at a retention time of 7.27 min and the corresponding doubly 
charged molecular ion of ISA*SR, [M+2H]2+ = 269.16 at a retention time of 7.29 min is 
shown in the bottom panel.  
The extracted ion chromatograms for RPTLR from the recombinant TnI are 
shown in Figure 4.13, with the top panel displays the base peak chromatogram. The second 
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panel corresponds to the extracted doubly charged molecular ion of RPTLR, [M+2H]2+ = 
321.71 at a retention time of 11.17 min. The bottom panel is the extracted doubly charged 
molecular ion of RPTL*R, [M+2H]2+ = 325.22 at a retention time of 11.16 min, where L*is 
[13C615N]leucine.  
Figure 4.14 shows the extracted ion chromatogram of RPTLR and RPTL*R in a 
mouse MFP digestion. The top panel displays the base peak chromatogram of the mouse 
heart MFP digestion. The second panel corresponds to the extracted doubly charged 
molecular ion of RPTLR, [M+2H]2+ = 321.71 at a retention time of 10.22 min and the 
corresponding doubly charged molecular ion of RPTL*R [M+2H]2+ = 325.22 at a retention 
time of 10.21 min is shown in the bottom panel. 
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Table 4.5: SIL tryptic peptide mixture. 
 # Peptide sequence [M+H] (Da) 
 TnI SIL peptides 
1 SSANY*R 707.38  
2 SSPANY*R 787.35  
3 RSSANY*R 863.48  
4 RSSPANY*R 943.45  
5 RSPSA*NY*R 947.46  
6 RSPSPANY*R 1,023.42  
7 RRSSPANY*R 1,099.56  
8 RRSPSA*NY*R 1,103.56  
9 RRSPSPA*NY*R 1,183.53  
10 ISA*SR 537.34  
11 ISA*SPR 617.31  
12 ISPA*SR 617.31  
13 ISPA*SPR 697.27  
14 ISA*SRK 665.43  
15 ISA*SPRK 745.40  
16 ISPA*SRK 745.40  
17 ISPA*SPRK 825.37  
18 RPTL*R 649.44  
19 RPTPL*R 729.42  
20 RPTPL*RR 885.52  
 MyBPC SIL peptides 
21 DSF*R 534.29  
22 DSPF*R 614.25  
23 RDSF*R 690.39  
24 RDPSF*R 770.35  
To each digestion 5 pmol of each of the SIL peptide was added. PPhosphorylated serine or 
threonine. A* = [13C315N]alanine, Y* = [13C915N]tyrosine, L* = [13C615N]leucine, and  
F* = [13C915N]phenylalanine.  
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Figure 4.9: Extracted ion chromatograms of SSANYR and SSANY*R in recombinant mouse troponin I. 
Top panel (red) is the base peak chromatogram. The second panel (purple) is the extracted chromatogram of SSANYR, 
[M+2H]2+ = 349.17. The bottom panel (green) is the extracted chromatogram of SSANY*R, [M+2H]2+ = 354.18. Y* = 
[13C915N]tyrosine. A 10.4 pmol of the tryptic digested recombinant TnI was injected onto the column. 
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Figure 4.10: Extracted ion chromatograms of SSANYR and SSANY*R in mouse MFP digestion. 
Top panel (red) is the base peak chromatogram. The second panel (purple) is the extracted chromatogram of SSANYR, 
[M+2H]2+ = 349.17. The bottom panel (green) is the extracted chromatogram of SSANY*R, [M+2H]2+ = 354.18. Y* = 
[13C915N]tyrosine. Both SSANYR, and SSANY*R elute at 5.6 min. 
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Figure 4.11: Extracted ion chromatograms of ISASR and ISA*SR in recombinant mouse troponin I. 
Top panel (red) is the base peak chromatogram. The second panel (purple) is the extracted chromatogram of ISASR, 
[M+2H]2+ = 267.15. The bottom panel (green) is the extracted chromatogram of ISA*SR, [M+2H]2+ = 269.16. A* = 
[13C315N]alanine. 
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Figure 4.12: Extracted ion chromatograms of ISASR and ISA*SR in mouse heart MFP digestion. 
Top panel (red) is the base peak chromatogram. The second panel (purple) is the extracted chromatogram of ISASR, 
[M+2H]2+ = 267.15. The bottom panel (green) is the extracted chromatogram of ISA*SR, [M+2H]2+ = 269.16. A* = 
[13C315N]alanine. Both ISASR, and ISA*SR elute at 7.3 min. 
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Figure 4.13: Extracted ion chromatograms of RPTLR and RPTL*R in recombinant mouse troponin I. 
Top panel (red) is the base peak chromatogram. The second panel (purple) is the extracted chromatogram of RPTLR, 
[M+2H]2+= 321. 71. The bottom panel (green) is the extracted chromatogram of RPTL*R, [M+2H]2+= 325.22. L* = 
[13C615N]leucine. 
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Figure 4.14: Extracted ion chromatograms of RPTLR and RPTL*R in mouse heart MFP digestion. 
Top panel (red) is the base peak chromatogram. The second panel (purple) is the extracted chromatogram of RPTLR, 
[M+2H]2+ = 321. 71. The bottom pagnel (green) is the extracted chromatogram of RPTL*R, [M+2H]2+ = 325.22. L* = 
[13C615N]leucine. Both RPTLR, and RPTL*R elute at 10.2 min 
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The SIL peptides were important to identify where the unphosphorylated target 
peptides in the mouse heart digests would elute. The number of digests that the SIL peptides 
were identified in are summarized in Table 4.6. Each mouse heart had three replicate in-
solution tryptic digestions prepared, except for control mouse #13 (one tryptic digest 
containing the MFP broke during centrifuge and was lost). During the data acquisition, 
there were UPLC pressure and flow problems during the TAC mouse #16 runs; the 
sequence stopped multiple time during the TAC mouse #17 runs and the TAC mouse #19 
runs. The UPLC column was cleaned multiple times to get the column pressure down. The 
TAC mouse # 16, #17 and #19 were not rerun because the TIC of the runs was still within 
the expected range. However, during data processing, we were not able to find either the 
SIL peptide or the target peptide for TAC mouse #17. The deduction is that the intensity 
of the small peptides, dropped below the cutoff used for filtering the mass data. The same 
reason holds for ISASR peptides. ISASR intensity was consistently low even in the mouse 
heart samples in which it was identified in (almost half the intensity of SSANYR and 
RPTLR). The reason for not finding ISASR in all the samples could be because its signal 
intensity was at the range of the sensitivity of measurement. 
SSANYR that contains the PKA target sites is the focus of the current study, and 
was found in 70 mouse heart sample digests of 74 (both control and TAC). ISASR that 
contains the PKC target sites was found in only 29 of the 74 digests. RPTLR that contains 
the other PKC target site was identified in 62 of the 74 digests of control and TAC mouse 
hearts.  
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Table 4.6: Identification of TnI target peptides and the corresponding SIL peptides in the mouse myofibrillar 
digestions. 
Control TAC 
Mouse SSANYR SSANY*R ISASR ISA*SR RPLTR RPTL*R Mouse SSANYR SSANY*R ISASR ISA*SR RPLTR RPTL*R 
11 3 3 3 3 3 3 1 3 3 3 3 3 3 
12 3 3 3 3 3 3 2 3 3 3 3 3 3 
13 2 2 2 2 2 2 3 3 3 3 3 3 3 
21 3 3 3 3 3 3 4 3 3 3 3 3 3 
24 3 3 0 3 0 3 5 3 3 0 3 3 3 
25 3 3 0 3 0 3 6 3 3 0 3 3 3 
26 3 3 0 3 1 3 7 3 3 3 3 3 3 
27 3 3 0 3 3 3 14 3 3 3 3 3 3 
18 3 3 0 3 3 3 15 3 3 0 3 3 3 
28 3 3 0 3 3 3 16 3 3 0 3 3 3 
29 3 3 0 3 3 3 17 0 0 0 0 0 0 
19 2 2 0 2 2 2 
20 3 3 0 3 3 3 
22 3 3 0 3 3 3 
Total 32/32 32/32 11/32 32/32 24/32 32/32  38/42 38/42 18/42 38/42 38/42 38/42 
3,2,1,0 indicate the number of digests peptide were identified in a total of 3 digests per mouse heart. (Control 13 has 2 digests) 
*Indicates labeled amino acid.
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The scheme for quantification of phosphorylation only requires measurement of 
the unphosphorylated forms of the target peptides and measurement of one or more suitable 
reference peptides. These peptides are measured in both the recombinant protein and the 
protein from the mouse MFP digestions. The reference peptide must be identifiable and 
quantifiable. The entire list of expected tryptic peptides for TnI was generated using 
http://prospector.ucsf.edu/prospector/cgi-bin/msform.cgi?form=msdigest and is shown in 
Table 4.7. Only correctly, cleaved peptides are shown. It is from this list of correctly 
cleaved peptides that we would select the reference peptides. If a peptide was identified in 
any of the recombinant or the mouse heart samples either by the software or manually, it 
is displayed with a retention time in Table 4.7. Peptides that were identified in all the 
recombinant runs and the mouse hearts, i.e. both the control and TAC mice, are indicated 
by “yes”. Some peptides were identified with miscleaved or oxidized methionine. Theses 
peptides are indicated by “M” and “O” for identification of miscleaved or oxidized 
methionine forms, respectively.  
TnI is a small protein of 24 kDa and has a high density of R and K, therefore 
generating many small peptides. These peptides are generally hydrophilic and poorly 
retained on the reversed phase column used for the peptide separation. In TnI expected 
tryptic peptides, 14 of them are less than 4 amino acid residues in length and were not 
identified. The TnI sequence starts with M, but this residue is excised during the translation 
of the protein. Mouse cardiac TnI does not have the N-terminus M, but the recombinant 
TnI that was synthesized does, and this methionine is partially oxidized. Hence, this peptide 
was not used as a reference peptide. Large hydrophobic peptides are so well retained on 
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the column that they may likely not elute, or elute during the final wash part of the gradient. 
This could be the reason for not finding the CQPLELDGLGFEELQDLCR peptide.  
Table 4.7: Expected tryptic peptides for mouse cardiac TnI and the peptides 
identified in recombinant protein and the myofibrillar samples. 
Position 
Sequence 
[M+H]  
(Da) 
RT 
(min) 
Identified  
in all runs 
Problems‡ 
Start End 
1 20 (-)MADESSDAAGEPQP 
APAPVR(R) 
1,995.91  27.1  M and O 
23 28 (R)SSANYR(A) 697.33  4.32   
29 37 (R)AYATEPHAK(K) 987.49  13.83 yes  
40 41 (K)SK(I) 234.14     
42 46 (K)ISASR(K) 533.30  7.78   
48 51 (K)LQLK(T)  501.34     
52 59 (K)TLMLQIAK(Q) 917.55  45.29 yes O 
60 64 (K)QEMER(E) 692.30  7.18 yes  
65 69 (R)EAEER(R) 633.28  2.38   
71 73 (R)GEK(G) 333.18     
74 75 (K)GR(V) 232.14     
76 78 (R)VLR(T) 387.27     
79 80 (R)TR(C) 276.17     
81 99 (R)CQPLELDGLGF 
EELQDLCR(Q) 
2,178.02    
100 104 (R)QLHAR(V) 624.36  3.96   
105 107 (R)VDK(V) 361.21     
108 112 (K)VDEER(Y) 647.30    M 
113 118 (R)YDVEAK(V) 724.35  17.26 yes M 
119 121 (K)VTK(N) 347.23     
122 132 (K)NITEIADLTQK(I) 1,245.67  44.21 yes  
133 137 (K)IYDLR(G) 679.38  29.08   
138 139 (R)GK(F) 204.13     
140 141 (K)FK(R) 294.18     
142 146 (K)RPTLR(R) 642.40  11.17   
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Position 
Sequence 
[M+H]  
(Da) 
RT 
(min) 
Identified  
in all runs 
Problems‡ 
Start End 
148 149 (R)VR(I) 274.19     
150 163 (R)ISADAMMQALLGTR(A) 1,477.75  67.5  O 
164 165 (R)AK(E) 218.15     
166 171 (K)ESLDLR(A) 732.39  28.12   
172 175 (R)AHLK(Q) 468.29     
176 178 (K)QVK(K) 374.24     
180 184 (K)EDIEK(E) 633.31  5.93  M 
185 187 (K)ENR(E) 418.20     
188 193 (R)EVGDWR(K) 761.36  25.89   
195 205 (K)NIDALSGMEGR(K) 1,162.55  38.32 yes O 
209 211 (K)FEG(-) 352.15     
The expected tryptic peptides for mouse cardiac TnI were generated using 
http://prospector.ucsf.edu/prospector/cgi-bin/msform.cgi?form=msdigest. Peptides with 
known phosphorylation sites are highlighted in red. RT = retention time of the peptide 
identified in either the recombinant or the myofibrillar sample. Problems‡: M = partial 
miscleavage of the peptide, and O = partial oxidation of methionine at intensities >15%. 
 
The criteria for a peptide to be a reference peptide are: 1) the peptide should be 
identified in all the samples, as well as the recombinant samples. From Table 4.7, only 6 
peptides were identified in all the samples in TnI. 2) Ideally, the peptide should not have 
multiple miscleavages, or modifications like oxidation, as this leads to fractionation of 
signal intensities and can skew the calculations. Although YDVEAK was found in all the 
digests, it had a prominent miscleaved form with the precursor peptide VDEER. Therefore, 
this peptide was excluded from the reference peptides. Two of the peptides, TLMLQIAK 
and NITEIADLTQK, had partial oxidized forms (about 20% or less), but were still initially 
considered for phosphorylation calculations. In addition, the last criterion 3) is that the 
calculated % phosphorylation is positive. A negative phosphorylation value could mean 
that the potential reference peptide behavior is different in the recombinant vs the tissue 
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digests. The target peptides and the five potential reference peptides are summarized in 
Table 4.8. 
Table 4.8: Target peptides with phosphorylation sites and potential reference 
peptides for TnI. 
Position Sequence [M+H] 
(Da) 
Charge state 
(z) 
Retention Time 
(min) Start End 
23 28 (R)SSANYR(A) 697.33  1.66 4.32 
42 46 (K)ISASR(K) 533.30  1.68 7.78 
142 146 (K)RPTLR(R) 642.40  1.88 11.17 
29 37 (R)AYATEPHAK(K) 987.49  2.60 13.83 
52 59 (K)TLMLQIAK(Q) ‡  917.55  1.96 45.29 
60 64 (K)QEMER(E) 692.30  1.79 7.18 
122 132 (K)NITEIADLTQK(I) 1,245.67  2.11 44.21 
195 205 (K)NIDALSGMEGR(K) ‡ 1,162.55  1.99 38.32 
A total of 6 peptides were found in all samples. ‡Partial oxidation of methionine. The target 
peptides with phosphorylation sites are highlighted in red. The highlighted peptides in 
yellow are peptides that meet the reference peptide criteria. 
 
4.3.5. Phosphorylation measurements of mouse cardiac TnI.  
A total of 11 control mouse hearts and 14 TAC mouse hearts were obtained, and 
three digests were prepared for each heart sample. The samples were run in 3 batches along 
with recombinant TnI and recombinant MyBPC digests, respectively. For the 
phosphorylation calculation, abundances of the target peptides and reference peptides were 
extracted from Progenesis data. All the charge states were summed together. For 
NIDALSGMEGR, the abundance of the oxidation states were added together as well. 
AYATEPHAK and TLMLQIAK both gave negative phosphorylation values and were not 
considered for phosphorylation measurements. AYATEPHAK is right next to the target 
peptide SSANYR that was found to be phosphorylated, and hence it may be influenced by 
the proximity of the phosphate group and its effect on trypsin cleavage.  
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The results for the phosphorylation of SSANYR in each of the control and TAC 
mouse hearts are displayed in Table 4.9. The mean phosphorylation calculated with the 
three reference peptides QEMER, NITEIADLTQK, and NIDALSGMEGR in the control 
and TAC show a high degree of phosphorylation.  
We also found a high degree of phosphorylation at ISASR in the control and TAC 
mouse hearts (Table 4.10). RPTLR in the control and TAC mouse hearts showed the least 
phosphorylation (Table 4.11) compared to SSANYR and ISASR.  
Some of the measurements in RPTLR gave negative phosphorylation values. 
Looking at the intensities used for the calculation, there was a variation in the intensity 
corresponding to the RPTLR peptide among the mice. In the digests with low (negative) 
phosphorylation, the numerator in Equation 4.13,  𝐼𝐼0 𝐼𝐼𝑧𝑧(0)� , was found to be higher than the 
denominator.  
The mean phosphorylation (%p) for the three target peptides in TnI are 
represented in Figure 4.15. Panel A) shows the % p of SSANYR between the control and 
the TAC mouse hearts with the three reference peptides. Panel B) shows the % p of ISASR 
between the control and the TAC mouse hearts, and Panel C) shows the % p of RPTLR 
between the control and the TAC mouse hearts respectively.  
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Table 4.9: Phosphorylation of SSANYR in mouse cardiac TnI. 
Control TAC 
Mouse Ref 1 Ref 2 Ref 3 Mouse Ref 1 Ref 2 Ref 3 
11 71.3% 84.5% 80.6% 1 66.1% 83.1% 80.4% 
12 73.7% 87.4% 84.3% 2 73.4% 83.4% 82.1% 
13 76.2% 87.2% 85.2% 3 73.9% 82.7% 82.9% 
21 71.6% 86.1% 82.6% 4 73.4% 81.1% 80.8% 
24 85.8% 84.6% 86.4% 5 77.1% 77.5% 83.0% 
25 86.3% 84.7% 86.2% 6 72.1% 71.1% 78.3% 
26 85.1% 81.2% 83.6% 7 81.0% 46.7% 55.7% 
27 78.0% 79.3% 82.0% 14 79.8% 45.7% 54.0% 
18 64.0% 74.4% 72.0% 15 71.1% 54.9% 39.6% 
28 78.5% 78.8% 79.1% 16 82.2% 70.1% 63.7% 
29 86.7% 86.0% 84.8% 17     
    19 89.7% 83.8%   
    20 82.6% 61.6%   
    22 85.5% 72.6%   
Mean 77.9% 83.1% 82.4%  77.5% 70.3% 70.1% 
SD 7.5% 4.1% 4.1%  6.6% 13.9% 15.6% 
SE 2.3% 1.2% 1.2%  1.8% 3.9% 4.9% 
N 11 11 11  13 13 10 
Each phosphorylation value (%p) is an average of 3 measurements from 3 tryptic digests 
of each mouse MFP sample.  
Ref 1 = QEMER 
Ref 2 = NITEIADLTQK 
Ref 3 = NIDALSGMEGR 
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Table 4.10: Phosphorylation of ISASR in mouse cardiac TnI. 
Control TAC 
Mouse Ref 1 Ref 2 Ref 3 Mouse Ref 1 Ref 2 Ref 3 
11 75.7% 86.8% 83.5% 1 66.3% 83.2% 80.6% 
12 73.4% 87.2% 84.1% 2 73.3% 83.2% 81.9% 
13 79.2% 88.8% 87.1% 3 75.5% 83.6% 83.9% 
21 75.1% 87.8% 84.8% 4 70.4% 79.0% 78.7% 
24    5     
25    6     
26    7 89.2% 69.9% 75.0% 
27    14 89.3% 71.4% 75.8% 
18    15    
28    16    
29    17    
    19    
    20    
    22    
Mean 75.8% 87.7% 84.9%  77.3% 78.4% 79.3% 
SD 2.5% 0.9% 1.6%  9.7% 6.3% 3.5% 
SE 1.2% 0.4% 0.8%  4.0% 2.6% 1.4% 
N 4 4 4  6 6 6 
Each phosphorylation value (%p) is an average of 3 measurements from 3 tryptic digests 
of each mouse MFP sample.  
Ref 1 = QEMER 
Ref 2 = NITEIADLTQK 
Ref 3 = NIDALSGMEGR 
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Table 4.11: Phosphorylation of RPTLR in mouse cardiac TnI. 
Control TAC 
Mouse Ref 1 Ref 2 Ref 3 Mouse Ref 1 Ref 2 Ref 3 
11 5.5% 48.8% 36.1% 1 -6.5% 46.9% 38.4% 
12 40.5% 71.5% 64.6% 2 20.0% 50.3% 46.3% 
13 17.0% 55.3% 48.4% 3 55.4% 70.3% 70.8% 
21 38.1% 69.6% 62.2% 4 25.0% 46.7% 46.0% 
24     5 -45.5% -43.3% -8.1% 
25     6 -37.7% -42.7% -7.1% 
26 29.5% 22.6% 36.4% 7 62.3% -4.8% 13.1% 
27 15.0% 20.0% 30.5% 14 70.6% 21.3% 33.4% 
18 20.8% 42.5% 37.4% 15 45.1% 13.1% -16.2% 
28 46.1% 46.6% 47.5% 16 49.9% 13.7% -4.7% 
29 28.9% 23.5% 17.2% 17     
    19 46.6% 23.0%   
    20 76.0% 46.1%   
    22 69.4% 43.2%   
Mean 26.8% 44.5% 42.2%  33.1% 21.8% 21.2% 
SD 13.3% 19.4% 15.1%  40.3% 35.0% 29.7% 
SE 4.4% 6.5% 5.0%  11.2% 9.7% 9.4% 
N 9 9 9  13 13 10 
Each phosphorylation value (%p) is an average of 3 measurements from 3 tryptic digests 
of each mouse MFP sample.  
Ref 1 = QEMER 
Ref 2 = NITEIADLTQK 
Ref 3 = NIDALSGMEGR 
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Figure 4.15: Phosphorylation (%p) of TnI with the finalized three reference 
peptides in control and TAC mouse hearts.  
A) %p of S23 and S24 (SSANYR), B) %p of S43 and S45 (ISASR), and C) %p 
of T 144 (RPTLR). The graphs show SE error bars. 
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To determine the statistical significance of the measurements between the 11 
control and 14 TAC mouse hearts, a three-way ANOVA was performed. Each mouse MFP 
sample had three replicate tryptic digestions. The phosphorylation measurements were 
calculated with respect to three reference peptides. The three-way ANOVA results are 
given in Table 4.12. 
The mean square values can be used to determine whether factors (treatment, 
mice, reference peptides, replicate measurements) are significant. The mean square is 
obtained by dividing the sum of squares by the degree of freedom. The residual mean 
square values represent the variance within the three replicate digestions of each mouse 
heart. The residual mean square value for the three target peptides is low (< 0.005), 
indicating that there is very little variance within the three replicate digestions of each 
mouse heart. However, the mean square values were several fold higher among mice. For 
all the three target peptides, the P value (P <0.001) indicates that there was a significant 
difference among the mice. No significant difference was observed between the three 
reference peptides. Lastly for the effect of treatment, there was a small significant 
difference between the TAC and control for SSANYR (P<0.05). For the other two peptides 
there was no significant treatment effect (P>0.05). 
Because the variance among mice is several fold higher than the variance due to 
digestion and LC-MS measurement, the ANOVA was reduced to a two-way design by 
taking the mean of the digestions for each individual mouse heart. The two-way ANOVA 
results are summarized in Table 4.13. For all three target peptides: there was no significant 
effect due to the three reference peptides, and neither was there a significant difference due 
to the treatment between the TAC and control mouse hearts inferred from the P values. 
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Table 4.12: Three-way ANOVA of mouse cardiac TnI phosphorylation. 
SSANYR      
Source of variation SS df MS F P 
Control vs TAC 0.366 1 0.3660 8.459 0.044 
3 Reference peptides 0.173 4 0.0433 1.558 0.196 
Mice 1.749 63 0.0278 21.121 <0.001 
Residual 0.175 133 0.0013     
ISASR      
Source of variation SS df MS F P 
Control vs TAC 0.037 1 0.0369 1.636 0.270 
3 Reference peptides 0.090 4 0.0226 2.399 0.078 
Mice 0.226 24 0.0094 16.820 <0.001 
Residual 0.032 57 0.0006     
RPTLR      
Source of variation SS df MS F P 
Control vs TAC 0.713 1 0.7129 3.598 0.131 
3 Reference peptides 0.793 4 0.1981 0.785 0.540 
Mice 14.384 57 0.2523 52.771 <0.001 
Residual 0.550 115 0.0048     
ANOVA factor comparison: (1) differences between control and TAC mice, (2) differences 
among the 3 reference peptides, and (3) differences among the mice. Residual error is the 
variance among the 3 replicate digestions.The 3 reference peptides used are QEMER, 
NITEIADLTQK, and NIDALSGMEGR 
Abbreviations: SS = sum of squares, df = degrees of freedom, MS = mean squares = SS/df, 
and F= ratio of the variances. 
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Table 4.13: Two-way ANOVA of mouse cardiac TnI phosphorylation. 
SSANYR      
Source of variation SS df MS F P 
Control vs TAC 0.119 1 0.1190 7.711 0.050 
3 Reference peptides 0.062 4 0.0154 1.634 0.177 
Mice 0.595 63 0.0094 
  
ISASR      
Source of variation SS df MS F P 
Control vs TAC 0.014 1 0.0143 1.797 0.251 
3 Reference peptides 0.032 4 0.0079 2.510 0.068 
Mice 0.076 24 0.0032   
RPTLR      
Source of variation SS df MS F P 
Control vs TAC 0.291 1 0.2908 5.933 0.072 
3 Reference peptides 0.196 4 0.0490 0.579 0.679 
Mice 4.827 57 0.0847   
ANOVA factor comparison: (1) differences between control and TAC mice, (2) differences 
among the 3 reference peptides, and (3) differences among the mice. The 3 reference 
peptides used are QEMER, NITEIADLTQK, and NIDALSGMEGR 
Abbreviations: SS = sum of squares, df = degrees of freedom, MS = mean squares = SS/df, 
and F= ratio of the variances. 
 
Although statistically there was no significant difference between the three 
reference peptides, we observed from Figure 4.15 that NITEIADLTQK and 
NIDALSGMEGR behaved differently compared to QEMER. Ideally, a reference peptide 
should have measurement response characteristics similar to the target peptide, i.e. of a 
similar length and eluting in the same proximity, to keep the physicochemical parameters 
that affect the ionization as close as possible. QEMER, a smaller peptide like the target 
peptides in TnI, eluted at 7.8 min, a much closer elution time to the target peptides 
compared to NITEIADLTQK and NIDALSGMEGR that eluted at 44.2 and 38.3 min, 
respectively. Hence, QEMER should have less bias as a reference peptide compared to the 
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other two large peptides. Figure 4.16 summarizes the results of the % p with the reference 
peptide QEMER in mouse cardiac TnI for the phosphorylation of. SSANYR, ISASR, and 
RPTLR respectively. The mean difference between the treatments, i.e. TAC vs control for 
each of the target peptides, was determined for the reference peptide QEMER. An unpaired 
student t-test was performed and showed no significant change for any of the three target 
peptides between the TAC and control mouse hearts, the same results as the two-way 
ANOVA. The results for the %p of the PKA and PKC sites in mouse cardiac TnI are 
tabulated in Table 4.14. 
Figure 4.16: Phosphorylation (%p) of TnI with only QEMER as reference peptide 
in control and TAC mouse hearts.  
The graphs show SE error bars 
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Table 4.14: Phosphorylation of target peptides in mouse cardiac TnI with only QEMER as the reference peptide. 
Site 
Target 
peptides 
CONTROL TAC TAC vs Control Unpaired 
 t test 
Mean ± SE N Mean ± SE N 
Mean 
difference 
± SE 
S23 and S24 SSANYR 77.9% ± 2.3% 11 77.5% ± 1.8% 13 -0.4% ± 2.9% NS 
S43 and S45 ISASR 75.8% ± 1.2% 4 77.3% ± 4.0% 6 1.5% ± 4.2% NS 
T144 RPTLR 26.8% ± 4.4% 9 33.1% ± 11.2% 13 6.3% ± 12.0% NS 
NS = not significant 
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4.3.6. Measurement of target peptides of MyBPC in the recombinant-MyBPC and 
the mouse heart myofibrillar sample preparations. 
The amino acid sequence of mouse cardiac MyBPC is given in Figure 4.17. The 
PKA target sites S273, S282, S302, S307 are indicated in red, and the potential tryptic 
peptides are indicated by the black underline, including the possible miscleavages that can 
form. MyBPC is a large protein of 1,270 amino acids. The mouse recombinant cardiac C0-
C3 fragment of MyBPC (1-539 amino acids) that contains the M-domain with the PKA 
target phosphorylation sites is shown in black in Figure 4.17. Thus, the reference peptides 
would need to be selected from 1-539 amino acids in MyBPC. 
DSFR is a small target peptide in MyBPC. Figure 4.18 shows the extracted 
chromatograms of DSFR and the corresponding SIL peptide DSF*R. The top panel 
displays the base peak chromatogram of the recombinant-MyBPC. The doubly charged 
molecular ion of DSFR, [M+2H]2+ = 262.63 is displayed in the second panel at a retention 
time 11.16 min. The bottom panel is the extracted ion chromatogram of DSF*R, [M+2H]2+ 
= 267.64 at retention time 11.16 min where F* is [13C9,15N]phenylalanine labeled.  
The extracted chromatograms of DSFR and DSF*R in a mouse MFP digestion is 
displayed in Figure 4.19. The top panel displays the base peak chromatogram of the mouse 
heart MFP tryptic digestion. The second panel corresponds to the extracted doubly charged 
molecular ion of DSFR, [M+2H]2+ = 262.63, at a retention time of 10.71 min. We observed 
multiple extracted peaks in second panel, reflecting the complexity of the in-solution 
mouse MFP digestions. The knowledge and confirmation of the doubly charged molecular 
ion of the SIL peptide DSF*R, [M+2H]2+ = 267.62 at a retention time of 10.72 min (bottom 
panel) confirms the identification of DSFR in the mouse heart sample. The recombinant 
151 
 
and the mouse samples were run several day apart, and a slight retention time change (<1 
min) was noticed.  
No SIL peptides were obtained for TSLAGAGR, TSDSHEDAGTLDFSSLLK, or 
LEAPAEEDVWEILR. These larger peptides were well retained on the reversed phase 
column, and were readily extracted from the preliminary test TX heart LC-MS runs. The 
extracted ion chromatograms of these three target peptides in the recombinant mouse 
MyBPC are displayed in Figure 4.20. The top panel is the base peak chromatogram of the 
recombinant MyBPC. The second panel corresponds to the extracted doubly charged 
molecular ion of TSLAGAGR, [M+2H]2+ = 366.71 at retention time 15.81 min. The third 
panel is the extracted ion chromatogram of the triply charged molecular ion of 
TSDSHEDAGTLDFSSLLK, [M+3H]3+ = 641.64 at retention time 55.63 min, and the 
bottom panel is the extracted ion chromatograms of LEAPAEEDVWEILR, [M+2H]2+ = 
835.426 at retention time 65.28 min.  
The three target peptides were extracted in the mouse MFP digestion and the 
extracted chromatograms are given in the Figure 4.21. The top panel is the base peak 
chromatogram of the mouse MFP digestion. The second panel corresponds to the extracted 
doubly charged molecular ion of TSLAGAGR, [M+2H]2+ = 366.71 at retention time 15.35 
min. The third panel is the extracted ion chromatogram of the triply charged molecular ion 
of TSDSHEDAGTLDFSSLLK, [M+3H]3+ = 641.64 at retention time 55.17 min, and the 
bottom panel is the extracted ion chromatograms of LEAPAEEDVWEILR, [M+2H]2+ = 
835.426 at retention time 64.97 min. 
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        10         20         30         40         50         
MPEPGKKPVS AFNKKPRSAE VTAGSAAVFE AETERSGVMV RWQRDGSDIT 
ANDKYGLAAE GKRHTLTVRD ASPDDQGSYA VIAGSSKVKF DLKVTEPAPP 
EKAESEVAPG APKEVPAPAT ELEESVSSPE GSVSVTQDGS AAEHQGAPDD 
PIGLFLMRPQ DGEVTVGGSI VFSARVAGAS LLKPPVVKWF KGKWVDLSSK 
VGQHLQLHDS YDRASKVYLF ELHITDAQTT SAGGYRCEVS TKDKFDSCNF 
NLTVHEAIGS GDLDLRSAFR RTSLAGAGRR TSDSHEDAGT LDFSSLLKKR 
DSFRRDSKLE APAEEDVWEI LRQAPPSEYE RIAFQHGVEA CHRPLKRLKG 
MKQDEKKSTA FQKKLEPAYQ VNKGHKIRLT VELADPDAEV KWLKNGQEIQ 
MSGSKYIFES VGAKRTLTIS QCSLADDAAY QCVVGGEKCS TELFVKEPPV 
LITRSLEDQL VMVGQRVEFE CEVSEEGAQV KWLKDGVELT REETFKYRFK 
KDGRKHHLII NEATLEDAGH YAVRTSGGQS LAELIVQEKK LEVYQSIADL 
AVGAKDQAVF KCEVSDENVR GVWLKNGKEL VPDNRIKVSH IGRVHKLTID 
DVTPADEADY SFVPEGFACN LSAKLHFMEV KIDFVPRQEP PKIHLDCPGS 
TPDTIVVVTG NKLRLDVPIS GDPAPTVVWQ KTVTQGKKAS AGPHPDAPED 
AGADEEWVFD KKLLCETEGR VRVETTKDRS VFTVEGAEKE DEGVYTVTVK 
NPVGEDQVNL TVKVIDVPDA PAAPKISNVG EDSCTVQWEP PAYDGGQPVL 
GYILERKKKK SYRWMRLNFD LLRELSHEAR RMIEGVAYEM RVYAVNAVGM 
SRPSPASQPF MPIGPPGEPT HLAVEDVSDT TVSLKWRPPE RVGAGGLDGY 
SVEYCQEGCS EWTPALQGLT ERRSMLVKDL PTGARLLFRV RAHNVAGPGG 
PIVTKEPVTV QEILQRPRLQ LPRHLRQTIQ KKVGEPVNLL IPFQGKPRPQ 
VTWTKEGQPL AGEEVSIRNS PTDTILFIRA ARRTHSGTYQ VTVRIENMED 
KATLILQIVD KPSPPQDIRI VETWGFNVAL EWKPPQDDGN TEIWGYTVQK 
ADKKTMEWFT VLEHYRRTHC VVSELIIGNG YYFRVFSHNM VGSSDKAAAT 
KEPVFIPRPG ITYEPPKYKA LDFSEAPSFT QPLANRSIIA GYNAILCCAV 
RGSPKPKISW FKNGLDLGED ARFRMFCKQG VLTLEIRKPC PYDGGVYVCR 
ATNLQGEAQC ECRLEVRVPQ  
Figure 4.17: Amino acid sequence of mouse cardiac MyBPC. 
(Uniprot: O70468) Length: 1,270 amino acids, Mass: 140,632 Da. The sites 
highlighted in red are the known phosphorylation sites, with the underlines indicating 
the tryptic peptides along with possible miscleavages that can form. The recombinant 
MyBPC procured is from 1-539 amino acids as indicated above. The reference peptides 
are selected from this region. The rest of the MyBPC sequence is indicated in blue. 
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Figure 4.18: Extracted ion chromatograms of DSFR and DSF*R in recombinant mouse MyBPC. 
Top panel (red) is the base peak chromatogram. The second panel (purple) is the extracted chromatogram of DSFR, 
[M+2H]2+ = 262.63. The bottom panel (black) is the extracted chromatogram of DSF*R, [M+2H]2+ = 267.63. F* = 
[13C915N]phenylalanine. 
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Figure 4.19: Extracted ion chromatograms of DSFR and DSF*R in mouse heart MFP digestion. 
Top panel (red) is the base peak chromatogram. The second panel (purple) is the extracted chromatogram of DSFR, 
[M+2H]2+ = 262.63. The bottom panel (green) is the extracted chromatogram of DSF*R, [M+2H]2+ = 267.63. F* = 
[13C915N]phenylalanine. Both elute at 10.7 min. 
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Figure 4.20: Extracted ion chromatograms of the target peptides in recombinant mouse MyBPC. 
Top panel (red) is the base peak chromatogram. The second panel (green) is the extracted chromatogram of 
TSLAGAGR, [M+2H]2+ = 366.7 at retention time 15.8 min. The third panel (brown) is the extracted chromatogram of 
TSDSHEDAGTLDFSSLLK, [M+3H]3+ = 641.62 at retention time 55.6 min. The bottom panel (purple) is the extracted 
chromatogram of LEAPAEEDVWEILR, [M+2H]2+ = 835.41 at retention time 65.3 min. 
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Figure 4.21: Extracted ion chromatograms of the target peptides in mouse heart MFP digestion. 
Top panel (red) is the base peak chromatogram. The second panel (black) is the extracted chromatogram of 
TSLAGAGR, [M+2H]2+ = 366.7 at retention time 15.4 min. The third panel (purple) is the extracted chromatogram of 
TSDSHEDAGTLDFSSLLK, [M+3H]3+ = 641.62 at retention time 55.2 min. The bottom panel (green) is the extracted 
chromatogram of LEAPAEEDVWEILR, [M+2H]2+ = 835.41 at retention time 65.0 min.
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The SIL peptide DSF*R was important in the identification of the elution time of 
the unphosphorylated DSFR in the mouse heart digestions. DSF*R was found in all the 74 
(control and TAC) heart digests (Table 4.15). The corresponding target peptide DSFR was 
found in 73 of the 74 mouse heart digests. TSLAGAGR was found in 68 of 74 mouse heart 
digests. TSDSHEDAGTLDFSSLLK was found in all of the 74 mouse heart digests, and 
LEAPAEEDVWEILR was found in all of the 74 mouse heart digests. The MyBPC target 
peptides had greater intensities compared to TnI target peptides and, therefore, were found 
in majority of the samples, including the TAC mice #17 and #19. 
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Table 4.15: Identification of MyBPC target peptides and the corresponding SIL peptide in the mouse myofibrillar 
digestions. 
Control TAC 
Mouse TSLAGAGR 
TSDSHEDAG 
TLDFSSLLK 
DSFR DSF*R 
LEAPAEE 
DVWEILR 
Mouse TSLAGAGR 
TSDSHEDAG 
TLDFSSLLK 
DSFR DSF*R 
LEAPAEE 
DVWEILR 
11 3 3 3 3 3 1 3 3 3 3 3 
12 3 3 3 3 3 2 3 3 3 3 3 
13 2 2 2 2 2 3 3 3 3 3 3 
21 3 3 2 3 3 4 3 3 3 3 3 
24 2 3 3 3 3 5 2 3 3 3 3 
25 1 3 3 3 3 6 3 3 3 3 3 
26 3 3 3 3 3 7 3 3 3 3 3 
27 3 3 3 3 3 14 3 3 3 3 3 
18 3 3 3 3 3 15 3 3 3 3 3 
28 2 3 3 3 3 16 3 3 3 3 3 
29 3 3 3 3 3 17 3 3 3 3 3 
19 3 3 3 3 3 
20 3 3 3 3 3 
22 2 3 3 3 3 
Total 28/32 32/32 31/32 32/32 32/32  40/42 42/42 42/42 42/42 42/42 
3,2,1,0 indicate the number of digests peptide was identified in the 3 digests per mouse heart. (Control 13 has 2 digests) 
*Indicates labeled amino acid.
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For the quantification of phosphorylation, we need to identify the 
unphosphorylated target peptides as well as reference peptides. The list of the expected 
tryptic peptides for MyBPC was generated using http://prospector.ucsf.edu/prospector/cgi-
bin/msform.cgi?form=msdigest and is given in Table 4.16. The peptide list covers 1-539 
amino acid sequence only because of the length of the recombinant MyBPC that was 
synthesized. The retention times indicate if the peptide was identified in any of the 
recombinant or the mouse heart samples. Peptides that have been identified in all the 
recombinant runs and the mouse hearts i.e. both the control and TAC, are indicated with 
“yes”. Partially miscleaved peptides and methionine-oxidized forms were observed for a 
few peptides and are indicated by “M” for miscleaved and “O” for methionine oxidation, 
respectively.  
Table 4.16: Expected tryptic peptides for mouse cardiac MyBPC and the peptides 
identified in recombinant protein and the myofibrillar samples. 
Position 
 Sequence 
[M+H] 
(Da) 
RT 
(min) 
Identified 
in all runs 
Problems‡ 
Start End 
2 6 (-)PEPGK(K) 527.28 15.4   
7 14 (K)KPVSAFNK(K) 890.51 16.9  M 
15 17 (K)KPR(S) 400.27    
18 35 (R)SAEVTAGSAAVFEAE 
TER(S) 
1,824.86 43.2 yes  
36 41 (R)SGVMVR(W) 648.35    
42 44 (R)WQR(D) 489.26    
45 54 (R)DGSDITANDK(Y) 1,035.46 14.8 yes M 
55 62 (K)YGLAAEGK(R) 808.42 23.1   
64 69 (R)HTLTVR(D) 726.43 15.3 yes  
70 87 (R)DASPDDQGSYAVIAG 
SSK(V) 
1,767.80 34.0 yes  
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Position 
 Sequence 
[M+H] 
(Da) 
RT 
(min) 
Identified 
in all runs 
Problems‡ 
Start End 
88 89 (K)VK(F) 246.18    
90 93 (K)FDLK(V) 522.29    
94 102 (K)VTEPAPPEK(A) 967.51 21.4 yes M 
103 113 (K)AESEVAPGAPK(E) 1,055.54 20.3 yes M 
114 175 (K)EVPAPATELEESVSSP 
EGSVSVTQDGSAAEHQG 
APDDPIGLFLMRPQDGEV 
TVGGSIVFSAR(V) 
6307.03    
176 188 (R)VAGASLLKPPVVK(W) 1,278.81 42.4 yes  
189 191 (K)WFK(G) 480.26    
192 193 (K)GK(W) 204.13    
194 200 (K)WVDLSSK(V) 834.44 33.5   
201 213 (K)VGQHLQLHDSYDR(A) 1,567.76 26.0 yes  
214 216 (R)ASK(V) 305.18    
217 236 (K)VYLFELHITDAQTTSA 
GGYR(C) 
2,242.11 56.8   
237 242 (R)CEVSTK(D) 666.31 8.4   
243 244 (K)DK(F) 262.14    
245 266 (K)FDSCNFNLTVHEAIGS 
GDLDLR(S) 
2,423.13 59.3   
267 270 (R)SAFR(R) 480.26    
272 279 (R)TSLAGAGR(R) 732.40 15.7   
281 298 (R)TSDSHEDAGTLDFSS 
LLK(K) 
   
1,922.90  
55.6 yes  
301 304 (R)DSFR(R) 524.25 11.1   
306 308 (R)DSK(L) 349.17    
309 322 (K)LEAPAEEDVWEILR(Q) 1,669.84 65.3 yes  
323 331 (R)QAPPSEYER(I) 1,076.50 19.2   
332 346 (R)IAFQHGVEACHRPLK(R) 1,705.90 37.0   
348 349 (R)LK(G) 260.20    
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Position 
Sequence 
[M+H] 
(Da) 
RT 
(min) 
Identified 
in all runs 
Problems‡ 
Start End 
350 352 (K)GMK(Q) 335.17 
353 356 (K)QDEK(K) 519.24 
358 363 (K)STAFQK(K) 681.36 13.6 
365 373 (K)LEPAYQVNK(G) 1,061.56 24.6 yes M 
374 376 (K)GHK(I) 341.19 
377 378 (K)IR(L) 288.20 
379 391 (R)LTVELADPDAEVK(W) 1,399.73 44.9 yes 
392 394 (K)WLK(N) 446.28 
395 405 (K)NGQEIQMSGSK(Y) 1,178.55 20.3 yes O 
406 414 (K)YIFESVGAK(R) 1,013.53 39.9 yes 
416 438 (R)TLTISQCSLADDAAYQ 
CVVGGEK(C) 
2,372.11 57.7 
439 446 (K)CSTELFVK(E) 926.47 37.5 
447 454 (K)EPPVLITR(S) 924.55 36.3 yes 
455 466 (R)SLEDQLVMVGQR(V) 1,374.70 47.8 yes O 
467 481 (R)VEFECEVSEEGAQVK(W) 1,682.76 42.1 
482 484 (K)WLK(D) 446.28 
485 491 (K)DGVELTR(E) 789.41 24.5 
492 496 (R)EETFK(Y) 653.31 13.9 
497 498 (K)YR(F) 338.18 
499 500 (R)FK(K) 294.18 
502 504 (K)DGR(K) 347.17 
506 524 (K)HHLIINEATLEDA 
GHYAVR(T) 
2,159.10 43.9 yes M 
525 539 (R)TSGGQSLAELIVQEK(K) 1,559.83 52.1 yes 
The expected tryptic peptides for mouse cardiac TnI were generated using 
http://prospector.ucsf.edu/prospector/cgi-bin/msform.cgi?form=msdigest. Peptides with 
known phosphorylation sites are highlighted in red. RT = retention time of the peptide 
identified in either the recombinant or the myofibrillar sample. Problems‡: M = partial 
miscleavage of the peptide, and O = partial oxidation of methionine at intensities >15%. 
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As discussed earlier, peptides of smaller length, less than 4 amino acid residues, 
are hydrophilic and are not retained by the reversed phase column. A total of 17 peptides 
have less than 4 resides, and were not found in either the recombinant MyBPC or the mouse 
heart MFP samples. This includes the target peptide DSK. This peptide is measured 
indirectly by measuring the disappearance of the adjacent peptide LEAPAEEDVWEILR 
that is large, and readily identified in all the samples. Some large hydrophobic peptides 
could be strongly retained on C18 column or eluted during the wash part of the gradient. 
The large peptide EVPAPATELEESVSSPEGSVSVTQDGSAAEHQGAPDDPIGLFLM 
-RPQDGEVTVGGSIVFSAR falls into this category.  
The same criteria used for TnI were applied for MyBPC reference peptides. 1) 
The peptide should be identified in all the samples as well as the recombinant samples. 
From Table 4.16, 16 potential reference peptides are identified in all samples. 2) The 
peptide should not have multiple miscleavages, or modifications like oxidation or 
phosphorylation. DGSDITANDK was found to miscleave with the adjacent peptide. The 
two peptides VTEPAPPEK, and AESEVAPGAPK were also found to have a high intensity 
miscleaved peptide especially in the recombinant-MyBPC digests. LEPAYQVNK had a 
miscleaved KLEPAYQVNK and HHLIINEATLEDAGHYAVR had a miscleaved 
KHHLIINEATLEDAGHYAVR. These peptides were excluded from the potential 
reference peptide list.The peptides NGQEIQMSGSK and SLEDQLVMVGQR were found 
to have partial methionine oxidized forms, but were initially considered during the %p 
calculations. The target peptides of interest and the shortlisted potential reference peptides 
are summarized in Table 4.17. In addition, the last criteria 3) is the calculated % 
phosphorylation is positive. 
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Table 4.17: Target peptides with phosphorylation sites and potential reference 
peptides for MyBPC. 
Position 
Sequence 
[M+H]  
(Da) 
Charge 
state 
(mean z) 
Retention 
 Time 
(min) 
Start End 
272 279 (R)TSLAGAGR(R)      732.40  1.93 15.7 
281 298 (R)TSDSHEDAGTPDFSSLLK(K)   1,906.87  2.91 55.6 
301 304 (R)DSFR(R)      524.25  1.53 11.1 
306 308 (R)DSK(L)      349.17    
309 322 (K)LEAPAEEDVWEILR(Q)   1,669.84  2.28 65.3 
18 35 (R)SAEVTAGSAAVFEAETER(S)   1,824.86  2.42 43.2 
64 69 (R)HTLTVR(D)      726.43  2.03 15.3 
70 87 (R)DASPDDQGSYAVIAGSSK(V)   1,767.80  2.37 34.0 
176 188 (R)VAGASLLKPPVVK(W)   1,278.81  2.91 42.4 
201 213 (K)VGQHLQLHDSYDR(A)   1,567.76  3.55 26.0 
379 391 (R)LTVELADPDAEVK(W)   1,399.73  2.04 44.9 
395 405 (K)NGQEIQMSGSK(Y) ‡ 1,178.55 2.01 20.3 
406 414 (K)YIFESVGAK(R)   1,013.53  1.96 39.9 
447 454 (K)EPPVLITR(S)      924.55  1.99 36.3 
455 466 (R)SLEDQLVMVGQR(V) ‡ 1,374.70 2.22 47.8 
525 539 (R)TSGGQSLAELIVQEK(K)   1,559.83  2.36 52.1 
A total of 15 peptides were found in all samples. ‡Partial oxidation of methionine. The 
peptides with phosphorylation sites are highlighted in red. (306-308) DSK is the peptide 
with phosphorylation site, but measured indirectly by using the adjacent peptide (309-322) 
LEAPAEEDVWEILR. The highlighted peptides in yellow are peptides that meet the 
reference peptide criteria. 
 
4.3.7. Phosphorylation measurements of mouse cardiac MyBPC 
For the phosphorylation calculation using Equation 4.13, both the intensity of the 
target peptides and reference peptides in the recombinant and the mouse MFP sample 
digestions are needed. Data was extracted using the PLGS software that gives the total 
intensity of all the charge states. Initially calculations were performed with all the potential 
reference peptides in Table 4.17, but only four peptides SAEVTAGSAAVFEAETER, 
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HTLTVR, VGQHLQLHDSYDR, and TSGGQSLAELIVQEK met the last criteria 3) of 
reference peptide where the calculated %p is positive. These four peptides were to be used 
as the reference peptides for determination of phosphorylation for the four target peptides. 
The results for the phosphorylation of TSLAGAGR, calculated for the four 
reference peptides SAEVTAGSAAVFEAETER, HTLTVR, VGQHLQLHDSYDR, and 
TSGGQSLAELIVQEK in the control mouse hearts and TAC hearts are displayed in Table 
4.18. Of the four reference peptides, VGQHLQLHDSYDR gave a higher value compared 
to the other three reference peptides, both in control and TAC calculations. 
Table 4.19 summarizes the results for the phosphorylation of 
TSDSHEDAGTLDFSSLLK in each of the control and TAC mouse hearts. The mean 
phosphorylation calculated for the four reference peptides. In this case, too, the reference 
peptide VGQHLQLHDSYDR gave a higher value relative to the other three reference 
peptides. The results for the phosphorylation of DSFR (Table 4.20) in each of the control 
and TAC mouse hearts show that this peptide had the highest phosphorylation in MyBPC 
both in control and mouse hearts. The reference peptide VGQHLQLHDSYDR gave a 
higher value relative to the other three reference peptides. The results for the 
phosphorylation of DSK (Table 4.21) in each of the control and TAC mouse hearts indicate 
that this peptide has the least phosphorylation among the four target peptides. The mean 
phosphorylation calculated with VGQHLQLHDSYDR was higher in TAC mouse hearts 
compared to the other three reference peptides.  
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Table 4.18: Phosphorylation of TSLAGAGR in the mouse cardiac MyBPC.  
Control TAC  
Mouse Ref 1 Ref 2 Ref 3 Ref 4 Mouse Ref 1 Ref 2 Ref 3 Ref 4 
11 33.8% 21.2% 46.7% 37.8% 1 47.9% 31.2% 59.2% 54.2% 
12 41.3% 26.9% 48.8% 44.2% 2 23.6% 14.8% 40.4% 30.8% 
13 25.3% 23.2% 41.0% 32.6% 3 15.4% 14.4% 34.6% 23.6% 
21 41.4% 28.2% 48.7% 46.6% 4 2.0% 17.0% 35.0% 4.5% 
24 69.9% 31.2% 51.4% 51.7% 5 49.4% 28.8% 48.1% 8.3% 
25 74.3% 37.9% 57.9% 61.1% 6 49.3% 19.3% 46.5% 19.2% 
26 38.5% 5.9% 27.5% 11.5% 7 -13.1% 16.7% -4.2% -50.3% 
27 37.1% 18.8% 26.0% 3.9% 14 0.1% 26.7% 12.7% -37.5% 
18 49.7% 59.6% 80.5% 49.5% 15 54.4% 54.7% 78.9% 51.4% 
28 26.6% 53.1% 74.6% 17.0% 16 38.6% 54.9% 72.7% 50.1% 
29 -12.3% 40.9% 61.4% -12.5% 17 13.5% 48.0% 60.0% 38.0% 
     19 47.2% 56.5% 69.2% 69.8% 
     20 0.6% 35.7% 56.0% 29.7% 
     22 46.5% 58.5% 74.5% 58.0% 
Mean 38.7% 31.5% 51.3% 31.2%  26.8% 34.1% 48.8% 25.0% 
SD 23.1% 15.5% 17.0% 23.1%  23.4% 17.1% 23.9% 34.9% 
SE 7.0% 4.7% 5.1% 7.0%  6.2% 4.6% 6.4% 9.3% 
N 11 11 11 11  14 14 14 14 
Each phosphorylation value (%p) is an average of 3 measurements from 3 tryptic digests 
of each mouse MFP sample.  
Ref 1 = SAEVTAGSAAVFEAETER 
Ref 2 = HTLTVR 
Ref 3 = VGQHLQLHDSYDR 
Ref 4 = TSGGQSLAELIVQEK 
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Table 4.19: Phosphorylation of TSDSHEDAGTLDFSSLLK in the mouse cardiac 
MyBPC.  
Control TAC 
Mouse Ref 1 Ref 2 Ref 3 Ref 4 Mouse Ref 1 Ref 2 Ref 3 Ref 4 
11 48.8% 39.0% 59.0% 52.3% 1 41.2% 22.1% 54.0% 48.4% 
12 50.0% 37.3% 56.1% 52.7% 2 43.8% 37.2% 56.2% 49.2% 
13 52.1% 50.7% 62.1% 57.0% 3 27.2% 25.6% 43.4% 34.4% 
21 51.3% 40.9% 57.7% 55.8% 4 22.8% 34.1% 48.7% 25.4% 
24 61.9% 8.3% 34.1% 40.9% 5 54.0% 34.7% 52.6% 19.6% 
25 63.9% 13.2% 42.6% 45.5% 6 58.0% 33.0% 55.6% 33.0% 
26 54.2% 28.2% 45.2% 34.0% 7 61.3% 71.3% 64.2% 48.5% 
27 44.6% 28.0% 34.8% 15.5% 14 49.3% 62.6% 55.7% 30.6% 
18 53.0% 59.6% 80.4% 54.2% 15 58.6% 58.9% 80.9% 56.0% 
28 63.7% 76.8% 87.5% 59.0% 16 41.8% 54.5% 72.3% 55.0% 
29 60.5% 79.2% 86.4% 60.5% 17 25.8% 55.1% 65.2% 47.1% 
19 12.1% 27.4% 48.9% 50.1% 
20 45.8% 64.7% 75.7% 62.0% 
22 36.4% 46.7% 67.6% 52.4% 
Mean 54.9% 41.9% 58.7% 48.0% 41.3% 44.8% 60.1% 43.7% 
SD 6.6% 23.1% 19.3% 13.4% 14.9% 16.2% 11.1% 12.7% 
SE 2.0% 7.0% 5.8% 4.1% 4.0% 4.3% 3.0% 3.4% 
N 11 11 11 11 14 14 14 14 
Each phosphorylation value (%p) is an average of 3 measurements from 3 tryptic digests 
of each mouse MFP sample.  
Ref 1 = SAEVTAGSAAVFEAETER 
Ref 2 = HTLTVR 
Ref 3 = VGQHLQLHDSYDR 
Ref 4 = TSGGQSLAELIVQEK 
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Table 4.20: Phosphorylation of DSFR in the mouse cardiac MyBPC.  
Control TAC  
Mouse Ref 1 Ref 2 Ref 3 Ref 4 Mouse Ref 1 Ref 2 Ref 3 Ref 4 
11 81.7% 78.2% 85.3% 82.8% 1 79.5% 72.8% 83.9% 81.9% 
12 84.7% 81.0% 86.7% 85.4% 2 80.2% 77.8% 84.5% 81.9% 
13 78.1% 77.4% 82.6% 80.2% 3 76.2% 75.8% 81.6% 78.4% 
21 79.8% 77.5% 83.7% 81.7% 4 70.3% 74.7% 80.3% 71.1% 
24 80.3% 52.8% 65.9% 69.1% 5 62.6% 47.0% 61.5% 34.3% 
25 79.6% 51.4% 67.6% 69.1% 6 56.4% 30.7% 53.9% 30.1% 
26 69.8% 54.1% 64.3% 56.3% 7 39.6% 55.7% 44.6% 19.8% 
27 66.4% 56.6% 60.5% 48.6% 14 42.1% 57.5% 49.5% 20.7% 
18 42.8% 50.9% 76.2% 44.3% 15 10.9% 11.6% 58.9% 5.3% 
28 41.4% 62.6% 79.8% 33.9% 16 55.1% 66.5% 79.7% 64.1% 
29 57.1% 77.5% 85.3% 57.1% 17 32.8% 59.4% 68.5% 52.2% 
     19 44.8% 54.7% 68.0% 68.5% 
     20 32.8% 56.5% 70.1% 52.7% 
     22 47.4% 58.4% 74.4% 59.4% 
Mean 69.2% 65.4% 76.2% 64.4%  52.2% 57.1% 68.5% 51.5% 
SD 15.6% 12.7% 9.8% 17.5%  20.3% 18.2% 13.2% 25.3% 
SE 4.7% 3.8% 2.9% 5.3%  5.4% 4.9% 3.5% 6.8% 
N 11 11 11 11  14 14 14 14 
Each phosphorylation value (%p) is an average of 3 measurements from 3 tryptic digests 
of each mouse MFP sample.  
Ref 1 = SAEVTAGSAAVFEAETER 
Ref 2 = HTLTVR 
Ref 3 = VGQHLQLHDSYDR 
Ref 4 = TSGGQSLAELIVQEK 
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Table 4.21: Phosphorylation of DSK in the mouse cardiac MyBPC.  
Control TAC  
Mice Ref 1 Ref 2 Ref 3 Ref 4 Mice Ref 1 Ref 2 Ref 3 Ref 4 
11 15.6% -0.7% 32.2% 21.0% 1 28.7% 5.3% 44.1% 37.1% 
12 15.7% -6.2% 25.7% 20.1% 2 15.2% 5.0% 33.8% 23.0% 
13 9.3% 6.4% 28.0% 18.1% 3 14.7% 12.4% 33.4% 22.7% 
21 16.7% -2.4% 26.6% 24.0% 4 17.0% 29.0% 44.7% 19.7% 
24 49.7% -21.9% 11.8% 21.6% 5 48.0% 25.8% 46.1% 8.7% 
25 54.5% -9.4% 27.4% 31.0% 6 31.7% -9.0% 27.6% -9.3% 
26 27.5% -12.1% 13.6% -5.2% 7 14.9% 36.8% 21.0% -13.4% 
27 22.0% -1.8% 7.7% -19.7% 14 31.7% 49.6% 40.3% 6.4% 
18 36.3% 45.9% 73.9% 38.1% 15 39.7% 40.5% 72.3% 36.2% 
28 28.7% 54.7% 75.4% 19.9% 16 33.5% 49.0% 69.0% 48.4% 
29 10.9% 53.4% 69.7% 11.3% 17 -2.7% 38.7% 52.5% 27.2% 
     19 -29.8% -6.5% 24.9% 26.6% 
     20 -21.4% 21.2% 45.7% 15.2% 
     22 16.1% 32.9% 58.9% 36.1% 
Mean 26.1% 9.6% 35.6% 16.4%  16.9% 23.6% 43.9% 20.3% 
SD 15.2% 27.8% 25.2% 16.2%  22.2% 19.4% 15.5% 17.6% 
SE 4.6% 8.4% 7.6% 4.9%  5.9% 5.2% 4.1% 4.7% 
N 11 11 11 11  14 14 14 14 
Each phosphorylation value (%p) is an average of 3 measurements from 3 tryptic digests 
of each mouse MFP sample.  
Ref 1 = SAEVTAGSAAVFEAETER 
Ref 2 = HTLTVR 
Ref 3 = VGQHLQLHDSYDR 
Ref 4 = TSGGQSLAELIVQEK 
 
The phosphorylation measurements of the four target peptides are displayed in 
Figure 4.22. Panel A) shows the %p of TSLAGAGR between the control and the TAC 
mouse hearts. Panel B) shows the %p of TSDSHEDAGTLDFSSLLK. Panel C) displays 
the %p of DSFR for the four reference peptides. The last panel D) displays the %p of DSK 
(measured by the LEAPAEEDVWEILR).  
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Figure 4.22: Phosphorylation (%p) of MyBPC with the four reference peptides in 
control and TAC mouse hearts.  
A) %p of S 273 (TSLAGAGR), B) %p of S 282 (TSDSHEDAGTLDFSSLLK), 
C) %p of S302 (DSFR), and D) %p of S307 (DSK measured by LEAPAEEDVWEILR) 
The graphs show SE error bars. 
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To determine the statistical significance of the measurements between the control 
and TAC mouse hearts, a three-way ANOVA was performed. The results are shown in 
Table 4.22. The variance (residual mean square values) representing the error associated 
with the triplicate digestions is very small <0.009 for each of the four target peptides. 
However, the variance (mean square) is several fold higher among the mice, compared to 
the variance within the digestions. All four target peptides showed a significant difference 
among the mice (P <0.001). There was a significant difference observed between the 
reference peptides as well (P < 0.05). This could be due to the VGQHLQLHDSYDR 
peptide that gave higher values for all the calculations. Lastly, for the effect of treatment, 
there was no significant effect due to the TAC treatment.  
From Figure 4.22, we observe that VGQHLQLHDSYDR reference peptide in all 
the four measurements did not line up with the other three reference peptides. This was 
confirmed statistically by Tukey’s multiple comparison test (95% confidence limit) to find 
if there is a significant difference within the four reference peptides. The 
VGQHLQLHDSYDR reference peptide was found to be significantly different (P < 0.05) 
for the majority of the comparisons, and hence was not considered for the final %p 
calculations (Figure 4.23). The three-way ANOVA was repeated again with the finalized 
three reference peptides. The results of ANOVA are given in Table 4.23. For all the four 
target peptide calculations, variance among the mice was significantly higher than within 
the triplicate digestions. There was no significant difference among the three reference 
peptides. Lastly for the effect of treatment, Only DSFR displayed a significant difference 
(P<0.05) between the control and TAC. 
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Table 4.22: Three-way ANOVA of mouse cardiac MyBPC phosphorylation. 
TSLAGAGR      
Source of variation SS df MS F P 
Control vs TAC 0.051 1 0.0513 0.136 0.725 
4 Reference peptides 2.269 6 0.3782 2.528 0.026 
Mice 13.765 92 0.1496 16.042 <0.001 
Residual 1.604 172 0.0093     
TSDSHEDAGTLDFSSLLK      
Source of variation SS df MS F P 
Control vs TAC 0.078 1 0.0776 0.317  0.594  
4 Reference peptides 1.466 6 0.2444 3.525  0.003  
Mice 6.379 92 0.0693 24.012  <0.001 
Residual 0.566 196 0.0029     
DSFR      
Source of variation SS df MS F P 
Control vs TAC 0.827 1 0.8269 4.637 0.075 
4 Reference peptides 1.070 6 0.1783 1.958 0.080 
Mice 8.380 92 0.0911 39.401 <0.001 
Residual 0.444 192 0.0023     
DSK       
Source of variation SS df MS F P 
Control vs TAC 0.12 1 0.1190 0.229 0.649 
4 Reference peptides 3.11 6 0.5191 4.263 0.001 
Mice 11.20 92 0.1217 21.066 <0.001 
Residual 1.13 196 0.0058     
ANOVA factor comparison: (1) differences between control and TAC mice, (2) differences 
among the 3 reference peptides, and (3) differences among the mice. Residual error is the 
variance among the 3 replicate digestions.  
The 4 reference peptides used are SAEVTAGSAAVFEAETER, HTLTVR, 
VGQHLQLHDSYDR, and TSGGQSLAELIVQEK. 
Abbreviations: SS = sum of squares, df = degrees of freedom, MS = mean squares = SS/df, 
and F = ratio of the variances. 
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Figure 4.23: Phosphorylation (%p) of MyBPC with the finalized three reference 
peptides in control and TAC mouse hearts.  
A) %p of S 273 (TSLAGAGR), B) %p of S 282 (TSDSHEDAGTLDFSSLLK), 
C) %p of S302 (DSFR), and D) %p of S307 (DSK measured by LEAPAEEDVWEILR) 
The graphs show SE error bars. 
0%
20%
40%
60%
TS273LAGAGR
20%
40%
60%
80%
Ph
os
ph
or
yl
at
io
n
TS282DSHEDAGTLDFSSLLK
20%
40%
60%
80%
DS302FR
0%
20%
40%
60%
CONTROL TAC
DS307K
SAEVTAGSAAVFEAETER HTLTVR TSGGQSLAELIVQEK
A)
B)
C)
D)
173 
 
Table 4.23: Three-way ANOVA of mouse cardiac MyBPC phosphorylation with the 
finalized 3 reference peptides. 
TSLAGAGR      
Source of variation SS df MS F P 
Control vs TAC 0.047 1 0.0466 0.684 0.455 
3 Reference peptides 0.272 4 0.0681 0.433 0.784 
Mice 10.846 69 0.1572 13.514 <0.001 
Residual 1.500 129 0.0116     
TSDSHEDAGTLDFSSLLK      
Source of variation SS df MS F P 
Control vs TAC 0.128 1 0.1277 1.629 0.271 
3 Reference peptides 0.314 4 0.0784 1.131 0.349 
Mice 4.786 69 0.0694 21.607 <0.001 
Residual 0.472 147 0.0032     
DSFR      
Source of variation SS df MS F P 
Control vs TAC 0.765 1 0.7648 24.409 0.008 
3 Reference peptides 0.125 4 0.0313 0.291 0.883 
Mice 7.430 69 0.1077 38.507 <0.001 
Residual 0.403 144 0.0028     
DSK       
Source of variation SS df MS F P 
Control vs TAC 0.041 1 0.0405 0.291 0.618 
3 Reference peptides 0.557 4 0.1392 1.148 0.342 
Mice 8.366 69 0.1212 19.822 <0.001 
Residual 0.899 147 0.0061     
ANOVA factor comparison: (1) differences between control and TAC mice, (2) differences 
among the 3 reference peptides, and (3) differences among the mice. Residual error is the 
variance among the 3 replicate digestions. The 3 reference peptides used are 
SAEVTAGSAAVFEAETER, HTLTVR, and TSGGQSLAELIVQEK 
Abbreviations: SS = sum of squares, df = degrees of freedom, MS = mean squares = SS/df, 
and F = ratio of the variances. 
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Because the variance among the mice was significantly higher than the variance 
of the triplicate digestions, the ANOVA was reduced to a two-way design by taking the 
mean of the digestions for each individual mouse heart. The two-way results are 
summarized in Table 4.24. There was no significant effect among the three reference 
peptides. The TAC treatment showed a statistically significant difference only for DSFR 
(P<0.05). The mean difference between the treatments, i.e. TAC vs control was determined 
for the finalized reference peptides given in Table 4.25. TAC treatment reduced S302 
phosphorylation from 66.4 ± 8.1% to 53.6 ± 9.9%.  
Figure 4.24 displays the final results of the mean of %p in MyBPC for the four 
phosphorylation sites S273, S282, S302, and S307 (TSLAGAGR, 
TSDSHEDAGTLDFSSLLK, DSFR, and DSK respectively). We found that S302 is the 
site with the highest phosphorylation in both control and TAC hearts followed by S282 and 
S273. The least phosphorylated site was found to be S307.  
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Table 4.24: Two-way ANOVA of mouse cardiac MyBPC phosphorylation with the 
finalized 3 reference peptides. 
TSLAGAGR 
Source of variation SS df MS F P 
Control vs TAC 0.050 1 0.0497 1.911 0.239 
3 Reference peptides 0.104 4 0.0260 0.451 0.772 
Mice 3.982 69 0.0577 
TSDSHEDAGTLDFSSLLK 
Source of variation SS df MS F P 
Control vs TAC 0.046 1 0.0462 1.807 0.250 
3 Reference peptides 0.102 4 0.0255 1.101 0.363 
Mice 1.601 69 0.0232 
DSFR 
Source of variation SS df MS F P 
Control vs TAC 0.302 1 0.3018 29.811 0.005 
3 Reference peptides 0.040 4 0.0101 0.278 0.891 
Mice 2.513 69 0.0364 
DSK 
Source of variation SS df MS F P 
Control vs TAC 0.02 1 0.0157 0.347 0.588 
3 Reference peptides 0.18 4 0.0454 1.120 0.354 
Mice 2.80 69 0.0406 
ANOVA factor comparison: (1) differences between control and TAC mice, (2) differences 
among the 3 reference peptides, and (3) differences among the mice. The 3 reference 
peptides used are SAEVTAGSAAVFEAETER, HTLTVR, and TSGGQSLAELIVQEK 
Abbreviations: SS = sum of squares, df = degrees of freedom, MS = mean squares = SS/df, 
and F = ratio of the variances. 
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Figure 4.24: Mean phosphorylation (%p) of MyBPC for the four target peptides in 
control and TAC mouse hearts.  
%p of DSK is measured by LEAPAEEDVWEILR peptide.  
The graphs show SE error bars. 
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Table 4.25: Phosphorylation of target peptides in mouse cardiac MyBPC with finalized three reference peptides 
Site 
Target 
peptides 
CONTROL TAC TAC vs control Two-way 
ANOVA Mean ± SE N Mean ± SE N Mean 
difference 
± SE 
S273 TSLAGAGR 33.8% ± 10.9% 11 28.6% ± 12.1% 14 -5.2% ± 9.4% NS 
S282 TSDSHEDAGTLDFSSLLK 48.3% ± 8.3% 11 43.3% ± 6.8% 14 -5.0% ± 6.2% NS 
S302 DSFR 66.4% ± 8.1% 11 53.6% ± 9.9% 14 -12.8% ± 7.4% P<0.05 
S307 DSK 17.4% ± 10.7% 11 20.3% 9.2% 14 2.9% ± 8.2% NS 
NS = not significant 
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4.3.8. Identification of PKA phosphorylation sites in TnI and MyBPC tryptic 
peptides from mouse hearts  
PLGS software was used to identify the phosphorylated peptides, along with the 
identification of molecular ions and the retention times of SIL phosphopeptides that were 
added to the mouse digests. The PLGS processed output data files are large and exhaustive 
in data. Hence, for manual identification purposes, one control heart (three replicate runs) 
and one TAC mouse heart sample (three replicate runs) were selected. Table 4.26 
summarizes the SIL peptides that were identified in the control and the TAC mouse heart 
MFP samples from the PLGS output datafile_Pep3DAMRT. All the SIL peptides added to 
the samples were identified except for ISPA*SPR. The reasons for not finding this 
phosphopeptide could be because the ion intensities of either the MS or the MSE ions were 
lower than the cutoff used for processing the data or could be due to issues associated with 
the ionization efficiency and column interactions of the phosphopeptides that were 
described in Chapter 3. 
We manually searched for the corresponding unlabeled phosphopeptides at the 
retention times where the SIL peptides eluted. For SSANYR, molecular ions corresponding 
to two singly phosphorylated forms SSANYR-1P and miscleaved RSSANYR-1P were 
identified. Molecular ions corresponding to the doubly phosphorylated (miscleaved) 
RSSANYR-2P and RSSANYR-2P were also identified (Table 4.27). Although ISASR and 
RPTLR of TnI appear to be phosphorylated based on the %p calculations, the 
phosphorylated forms of these peptides were not identified.  
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Table 4.26: SIL peptides identified in the control and TAC mouse heart MFP 
samples  
 # Peptide sequence [M+H] (Da) Retention Time (min) 
 TnI SIL peptides  
1 SSANY*R 707.38  5.61  
2 SSPANY*R 787.35  7.50  
3 RSSANY*R 863.48  3.53  
4 RSSPANY*R 943.45  5.48  
5 RSPSA*NY*R 947.46  5.48  
6 RSPSPANY*R 1,023.42  7.12  
7 RRSSPANY*R 1,099.56  3.51  
8 RRSPSA*NY*R 1,103.56  3.51  
9 RRSPSPA*NY*R 1,183.53  5.23  
10 ISA*SR 537.34  6.79  
11 ISA*SPR 617.31  7.83  
12 ISPA*SR 617.31  8.41  
13 ISPA*SPR 697.27   
14 ISA*SRK 665.43  3.35  
15 ISA*SPRK 745.40  5.35  
16 ISPA*SRK 745.40  5.50  
17 ISPA*SPRK 825.37  7.26  
18 RPTL*R 649.44  10.23  
19 RPTPL*R 729.42  14.37  
20 RPTPL*RR 885.52  12.74  
 MyBPC SIL peptides  
21 DSF*R 534.29  10.26  
22 DSPF*R 614.25  11.63  
23 RDSF*R 690.39  7.71  
24 RDPSF*R 770.35  10.26  
To each digestion 5 pmol of each of the SIL peptide was added. PPhosphorylated serine or 
threonine. A* = [13C315N]alanine, Y* = [13C915N]tyrosine, L* = [13C615N]leucine, and  
F* = [13C915N]phenylalanine.   
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Table 4.27: Phosphopeptides identified from the control and TAC mouse heart MFP 
samples 
 # Peptide sequence [M+H] (Da) Retention Time (min) 
 TnI peptides  
1 SSANYR-1P 777.29 7.49 
2 RSSANYR-1P 933.39 5.49 
3 RSSANYR-2P 1013.36 7.13 
4 RRSSANYR-2P 1169.46 5.24 
 MyBPC peptides  
5 RTSLAGAGR-1P 968.47 14.24 
6 TSDSHEDAGTLDFSSLLK-1P 2002.86 56.73 
7 RTSDSHEDAGTLDFSSLLK-1P 2158.86 53.28 
8 RDSKLEAPAEEDVWEILR-1P 2236.06 58.47 
To each digestion 5 pmol of each of the SIL peptide was added. PPhosphorylated serine or 
threonine. A* = [13C315N]alanine, Y* = [13C915N]tyrosine, L* = [13C615N]leucine, and  
F* = [13C915N]phenylalanine 
 
Figure 4.25 shows the extracted chromatogram of the correctly cleaved, singly 
phosphorylated SSANYR-1P and SIL peptide SSPANY*R. We did not have a SIL peptide 
corresponding to SPSANY*R. Figure 4.26 shows the extracted chromatogram of the singly 
phosphorylated miscleaved peptide, RSSANYR-1P and the SIL peptides RSSPANY*R and 
RSPSA*NY*R. The SIL peptides, RSSPANY*R and RSPSA*NY*R both eluted at the 
same retention time. Figure 4.27 shows the extracted chromatogram of the doubly 
phosphorylated miscleaved peptides, RSSANYR-2P and RRSSANYR-2P along with the 
corresponding SIL peptides RSPSPA*NY*R and RRSPSPANY*R. 
We reviewed the PLGS processed MSE output data to determine the position of 
phosphorylation (S23 or S24) in the singly phosphorylated forms SSANYR-1P and 
RSSANYR-1P. Only the MSE spectrum of RSSANYR-1P was assigned by PLGS. The top 
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panel of Figure 4.28 is the MSE spectra (high-energy) collected at the retention time 5.5 
min during the data acquisition and the ions that were assigned. Because all ions eluting at 
the time of 5.5 min are fragmented, the top panel has many ions that may not correspond 
to the phosphopeptide of interest. The bottom panel shows the b- and y-ions and the loss 
of the phosphate moiety that were assigned to the phosphopeptide. These ions can be used 
to identify the position of phosphorylation. The identification of the y6-H3PO4 ion and the 
b3-H3PO4 indicate that the phosphate group is on either S23 or S24. The identification of 
y5-NH3 and a weak b2 ion localize the phosphorylation site to S23. 
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Figure 4.25: Extracted ion chromatograms of the peptides of SSANYR-1P in control mouse heart MFP digestion. 
Top panel (red) is the base peak chromatogram. The second panel (purple) is the extracted chromatogram of SSANYR-
1P, [M+2H]2+ = 389.14 at retention time 7.5 min. The third panel (green) is the extracted chromatogram of SSPANY*R, 
[M+2H]2+ = 394.15 at retention time 7.5 min.  
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Figure 4.26: Extracted ion chromatograms of the peptides of RSSANYR-1P in control mouse heart MFP digestion. 
Top panel (red) is the base peak chromatogram. The second panel (purple) is the extracted chromatogram of RSSANYR-1P, 
[M+2H]2+ = 467.2 at retention time 5.5 min. The third panel (green) is the extracted chromatogram of RSSPANY*R, [M+2H]2+ 
= 472.2 at retention time 5.5 min. The bottom panel (black) is the extracted chromatogram of RSPSA*NY*R, [M+2H]2+ = 474.2 
at retention time 5.5 min. 
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Figure 4.27: Extracted ion chromatograms of the peptides of RSSANYR-2P and RRSSANYR-2P in control mouse 
heart MFP digestion. 
Top panel (red) is the base peak chromatogram. The second panel (brown) is the extracted chromatogram of 
RSSANYR-2P, [M+2H]2+ = 507.18 at retention time 7.2 min. The third panel (black) is the extracted chromatogram of 
RSPSPA*NY*R, [M+2H]2+ = 512.18 at retention time 7.2 min. The third panel (purple) is the extracted chromatogram of 
RRSSANYR-2P, [M+2H]2+ = 585.23 at retention time 5.3 min. The bottom panel (green) is the extracted chromatogram of 
RRSPSPANY*R, [M+2H]2+ = 592.24 at retention time 5.3 min. 
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Figure 4.28: MSE (high-energy) spectra of RSPSANYR at retention time 5.5 min of the mouse heart MFP digestion 
analyzed by the PLGS software.  
Top panel is the MSE spectra (high-energy) collected at the retention time 5.5 min. Bottom panel is the MSE ions 
identified to the fragmentation of RSPSANYR ([M+H]+ = 933.3911). 
Annotations: y-ions (red), b-ions (blue), neutral losses of H2O or NH3 (green), Phosphorylation (brown), ions assigned to 
another peptide sequence (magenta), and unassigned ions (gray).  
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For SSANYR, a mixture of 0, 1 and 2 phosphorylated forms were detected. The 
amount (pmol) of each phosphorylated form of SSANYR was calculated using the known 
amounts of each SIL peptide that were added to the mouse heart MFP samples. The amount 
of SSANYR and the various forms of the phosphorylated SSANYR for control mouse 27 
(three tryptic digestions) and TAC mouse 5 (three tryptic digestions) are summarized in 
Table 4.28. The singly phosphorylated SSANYR (both correctly cleaved and miscleaved) 
is the predominant form compared to the doubly phosphorylated SSANYR. In the doubly 
phosphorylated SSANYR, the doubly miscleaved form seems to be the favored.  
Table 4.28: Amount (pmol) of the 0, 1, and 2 phosphorylated SSANYR and its 
miscleaved forms in the mouse heart MFP samples. 
Control ( mouse 27) TAC (mouse 5) 
Mean ± SD Mean ± SD 
SSANYR 3.90 ± 0.45 2.91 ± 0.16 
SSANYR-1P 7.59 ± 0.36 4.73 ± 0.22 
RSSANYR-1P 6.56 ± 0.52 6.13 ± 0.79 
RSSANYR-2P 2.27 ± 0.13 0.92 ± 0.35 
RRSSANYR-2P 4.16 ± 0.54 3.76 ± 0.26 
N = 3 (triplicate tryptic digestions) 
The fractional phosphorylation can be determined by taking the ratio of each form 
(i.e. 0, 1, or 2) to the sum of all the forms of SSANYR identified. The singly phosphorylated 
is the sum of both SSANYR-1P and RSSANYR-1P. Similarly, the doubly phosphorylated 
is the sum of RSSANYR-2P and RRSSANYR-2P. The fraction of 0, 1, and 2 
phosphorylated SSANYR are summarized in Table 4.29. The singly phosphorylated form 
was predominant both in control and TAC at about 58% followed by the doubly 
phosphorylated at about 26%. The mean total phosphorylation on SSANYR for both 
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control and the TAC mouse was 84% comparable to the degree of phosphorylation of 
SSANYR 78% ± 7.1% (SD) for control and TAC determined using the mass balance 
approach. 
Table 4.29: Fraction of 0, 1, and 2 phosphorylations on SSANYR in the mouse heart 
MFP samples. 
Phosphates on SSANYR 
Control ( mouse 27) TAC (mouse 5) 
Mean ± SD Mean ± SD 
0 15.9% ± 0.9% 15.8% ± 0.7% 
1 57.8% ± 0.7% 58.8% ± 2.3% 
2 26.3% ± 1.3% 25.4% ± 1.6% 
1+2 84.1% ± 0.9% 84.8% ± 0.7% 
N = 3 (triplicate tryptic digestions) 
In MyBPC, we were not able to find the phosphopeptide corresponding to DSFR, 
either DSPFR, or RDSPFR, although the corresponding SIL peptides added to the sample 
were identified (Table 4.26). The reasons for not finding the phosphopeptides could be 
because the ion intensity of either the MS or the MSE ions were lower than the cutoff used 
for processing the data. The other three target peptides in MyBPC are larger, and the 
phosphopeptides either correctly or miscleaved were identified. The extracted 
chromatograms of the identified singly phosphopeptides corresponding to TSLAGAGR, 
TSDSHEDAGTLDFSSLLK, and DSK(LEAPAEEDVWEILR) are shown in Figure 4.29. 
The singly phosphorylated form of TSLAGAGR was a miscleaved form corresponding to 
RTSLAGAGR-1P (second panel). TSDSHEDAGTLDFSSLLK had two singly 
phosphorylated forms, a miscleaved form of RTSDSHEDAGTLDFSSLLK-1P (third 
panel) and a correctly cleaved phosphopeptide TSDSHEDAGTLDFSSLLK-1P (fourth 
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panel). The phosphopeptide corresponding to DSK is miscleaved form corresponding to 
RDSKLEAPAEEDVWEILR-1P. 
The RTSLAGAGR-1P peptide has two potential sites of phosphorylation (T272 
and S273). Top panel of Figure 4.30 is the PLGS assigned MSE spectrum (high-energy) 
collected at the retention time 14.3 min during the data acquisition and the ions that were 
assigned. The top panel has all the fragment ions of the precursors eluting at 14.3. 
Therefore, the MSE spectrum is dense with unidentified ions (indicated in gray) and 
fragment ions that have been assigned to other precursor ions eluting at the same time 
(indicated in magenta). The bottom panel shows the b- and y-ions and the loss of the 
phosphate moiety that were assigned to identify the position of phosphorylation. The 
identification of y7-H3PO4 ion is the marker ion to localize the phosphorylation site to S273 
and not T272. 
The TSDSHEDAGTLDFSSLLK-1P has multiple potential phosphorylation sites 
(T281, S282, S284, T190, S294, and S295). The MSE spectrum (Figure 4.31) shows the 
presence of b4-H3PO4 and b5-H3PO4 ions, limiting the phosphorylation location to T281, 
S282, S284. In addition, a y17-H3PO4 ion was observed implying that the phosphorylation 
is not on T281. The conformation that the phosphorylation is on S282 and not on S284 can 
be obtained from the MSE spectrum of the miscleaved peptide (Figure 4.32) with the 
identification of the marker ions y16. 
For the last site S307 (DSK), the miscleaved phosphopeptide 
RDSPKLEAPAEEDVWEILR was identified. Figure 4.33 gives the MSE spectrum of 
RDSPKLEAPAEEDVWEILR. Due to the low intensity of the peptide, the top panel has 
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high intensity of unidentified (indicated in gray) ions or ions assigned to other peptides 
(indicated in magenta), but nevertheless PLGS was able to identify b- and y-ions and b-
ions with the loss of phosphate group (bottom panel) to show the phosphorylation. The site 
can be assigned unambiguously to S307 (DSPKLEAPAEEDVWEILR) because it is the 
only possible phosphorylation site in the peptide.  
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Figure 4.29: Extracted ion chromatograms of phosphopeptides of the target peptides in MyBPC in the control mouse 
heart MFP digestion. 
Top panel (red) is the base peak chromatogram. The second panel (brown) is the extracted chromatogram of RTSLAGAGR-1P, 
[M+2H]2+ = 484.6 at retention time 14.3 min. The third panel (black) is the extracted chromatogram of 
RTSDSHEDAGTLDFSSLLK-1P, [M+3H]3+ = 720.2 at retention time 53.3 min. The fourth panel (purple) is the extracted 
chromatogram of TSDSHEDAGTLDFSSLLK-1P, [M+3H]3+ = 668.2 at retention time 56.7 min.The bottom panel (green) is the 
extracted chromatogram of RDSKLEAPAEEDVWEILR-1P, [M+2H]2+ = 1118.3 at retention time 59.2 min. 
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Figure 4.30: MSE (high-energy) spectra of RTSPLAGAGR at retention time 14.3 min for the mouse heart MFP 
digestion analyzed by the PLGS software.  
Top panel is the MSE spectra (high-energy) collected at the retention time 14.3 min. Bottom panel is the MSE ions 
identified to the fragmentation of RTSPLAGAGR ([M+H]+ = 968.4651). 
Annotations: y-ions (red), b-ions (blue), neutral losses of H2O or NH3 (green), Phosphorylation (brown), ions assigned to 
another peptide sequence (magenta), and unassigned ions (gray).  
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Figure 4.31: MSE (high-energy) spectra of TSPDSHEDAGTLDFSSLLK at retention time 56.7 min for the mouse heart 
MFP digestion analyzed by the PLGS software.  
Top panel is the MSE spectra (high-energy) collected at the retention time 56.7min. Bottom panel is the MSE ions 
identified to the fragmentation of TSPDSHEDAGTLDFSSLLK ([M+H]+ = 2002.8667). 
Annotations: y-ions (red), b-ions (blue), neutral losses of H2O or NH3 (green), Phosphorylation (brown), ions assigned to 
another peptide sequence (magenta), and unassigned ions (gray).  
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Figure 4.32: MSE (high-energy) spectra of RTSPDSHEDAGTLDFSSLLK at retention time 53.3 min for the mouse 
heart MFP digestion analyzed by the PLGS software.  
Top panel is the MSE spectra (high-energy) collected at the retention time 53.3 min. Bottom panel is the MSE ions 
identified to the fragmentation of RTSPDSHEDAGTLDFSSLLK ([M+H]+ = 2158.9697). 
Annotations: y-ions (red), b-ions (blue), neutral losses of H2O or NH3 (green), Phosphorylation (brown), ions assigned to 
another peptide sequence (magenta), and unassigned ions (gray).  
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Figure 4.33: MSE (high-energy) spectra of RDSPKLEAPAEEDVWEILR at retention time 59.16 min for the mouse 
heart MFP digestion analyzed by the PLGS software.  
Top panel is the MSE spectra (high-energy) collected at the retention time 59.16 min.Bottom panel is the MSE ions 
identified to the fragmentation of RDSPKLEAPAEEDVWEILR ([M+H]+ = 2236.071). 
Annotations: y-ions (red), b-ions (blue), neutral losses of H2O or NH3 (green), Phosphorylation (brown), ions assigned to 
another peptide sequence (magenta), and unassigned ions (gray).
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4.4. DISCUSSION 
Our aim was to determine phosphorylation changes of the PKA sites of both TnI 
and MyBPC at the beginning stages of symptoms associated with HFpEF and progression 
towards heart failure. The TAC mouse is a model for induced hypertension, causing cardiac 
hypertrophy, diastolic dysfunction resulting in HFpEF. A larger diameter constriction (0.4 
mm) on the transverse aorta was used to subject mice a slow development of LV 
hypertrophy, but not to progress to heart failure (81). The TAC treatment increased left 
ventricular posterior wall thickness (results not shown) in the mice. LV thickness is a 
common structural abnormality associated with HFpEF.  
4.4.1. PKA phosphorylation of TnI 
The top down mass spectrometry studies of mouse hearts show 0, 1, and 2 
phosphorylated TnI to be 41%, 46%, and 13% (58,59) and reported the phosphorylation 
sites to be S23 and S24. Our result for the control heart give 0, 1, and 2 phosphorylated 
SSANYR to be 16%, 58% and 26% respectively. We observed a slightly higher 
phosphorylation as both 1- and 2- phosphorylated forms. Zhang et al. (61) studied human 
heart biopsy samples and reported that the total phosphorylation (S23 and S24) in non-
failing hearts was 49.5% compared to 18.8% in end stage failing hearts at the PKA target 
sites S23 and S24. From both mouse and human heart data, S23 and S24 are predominantly 
phosphorylated in the range of 50-60%. Our degree of phosphorylation on SSANYR (S23 
and S24) was 77.9% (Table 4.14). 
We were able to localize the position of phosphorylation in the miscleaved peptide 
to be S23 i.e. RSPSANYR using the b- and y-ions assigned by PLGS. Therefore, our 
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assumption is that in the singly phosphorylated state, the phosphate is on S23, and in the 
doubly phosphorylated state, a second phosphate is then added to S24. Our assumption is 
backed by the evidence of sequential phosphorylation of SSNYR (human) by top down 
mass spectrometry studies where the mono-phosphorylated form was reported on S23, and 
the second site S24 was reported to be phosphorylated only in the di-phosphorylated form 
(61,151).  
Along with the PKA sites, we looked at the peptides with PKC target sites for 
phosphorylation measurements. The degree of phosphorylation on ISASR (S43 and S45) 
was 75.8%, and RPTLR (T144) was 26.8% for the control hearts (Table 4.14). The only 
reported phosphorylation measurements for these sites in literature were for human cardiac 
TnI measurements by Dr. Michel J Previs (62) in his doctoral thesis. He reported a no 
significant difference for the degree of phosphorylation of ISASR (14 ± 1.7% in normal 
hearts compared to 35 ± 9.5% in failing hearts) or RPTLR (5.4 ± 7.0% in normal hearts 
and 20 ± 4.2% the failing hearts). Our phosphorylation values for ISASR and RPTLR were 
higher than those reported for human studies. This could be due to a species difference.  
Although ISASR and RPTLR of TnI are shown to be phosphorylated based on the 
%p calculations, the phosphorylated forms of these peptides were not identified. The 
reason for not identifying the phosphorylated forms could be the low intensity of the 
phosphopeptides in the mouse heart MPF samples. Another reason could be the ionization 
and selective losses associated with phosphopeptides discussed in Chapter 3.  
4.4.2. PKA phosphorylation of MyBPC 
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Both in vivo and in vitro studies have shown MyBPC is extensively 
phosphorylated (65,72). Our results for the degree of phosphorylation in MyBPC along 
with those reported in two papers using the same mass spectrometry technique are given 
in Table 4.30.  
Table 4.30: Degree of phosphorylation of MyBPC from three different studies.  
 
Our results 
Control mice 
Previs et al. (152) 
Normal mice 
Palmer et al. (73) 
Mice (iodine-deficient diet) 
 Mean ± SE Mean ± SD Mean ± SD 
S273 34% ± 11% 73% ± 8% 76% ± 11% 
S282 48% ± 8% 90% ± 3% 100% ± 0% 
S302 66% ± 8% 37% ± 18% 31% ± 12% 
S307 17% ± 11% 57% ± 6% 11% ± 3% 
 
Previs et al. (152) results are for normal mice, while the mice in Palmer et al. (73) 
studies were on an iodine deficient diet. Both studies used the same MS methodology and 
reported a higher degree of phosphorylation of the first two sites S273, and S282, while in 
our results we observed S302 to be the highest phosphorylation site. The differences could 
be due to the techniques employed for the mass spectrometric measurements itself. The 
other two studies employed gel isolation of the MyBPC protein prior to digestion. For our 
studies, we performed direct in-solution digestions of the mouse MFPs. This gave an 
advantage in reducing the sample preparation steps. Moreover, we also ascertained that the 
in-solution digestions recoveries were better than the in-gel digestions in spite of the 
complexity of the myofibrillar protein preparation.  
Though the overall recovery of the protein was higher in the in-solution 
digestions, the complexity of the mouse MFP sample digestions was a limitation during 
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the selection of reference peptides. The potential reference peptides that we identified in 
the recombinant proteins were not identified in all the sample digestions or gave negative 
phosphorylation values. These results indicate that the correlation of peptides in the 
recombinant were different from that of the actual sample. A second factor is the 
integration of the areas for the %p calculations. We employed the sum of intensities of all 
charge states as well as the isotopes of each charge state for both the target peptides and 
the reference peptides. Moreover, our digestion protocol was optimized to produce 
correctly cleaved target peptides. The other two studies employed the intensity of the most 
intense charge state and do not mentions the presence or absence of miscleaved forms. 
From the mutation studies, the TG mice with PKA sites devoid of phosphorylation 
were reported to show slow LV relaxation causing impaired diastolic function and gave 
rise to phenotypes that are associated with HFpEF. In the case of TnI the diastolic 
dysfunction was reported to be due to an increased cardiac myofilament Ca2+ sensitivity. 
In the case of MyBPC, the diastolic dysfunction was found to be due to changes in the 
cross-bridging detachment rates. Our hypothesis was that the TAC mice that display 
HFpEF phenotypes would show reduced PKA mediated phosphorylation of cardiac TnI 
and MyBPC compared to control mice, irrespective of the absolute values of %p. Our 
results of TnI and MyBPC phosphorylation do not follow the hypothesis. Neither the PKA 
sites S23 and S24 of TnI nor the PKA sites S273, S282, and S307 of MyBPC showed a 
statistical difference in the degree of phosphorylation between the TAC and the control 
mouse hearts. Only one site S302 of MyBPC displayed a statistically significant reduction 
in phosphorylation by about 13% in TAC mice compared to control mice. Although, recent 
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mutation studies by Mamidi et al. (153) point towards the significance of S302 
phosphorylation for PKA-mediated enhancement of cross-bridge detachment, the 13% 
decrease we observed may not be physiologically significant.  
From our phosphorylation measurements of TAC and control mice, there was no 
significant change in the PKA mediated phosphorylation in either mouse cardiac TnI or 
MyBPC (except S302). These results suggest that PKA mediated phosphorylation may not 
be playing a functional role in the early stages of HFpEF. The mutation studies 
(54,55,57,71) and the murine and human heart failure studies (60-63,72-74) show that 
reduced phosphorylation is associated with heart failure. Therefore, we assume that 
reduced PKA mediated phosphorylation may be a symptom observed at the end stage heart 
failure. 
4.5. CONCLUSIONS  
The aim of this thesis was to determine the degree of phosphorylation of PKA 
phosphorylation sites in TnI and MyBPC from TAC and control mouse hearts. The 
quantification was carried out by using a mass-balance approach measuring the 
unphosphorylated peptides. This approach circumvents the problems associated with the 
ionization efficiency issues associated with phosphopeptides and the probable miscleaved 
peptides generated due to the presence of the phosphate group. During the development of 
the method, we optimized the digestion protocol to minimize the miscleaved peptide 
formation of the target peptides. We also ascertained that the in-solution digestions 
recoveries were better than the in-gel digestions in spite of the complexity of the 
myofibrillar protein preparation. The advantage of in-solution digestion of the entire MFP 
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samples is the reduced the sample preparation time and the ability to acquire data 
corresponding to all the proteins in the MFP samples. But, the complexity of the mouse 
MFP sample digestions was a limitation during the selection of reference peptides. There 
were differences in the correlation of peptides in the recombinant to that of the actual 
mouse samples, limiting the number of reference peptides we could use for our 
measurements. This issue related to reference peptides is of importance and needs to be 
addressed in the future. The LC-MS method developed is this chapter is not limited to 
phosphorylation measurements, but has a potential for broader applications in the 
proteomics field. The in-solution digestion sample preparation and the MSE data 
acquisition enables the identification and quantification of multiple proteins in the sample 
simultaneous. 
The research was focused on determining if PKA-mediated phosphorylation 
changes can be observed in cardiac TnI and MyBPC at the early stages of HFpEF. For this 
purpose, the TAC mouse model with slow development of HFpEF was used. Our results 
showed no significant change in the PKA phosphorylation of either cardiac TnI or MyBPC 
(except S302). Therefore, we conclude that in our TAC model, PKA dysfunction may not 
play a role in the initial development of HFpEF, but rather could be a symptom of end-
stage HF.  
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